

SIDNEY H. KENNEDY

I. PERSONAL DATA

- i.**
- | | |
|--|--|
| <p>Business Address 1
 St. Michael's Hospital
 193 Yonge St.
 Suite 6-001A
 Toronto, ON
 M5B 1M8
 ☎ (416) 864-6099
 ☎ (416) 864-5996
 ✉ KennedyS@smh.ca</p> | <p>Business Address 2
 Toronto Western Hospital
 399 Bathurst Street
 9MP-324
 Toronto, ON
 M5T 2S8
 ☎ (416)603-5760
 ☎ (416) 603-5368
 ✉ Sidney.Kennedy@uhn.ca</p> |
|--|--|
- ii. License Number** 32560 (Ontario Physicians and Surgeons)
- iii. CIHR P.I.N.** 29052

II. EDUCATION

- i. Undergraduate**
 1969-1975 Queens University Belfast, Northern Ireland
- ii. Postgraduate**
 1986-1989 Graduate Student, Queens University, Belfast
 1976-1980 Registrar Rotational Training Program in Psychiatry, Newcastle University, Newcastle-upon-Tyne, England
 2003 Rotman – UHN Leadership Development Program
- iii. Professional Qualifications**
- | | |
|---|--|
| <p>1990

1982
1981
1980
1979
1975</p> | <p>Doctor of Medicine, MD thesis on "Melatonin and Cortisol as Indices of Noradrenergic Function and Circadian Rhythm in Anorexia Nervosa and Bulimia Nervosa". Queen's University Belfast
 Diploma in Psychiatry, University of Toronto
 Licentiate of the Medical Council of Canada
 FRCPC
 MRC Psychiatry, (UK)
 MB, BCh, BAO</p> |
|---|--|

III. AWARDS

- | | |
|---|---|
| <p>2016
2010
2006
2004
2003
1990

1989
1988
1983
1981</p> | <p>Fellow of Canadian Academy of Health Sciences (CAHS)
 Hope Award from the Mood Disorders Association of Ontario
 Gold Medal recipient of the Canadian College of Neuropsychopharmacology
 JM Cleghorn Award for Excellence and Leadership in Clinical Research, CPA
 European College of Neuropsychopharmacology, Corresponding Member
 Recipient of American Psychiatric Association, Hospital and Community Psychiatry Achievement Award with Eating Disorder Group, The Toronto Hospital
 R.O. Jones Award for Best Paper, Canadian Psychiatric Association
 Robin Hunter Award for Excellence in Clinical Teaching
 McLaughlin Award for Diploma Thesis in Psychiatry
 Pfizer Prize, Research Day Award, University of Toronto</p> |
|---|---|

IV. APPOINTMENTS

i. Hospital

2017	Research Director, Mental Health and Addictions Service
2014-	Scientist, Li Ka Shing Knowledge Institute, St. Michael's Hospital
2014-	Staff Psychiatrist, University Health Network and St. Michael's Hospital
2014 -	Senior Scientist, Krembil Neuroscience, Toronto Western Research Institute
2002-	Consultant Psychiatrist, Centre for Addiction and Mental Health
2002- 2013	Psychiatrist-in-Chief, University Health Network
1999-2002	Director of Clinical Research, CAMH
1998-2002	Clinical Director, Mood & Anxiety Disorders Program, Centre for Addiction and Mental Health (CAMH).
1994-2002	Consultant Psychiatrist, The Toronto Hospital
1994-1998	Division Head, Mood and Anxiety Division, Clarke Institute of Psychiatry
1990-1994	Director, Mood Disorder Clinic, The Toronto Hospital
1989-1994	Research Director, Department of Psychiatry, The Toronto Hospital
1989-1994	Head, Programme for Eating Disorders, Toronto General Hospital
1982-1989	Staff Psychiatrist, Head of Affective Disorder and Nutrition Service, Toronto General Hospital
1981-1994	Consultant Psychiatrist, Clarke Institute of Psychiatry
1981-1982	Staff Psychiatrist, Homewood Sanitarium, Guelph, Ontario

ii. University of Toronto

2014-	Arthur Sommer Rotenberg Chair in Suicide and Depression Studies
1999-2002	Cameron Wilson Chair in Depression Studies
1996-	Member, Program in Neuroscience
1994-2001	Programme Head, Mood Disorders
1994-	Professor of Psychiatry
1993-1998	Graduate Faculty, Department of Nutritional Sciences
1992-	Member, Institute of Medical Science, School of Graduate Studies
1991-1994	Programme Head, Psychosomatic Medicine
1988-1994	Associate Professor, Department of Psychiatry
1987	Visiting Associate, University of London, Institute of Psychiatry
1983-1988	Assistant Professor, Department of Psychiatry
1981-1983	Lecturer in Psychiatry
1980-1981	Clinical Fellow in Psychiatry

iii. York University

1992-2002	Adjunct Faculty Member, Faculty of Graduate Studies
-----------	---

V. COMMITTEES

i. University of Toronto

2014 -	Senior Promotions Committee Member
2009	Search Committee, Cameron Wilson Chair, Department of Psychiatry
2005-2010	Appointments Committee, Department of Psychiatry
2004	Program Review Committee – Geriatric Psychiatry
1998	Search Committee Member, Program Head, Anxiety Disorders
1998	Search Committee Member, Program Head, Addiction Psychiatry
1997	Department of Ophthalmology Resident Selection Committee
1997-1999	Decanal Committee
1997	Search Committee Member, Program Head, Women's Mental Health
1997-1998	Search Committee Member, Program Head, Psychopharmacology

1997	Member, 5-year Review Committee, Department of Psychiatry, Sunnybrook Health Sciences Centre
1991-1993	Implementation Committee, Department of Psychiatry
1991-2013	Senior Advisory Committee, Department of Psychiatry
1988-1994	Research Executive Committee
1985-1987	Psychiatry Research Committee, Department of Psychiatry
1984-1986	Faculty of Medicine, Member of Faculty Council
1983	Academic Promotion Committee, Department of Psychiatry

ii. University Health Network (including The Toronto Hospital)

2010-2013	Senior Management Team
2002-2013	Medical Advisory Committee
2002-2013	Toronto Western Hospital Executive Advisory Council
1992-2013	Research Review Committee
1991-1994	Fiscal Advisory Committee
1990-1994	Department of Psychiatry, Executive Committee
1990-1994	Clinical Investigation Unit Users Committee
1985-1994	Eating Disorder Community Advisory Committee
1984	Neurosciences Committee
1983-1989	Pharmacy and Therapeutics Committee
1983-1984	Geriatric Committee

iii. Clarke Institute of Psychiatry/Centre for Addiction and Mental Health

1998-2002	Medical Advisory Committee
1997	Clarke Institute/Queen Street Mental Health Centre - Single Centre Proposal Governance Subcommittee
1994-1998	Research Executive Committee
1994-1998	Research Advisory Committee
1994-1998	Medical Staff Association
1994-1998	Medical Advisory Committee
1994-1998	Budget and Planning Committee
1994-1995	Clinical Advisory Committee

iii. Other

2015 – 2016	Co-Chair, CANMAT 2015 Depression Guidelines Update
2015 – 2016	Committee Member – Health Quality Ontario Depression Quality Standards Expert Panel
2015-	ISCTM Suicidal Ideation and Behaviour Workgroup on Trial Design and Methodology
2014 -	Co-Lead, Ontario Depression Network Hub (Canadian Depression Research Network)
2013	Co-Chair, CANMAT 2013 Bipolar Guidelines Update
2010-2014	Member American College of Neuropsychopharmacology Public Information Committee
2009	Co-Chair - Bipolar Disorder Guidelines, CANMAT
2009	Co-Chair - Depression Guidelines, CANMAT
2008-2013	Data Safety Monitoring Board, Member – Deep Brain Stimulation RCT (US 5 site study)
2006-	World Federation of Societies of Biological Psychiatry – Committee on Media Communication
2005-	The International Society of CNS Clinical Trials and Methodology (ISCTM) - Member
2004-2005	Co-Chair Bipolar Guidelines Work Group. CANMAT
2004-2005	Data Safety Monitoring Committee – Atypical antipsychotics in continuation and maintenance after an acute manic episode – CIHR Bipolar Consortium

2002-2005	Drug Safety Monitoring Board – Randomized Placebo Control Trial of Fluoxetine in Anorexia Nervosa - NIMH Trial
2002-present	Chair, Depression Working Group, Canadian Network for Mood and Anxiety Treatments CANMAT
2000-2001	Co-Chair, Depression Guidelines Work Group. CANMAT
1998-	International Scientific Advisory Board for Treatment of Bipolar Disorder
1998-	International Faculty of the Lundbeck International Neuroscience Foundation
1996-	Executive Chair and Founding Member. Canadian Network for Mood and Anxiety Disorders Treatment (CANMAT)
1991-1994	Genesis Foundation, Eating Disorder Advisory Board
1989-1998	Secretary Treasurer, Royal College of Psychiatrists, (North American Chapter)
1985	Canadian Psychiatric Research Foundation, Liaison Committee
1984-1985	Expert Advisory Committee on Psychotropic Drugs-Amphetamine Congeners. Health and Welfare Canada

v. Granting Agencies

2015 -	Royal-Mach-Gaensslen Prize Adjudicator (Royal Ottawa Hospital)
2013	National Institute of Mental Health, Interventions Committee for Adult Disorders
2012-	Pfizer, Psychiatry Research Awards Committee
1998, 1999, 2014	Medical Research Council of Canada - Behavioural Sciences "B" Committee Member
1995-1998	Canadian Psychiatric Research Foundation - Professional Advisory Board: Chair
1993-1995	Canadian Psychiatric Research Foundation - Professional Advisory Board: Vice Chair

vii. Conference Organization

2016	Co-Chair, CANMAT – University of Toronto Psychopharmacology Day, November 2016.
2015 -2016 2014	Co-Chair, Joint ISAD/ISBD International Conference, Amsterdam International Society of Affective Disorder, 6 th Biennial International Conference, Berlin, Germany. April 28-30, 2014. Organizing Committee & Scientific Committee.
2013	International Society of Affective Disorder Satellite Symposium, Hong Kong, November 2013.
2013	Canadian Network for Mood and Anxiety Treatments - Joint International Conference of Mood and Anxiety Disorder, Dubai. Organization Committee, April 2012.
2012	International Society of Affective Disorder, 5 th Biennial International Conference, London, UK. Organization Committee, April 2012.
2008	Organizing Committee Chair, Canadian College of Neuropsychopharmacology Annual Meeting, Toronto, June 2008.
2005	Mood and Anxiety Forum. CANMAT Update Program in 5 cities across Canada.
1999 - 2000	Executive Chair, Mood Fair 2000. Developed and delivered by CANMAT in Toronto, Montreal, Halifax and Vancouver.
1997	Canadian College of Neuropsychopharmacology (CCNP). Toronto, June 2-5. Organizing Committee Member.
1996	Conference on Relapse Prevention in Depression. Toronto, June 1. Co-chair of organizing committee with Dr. Z. Segal.
1990	Bristol Myers Squibb/Mead Johnson Symposium. The Biology of Feast and Famine: Relevance to Eating Disorders. Toronto, October 10-11. Co-chair of organizing committee with Dr. G.H. Anderson.
1990	Canadian Psychiatric Research Foundation. Conference on Nutrition and Mental Health. Toronto, August 2-3. Organizing Committee.

VI. PROFESSIONAL ASSOCIATIONS

2016 – Present.	Fellow, Canadian Academy of Health Sciences
2015 – Present.	Fellow, American College of Neuropsychopharmacology
2012 – Present.	Distinguished Fellow, Canadian Psychiatric Association
2008 – Present.	Fellow, Canadian Psychiatric Association
2007 – Present.	International Society for Affective Disorders (Past President)
2005 – Present.	Distinguished Fellow, American Psychiatric Association
2005 – Present.	American College of Neuropsychopharmacology
1997 – Present.	European College of Neuropsychopharmacology
1989 – Present.	Canadian College of Neuropsychopharmacology (Past President)
1989 – Present.	International College of Neuropsychopharmacology
1987 – Present.	Biological Psychiatry
1980 – Present.	Royal College of Physicians and Surgeons of Canada
1980 – Present.	Member, Canadian Psychiatric Association
1980 – Present.	Member, American Psychiatric Association
1979 – Present.	Royal College of Psychiatry (UK)

i. Executive Roles

2012-	Executive Chair, Canadian Biomarker Integration Network in Depression
2010-2014	President, International Society for Affective Disorders
2009-2010	President-Elect, International Society for Affective Disorders
2005-	Chair, Depression Work Group, Canadian Network for Mood and Anxiety Treatments.
2004-2006	Past-President – Canadian College of Neuropsychopharmacology
2002-2004	President – Canadian College of Neuropsychopharmacology
2000-2002	President - Elect Canadian College of Neuropsychopharmacology
1998-2000	Vice-President - Canadian College of Neuropsychopharmacology

- 1997-2002 Member, Task Force/Special Committee on Clinical Practice Guidelines, Canadian Psychiatric Association
- 1997-2002 Canadian Psychiatric Association - Research Network Advisory Committee Member
- 1995-2005 Founding Member and Executive Chair, Canadian Network for Mood and Anxiety Treatments (CANMAT)

VII. External/JOURNAL AD HOC REVIEWER

- 2017 World Journal of Biological Psychiatry, Journal of Affective Disorders, Therapeutic Advances in Psychopharmacology, Journal of Clinical Psychiatry (2), Journal of Neuropsychopharmacology, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, Journal of Psychopharmacology, Neuropsychiatric Disease and Treatment
- 2016 Journal of Psychopharmacology, Journal of Affective Disorders (2), Current Opinion in Psychiatry, Nature Reviews Disease Primers, Frontiers Psychiatry, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, American Journal of Psychiatry, Canadian Journal of Psychiatry, Psychiatry Research.
- 2013 Canadian Institutes for Health Research, Adhoc reviewer.
- 2013 Interventions Committee for Adult Disorders – NIMH’s Standing Committee
- 2012 Canadian Institutes for Health Research, Adhoc reviewer.
- 2008 Canadian Institute for Health Research
- 1998 Canadian Pharmacists Association (CPS)
- 1995-2000 Medical Research Council of Canada
- 1994-Current Primary Care Psychiatry, Editorial Board
- 1992 Ontario Ministry of Health, Health Research Personnel Award, Career Scientist Application
- 1991 Bickel Foundation, University of Toronto
- 1987-1990 Physicians Services Incorporated
- 1985-1990 Ontario Mental Health Foundation
- 1984-1996 Canadian Psychiatric Research Foundation

VIII.EDITORIAL BOARDS

- 2014- Current Opinion in Psychiatry, Section Editor Mood and Anxiety Disorders
- 2013- Journal of Clinical Psychopharmacology
- 2011- World Journal of Psychiatry
- 2009- Journal of Affective Disorders
- 2009- World Journal of Biological Psychiatry
- 2005- Psychiatry
- 2004- Neuropsychiatric Disease and Treatment
- 2004-2008 Journal of Psychiatry and Neuroscience
- 2004- Current Psychiatry Reports
- 2001-2009 Acta Neuropsychiatrica
- 1996-2006 Journal of Primary Care Psychiatry
- 1996-2000 Neurosciences in Psychiatry - Focus on Serotonin

IX. TEACHING

i. Postgraduate

- | | | |
|-----------|-----------|--|
| 1999-2012 | PG-Year 5 | UWO Annual Postgraduate Review Course – “Mood Disorders” |
| 1996-2007 | PG-Year 2 | Biology and Depression |
| 1994-2007 | PG-Year 1 | Psychobiology of Mood Disorders |
| 1991- | PG-Year 1 | Rational Use of Antidepressants |
| 1990-1994 | PG-Year 2 | Eating Disorders |
| 1989-1990 | PG-Year 1 | Coordinator: Lecture Series in Affective Disorders |

1983	PG-Year 1	Research Strategies in Affective Disorders
1983-1990	PG-Year 1	Etiology of Affective Disorders
ii. Undergraduate		
2016, 2017		Integrative models for Complex Illnesses (PCL345H course) - Ana Andrezza
1992-1994		Summer Scholarship Program Supervisor in Eating and Mood Disorders
1990-1992		PG-Year 3 Clinical Therapeutics, Management of Depression
iii. Seminars		
2012, 2013, 2015		Neuroscience School of Advance Studies, 1 Week Course Leader, Italy
1997-		Lundbeck International Neuroscience Foundation, Faculty Member
1983-1987		Clinical Interviewing Seminars for Y1 and Y2 Medical Students
1984-1989		Weekly Seminars on Current and Historical Papers in Psychiatry for Senior Residents Preparing for Fellowship Examination
iv. Clinical		
1982-1994		Responsible for Supervision of Two Psychiatric Residents Each Year
1982-1985		Responsible for Supervision of Rotating Interns in Psychiatry
1982-1993		Responsible for Supervision of Clinical Clerk on monthly basis
1982-1994		Responsible for Teaching Y3 Medical Students
v. Supervision of Fellows and Graduate Students		
2016-	Dr. Venkat Bhat - Fellow	Department Of Psychiatry
2016-	Ms. Tian Renton - PhD	Institute of Medical Sciences
2015-	Ms. Amanda Ceniti - MSc	Institute of Medical Sciences
2015-	Dr. Maryam Ibrahim - Fellow	Department of Psychiatry
2014-	Ms. Laura Schulze - PhD (in progress)	Institute of Medical Sciences
2013-2015	Dr. Shane McInerney - Fellow	Department of Psychiatry
2012- 2014	Ms. Trehani Fonseka - MSc	Institute of Medical Sciences
2012- 2014	Dr. Joseph Geraci - Fellow	Department of Psychiatry
2009-2011	Dr. Joanna Mansfield - MSc	Department of Psychiatry
2007-2008	Dr. Maria Lourenco - Fellow	Department of Psychiatry
2006-2014 ^{ce}	Dr. Sakina Rizvi - PhD	Pharmaceutical Sciences
2006-2014	Dr. Joanna Soczynska - PhD	Institute of Medical Sciences
2006-2007	Dr. Lakshmi Ravindran - Fellow	CIHR Fellowship
2002-2009	Ms. Beverley Bouffard - PhD	York University
2003-2009	Mr. Jakub Konarski PhD	Institute of Medical Sciences
2003-2005	Dr. Henry Moller - MSc	CIHR Fellowship/Institute of Medical Sciences
2001-2003	Dr. Saulo Castel	CIHR Fellowship
1999-2000	Dr. Stephanie Krüger (Fellow)	CAMH Fellowship
1998-2000	Dr. Jeff Meyer - PhD.	MRC Fellow/Institute of Medical Sciences
1998-2000	Dr. Roger McIntyre (Fellow)	GSK Mood Disorders Fellowship
1997-2000	Ms. Nicole Cohen - MSc.	York University
1997-2000	Dr. Hyob Sun Kim	Visiting Fellow, Korea
1996-1998	Mr. Mahan Javanmard - MSc.	Institute of Medical Sciences
1995-1998	Mr. David Rose - Msc.	Nutritional Sciences
1993-1997	Ms. Patricia Case - MSc.	Nutritional Sciences
1992-1998	Dr. Rajamannar Ramasubbu - MSc.	Institute of Medical Sciences
1991-1993	Dr. Jennifer Shaw	
1991-1993	Ms. Christine Ford MHK	
1989-1991	Dr. Richard Black	
1989-1990	Dr. Jacqueline Duncan	
1987-1988	Dr. Nick Arrizas	

1986-1987 Dr. Victor Parienti
1985-1986 Dr. Daniel Costa

vi. Committee Member for Graduate Student

2016	Troy Chow, MSc	Institute of Medical Sciences
2015	Laura Schultze, PhD	Institute of Medical Sciences
2014	Alexander Morzycki, MSc	Institute of Medical Sciences
2009	Joanna Mansfield, MD	Resident, Clinician Scientist Stream, MSc Clinical Epidemiology
2006-2012	Beata Eisfeld, MSc.	Faculty of Pharmaceutical Sciences
2005-2009	Dr. Kevin Chopra - PhD	CIHR Fellowship
2003	Nadine Gagnon MSc.	Institute of Medical Sciences
1999-2002	Lakshimi Voruganti PhD	Institute of Medical Sciences
1999-2000	Celia Lourand PhD	Department of Pharmacology
1997-1999	Sue Gilbert Evans MSc	Institute of Medical Sciences
1995	Christina Neitzert - MSc.	York University
1995-1998	Allison Potts - PhD.	Department of Psychology
1994-1996	Evelyn Lambe -MSc.	Institute of Medical Sciences
1992-1996	Mary Jane Esplen - PhD.	Institute of Medical Sciences
1992-1994	Janet de Groot - MSc.	Institute of Medical Sciences
1992	Peggy Richter - MSc.	Institute of Medical Sciences
1992	Stephen Sokolov - PhD.	Institute of Medical Sciences
1990-1995	Joanne Runions - PhD.	Institute of Medical Sciences

vii. External Examiner

1995	Kevin McKenna - MD, PhD.	University of Alberta
1995	Marta Biernacka - MSc.	Nutritional Sciences
1993	Terrence Sills - PhD.	Department of Psychology
1992	David Feifel - PhD.	Department of Psychology

Summary of Research Directions and Leadership

- Functional Neuroimaging and antidepressant treatment:** The first publication illustrates the use of Positron Emission Tomography (PET) to distinguish between depressed patients and healthy controls, and between depressed and remitted patients. The second and third publications illustrate similarities and differences in brain regions following response to pharmacotherapy and psychotherapy, as well as an evaluation of baseline predictors of response to both treatments.

Kennedy SH, Evans K et. al. Changes in regional glucose metabolism with positron emission tomography following paroxetine treatment of major depression. *Am J Psychiatry*. 2001;158:899-905.

Kennedy SH, Konarski JZ, et. al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. *Am J Psychiatry*, 2007; 164:778-788.

Konarski JZ, Kennedy SH, et. al. Predictors of nonresponse to cognitive behavioral therapy or venlafaxine using glucose metabolism in major depressive disorder. *J Psychiatry & Neurosci*. 2009; 34:175-180.
- Neurostimulation and Treatment Resistant Depression :** Functional neuroimaging advances have facilitated targeted neurostimulation interventions including Deep Brain Stimulation (DBS) for treatment resistant depression. I have been the lead psychiatrist within the DBS program for psychiatric indications at UHN since 2003. I have also led guideline initiatives for depression treatment including neurostimulation.

Mayberg HS, Lozano AM, Voon V, McNeeley HE, Seminowicz D, Hamani C, Schwab JM, Kennedy SH. Deep brain stimulation for treatment resistant depression. *Neuron*, 2005; 45:651-660.

Kennedy SH, Giacobbe P et. al. Deep brain stimulation for treatment resistant depression: follow-up after 3 to 6 years. *Am J Psychiatry*, 2011; 168:502-10.

Kennedy SH, Milev R et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the management of major depressive disorder in adults. IV. Neurostimulation Therapies. *J Affect Disord*. 2009; 117:S44:S53.

3. **Clinical trials and scale development:** I have led national and international clinical trials to evaluate new antidepressants and developed rating scales to evaluate antidepressant side effects and sexual dysfunction. My collaboration with Michael Thase resulted in a metaanalysis of escitalopram efficacy and the application of a novel statistical approach to compare antidepressant and placebo effects across individual patients. A new scale to evaluate anhedonia has been developed as part of Sakina Rizvi's PhD thesis and is currently under review. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. *Curr Med Research & Opinions* 2009;25:161-175
Thase ME, Larson KG, Kennedy SH. Assessing the true effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. *Br J Psychiatry*, 2011; 199:501-507.
Kennedy SH, Rizvi SJ et. al. The sex effects scale: validation in a healthy population. *Psychopharmacol Bull* 2010; 43:15-25.
4. **Guidelines development and dissemination:** As the founding chair of Canadian Network for Mood and Anxiety Treatments (CANMAT), I have been responsible for the initiation and continuation of guideline development in both major depressive disorder (MDD) and bipolar disorder (BD) including 2009 guidelines for the management of MDD and the guidelines for BD. Updated in 2013.
Kennedy SH, Lam RW, et. al, Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. *J Affect Disord*. 2009; 117:S1-S2.
Yatham LN, Kennedy SH et. al, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. *Bipolar Disord*. 2013;15:1-44.
5. **Canadian Biomarker Network for Depression (CAN-BIND):** I am the Principal Investigator for the clinical and research operations of CAN-BIND, the first and largest mood disorders research network involving 6 major research centres across Canada. This project aims to integrate clinical, imaging and molecular markers to identify key signatures of treatment response across a broad range of interventions.

XI. RESEARCH GRANT SUPPORT

1. Kennedy SH, Soares C. CAN-BIND Cares: Prevention and Self-Management of Depression in the Digital Age. Ontario Research Fund - Research Excellence (ORF-RE). \$1,000,000. 2016-2018.
2. Wen XY, Kennedy SH, Foster J, Rizvi SJ. Development of zebrafish models for treatment resistant depression. *Neuroscience Catalyst*. \$250,000. 2016-2018.
3. Rizvi SJ, Foussias G, Pizzagalli DA, Harmer CJ, McIntyre RS, Schweizer T, McInerney, SJ, Kennedy SH. A dimensional approach to evaluate reward processing in major depressive disorder before and after treatment with desvenlafaxine. Pfizer Canada Major Depressive Disorders Research Award. 2016-2018. \$100,000.
4. Rizvi SJ, McInerney S, Kennedy SH. An investigation of biological markers of suicidality. Canadian Biomarker Integration Network for Depression Pilot Project Funding. \$129,690. 2015-2016.
5. Hatcher S, Heisel M, Links P, Wilkins C, Schaffer A, Raimundo A, Sidahmed A, Thavorn K, Corsi D, Lavis J, Neufield E, Rizvi S, Colman I, Sinyor M, Marlin S, Mushquash C, Schellenberg M, Campbell JK, Kennedy SH. Suicide prevention in men: A cluster randomized control trial of smartphone assisted problem solving therapy compared to usual care in men who present with intentional self-harm to emergency departments. SPOR. \$1.85M CDN. 2015-2018.
6. Grigoriadis S, Bazinet R, Levitt A, Guyatt G, Kennedy SH, Dennis CL, Steiner M, Barrett J, Kiss A, Cheung A, Vigod S, Dalfen A. Prevent REcurrence of depression in mothers Vulnerable and ExpectaNT with omega 3 fatty acids: The PREVENT Trial Pilot. Canadian Institutes of Health Research (CIHR), Operating Grant - Transitional Operating Grant. CDN 482,492. 2015-2017.
7. Daskalakis, Z (PI), Blumberger D, Downar J, Honey C, Kennedy SH, Lam R, Rajji T, Turecki G, Vila-

- Rodriguez F, Voineskos A. Canadian rTMS Treatment and Biomarker Network in Depression (CARTBIND) Trial. Brain Canada Multi-Investigator Research Initiative (MIRI). CDN \$1.5M. 2015-2018.
8. Wen, XY (PI), Anderson R, Baker A, Brotchie J, Drapeau P, Gerlai R, Kennedy SH, Macdonald L, Wang A, Zoidl G. Z-BRAIN: A Zebrafish Drug Screening Platform Targeting Brain Disorders. Brain Canada Platform Support Grant (PSG) CDN \$2,600,000. 2015-2018.
 9. Addington J (PI), Bray S, Downar J, Goldstein B, Kennedy SH, Lebel C, McQueen G, Wang J. Adolescent Mental Health: Canadian Psychiatric Risk and Outcome Study (PROCAN). Ontario Brain Institute (OBI). CDN \$1.5M. 2015-2017.
 10. Kennedy SH, Rizvi SJ (co-PI). Meeting of the International Neurobiological Suicide Network. Ontario Brain Institute, Event Funding Award. \$4,900. 2015-2016.
 11. Downar J (PI), Blumberger DM, Daskalakis ZJ, Giacobbe P, Kennedy SH, Lam RW, Vila-Rodriguez F. Identifying fMRI and clinical predictors of treatment outcome for conventional and theta-burst repetitive transcranial magnetic stimulation in major depressive disorder. Canadian Institutes of Health Research, CDN \$151,663 per annum. 2014-2018.
 12. Kennedy SH (PI), Parikh SV. Ontario Depression Network: A CANMAT-CDRIN Collaboration to Enhance Patient Care, Research and Knowledge Translation. \$82,000. 2014-2015.
 13. Bartel L, Alter D, Chen R, Davis KD, Evans MJ, Freedman M, Gordon A, Kennedy SH, Lozano A, Renwick R, Ross, B. Music Medicine in Neuro-Rehabilitation: Foundations and Applications of Sound Stimulation. Connaught Foundation. \$100,000. 2014-2016.
 14. Kennedy SH (PI), MacQueen GM, Downar J, Evans K, Flint A, Frey B, Geraci J, Giacobbe P, Harkness K, Hassel S, Lam R, Liotti M, McIntyre R, Milev R, Minuzzi L, Parikh SV, Ravindran A, Salomons T, Turecki G, Young L. Predicting antidepressant treatment response in major depressive disorder: Canadian Biomarker Integration Network for Depression. Ontario Brain Institute (OBI). CDN\$12M + \$6M (Matching) 2013-2017.
 15. Kennedy SH (co-PI), MacQueen GM (co-PI), Downar J, Evans K, Flint A, Frey B, Geraci J, Giacobbe P, Harkness K, Hassel S, Lam R, Liotti M, McIntyre R, Milev R, Minuzzi L, Parikh S, Ravindran A, Salomons T, Turecki G, Young L. Predicting antidepressant treatment response in major depressive disorder: An integrated clinical and neuroimaging approach. Canadian Institutes of Health Research, CDN \$893,950. 2013-2017.
 16. Kennedy SH (PI), Giacobbe P, Styra R, Sinha S. A multicentre randomized double-blind active controlled study of the efficacy and safety of flexibly-dosed BMS-820836 in patients with treatment resistant major depression. Bristol-Myers Squibb Canada Co., CDN \$150,000. 2011-2012.
 17. Kennedy SH (PI), MacQueen, G, Lam, R, Milev, R, Soares, C, - Co-Investigators: Predicting antidepressant treatment response in major depressive disorder: An integrated clinical and neuroimaging approach. Ontario Brain Institute (OBI) \$150,000. Start up funding. June 2012-June 2013.
 18. Kennedy SH (PI). "CANMAT Biomarker Network" - Meetings. Planning and Dissemination Grant Institute of Neuroscience and Mental Health and Addiction; CIHR \$9,250. 2011.
 19. Kennedy SH (PI), Lam RW, MacQueen G, Soares C, Milev R, - Co-investigators: CANMAT Biomarker Network: Neuroimaging, molecular and clinical markers for diagnosis and treatment prediction in MDD and BD. Lundbeck. \$2.7 M. 2011-2016.
 20. Kennedy SH (PI), Giacobbe P, Styra R. A pilot placebo controlled, double-blind, randomized parallel group study to evaluate the efficacy of treatment with CLR3001 in depression. Clera Inc. \$103,000. 2010-2012.

21. Kennedy SH (PI), Lozano A, Giacobbe P, Krahn M. Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression: A double blind sham controlled trial. St. Jude's Medical - \$959,000. 2011-2014.
22. Grigoriadis SH, Barrett J, Bazinet R, Cheung A, Dennis C-L, Kennedy SH (CI), Kiss A, Levitt A, Soares C, Steiner M. Can fish oil a day keep depression away? The effectiveness of fish oil in preventing postpartum depression in mothers at high risk. Canadian Institutes of Health Research (CIHR) Omega RCT Grant. Oct 2010 – Oct 2015. \$559,538.
23. Lam RW, Parikh SV, Kennedy SH (CI). "A Randomized Controlled Trial of Escitalopram and Telephone-Based Cognitive Behaviour Therapy in Working People with Major Depressive Disorder. Lundbeck AS. 2008-2010. \$503,750.
24. Kennedy SH (PI), Styra R, Giacobbe P. A randomised double blind parallel group, placebo controlled, fixed dose study evaluating the efficacy and safety of orvepitant in subjects with major depressive disorder. GlaxoSmithKline, October 2009-2010. \$50,000.
25. Mansfield J, Cheung A, Kennedy SH (CI), Grigoriadis S, Tomlinson G. Serum Estradiol and Health Related Quality of Life in Healthy Postmenopausal Women Participating in a Breast Cancer Prevention Study: A Cross-Sectional Study. UHN Dept of Psychiatry Research Competition. September 2009-2010. \$14,920.
26. Giacobbe P, Daskalakis ZJ, Hamani C, Lozano AM, Parikh S, Ritvo P, Kennedy SH. Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression: Long-term Clinical Follow-up and Exploration of Mechanism of Action through Quantitative Electroencephalography. UHN Dept of Psychiatry Research Competition. September 2008- 2009. \$15,000.
27. Kennedy SH (PI), Giacobbe P, McIntyre R. A 6-Week Randomised Double-Blind Placebo-Controlled Study of BCI-540 80 mg q.d. and 80 mg t.i.d. in the Treatment of Adults with Major Depressive Disorder and Concomitant Anxiety (the "Protocol"). Brain Cells Inc. 2008-2009. \$90,000.
28. Kennedy SH (PI), Lozano AS. A pilot study for the management of patients with chronic or recurrent treatment resistant major depressive disorder. Advanced Neuromodulation Systems Inc. 2006-2008. \$141,603 .
29. Ravindran LN, Kennedy SH. Effect of treatment with two classes of antidepressants on neural circuitry and memory. Wyeth Pharmaceuticals and the Canadian Institutes of Health Research (CIHR). 2006-2008. \$45,000 per annum.
30. Kennedy SH (PI), Grigoriadis S, Styra R. A multi-centre, double blind, randomised, parallel group, placebo-controlled and active controlled phase III study of the efficacy and safety of quetiapine SR as monotherapy in the treatment of adult patients with major depressive disorder. AstraZeneca. 2006-2007. \$114,000.
31. Kennedy SH (PI), McIntyre RS, O'Donovan C, Milev R, Bisslerbe J-C, Zimmerman M, Le Melleo JM. Frequency and correlates of gambling problems in depressed and bipolar patients. Ontario Problem Gambling Research Centre. 2006-2007. \$208,950.
32. Grigoriadis S, Kennedy SH, Levitt AJ. Developing randomized controlled trials for women with postpartum depression – CIHR mentoring program. 2006-2008. \$160,000.
33. Kennedy SH (PI), Bouffard, B. Memory functioning and antidepressant treatment: A randomized controlled trial comparing escitalopram and bupropion XL. GlaxoSmith Kline (GSK) USA. 2005-2007. \$88,000 USD.
34. McIntyre RJ, Kennedy SH, Lewis G, MacQueen G. The cognitive enhancing effects of intranasal insulin in euthymic bipolar patients. Stanley Medical Research Institute. 2005-2007. \$425,000 USD.

35. Grigoriadis S, Kennedy SH. The effects of the menstrual cycle on the symptoms of depression and antidepressant blood levels: A comparison of premenopausal, perimenopausal and postmenopausal women. C.R. Younger Foundation. 2005-2006. \$20,000.
36. Kennedy SH (PI), Grigoriadis S, Srinivasan J, Panjwani G. Duloxetine in the treatment of melancholic depression: An 8-week open-label dose study. Eli Lilly Canada. 2004-2005. \$100,670.
37. Kennedy SH (PI), Eisfeld BS, Fulton K. Development and validation of a computer administered version of the Montgomery-Asberg Depression Rating Scale using interactive voice response. Health Technology Systems Inc. 2004, US\$25,400.
38. Moller, H, Kennedy SH, Shapiro CM. A randomized double blind prospective study of cognitive and psychomotor performance measured using a computerized driving simulator in patients with major depressive disorder treated with mirtazapine and venlafaxine. Neurosciences, Mental Health and Addiction & Wyeth Pharmaceuticals, Quebec – CIHR/Rx & D Research Program – Fellowships. 2004-2005. \$55,000.
39. Grigoriadis S, Kennedy SH. Depression in women. C.R. Younger Foundation. 2004-2005. \$20,000.
40. Kennedy SH (PI), Grigoriadis S, Brook S. A 6-week, randomized, double-blind, parallel group, active-and placebo-controlled trial to assess the efficacy of R228060 in adult subjects with major depressive disorder (MDD). Janssen-Ortho Inc. 2003-2004. \$238,560.
41. Kennedy SH (PI), McIntyre RS, Srinivasan J. An 8-week, randomized, double-blind, parallel-group, placebo-controlled, multicenter, fixed dose study comparing the efficacy and safety of GW5975998 or paroxetine to placebo in moderately to severely depressed patients with major depressive disorder. GlaxoSmithKline. 2002-2003. \$101,088.
42. McIntyre, RS, Kennedy SH. The validation of the abbreviated Hamilton Depression Rating Scale in Primary Care Practice. Wyeth/PREN. 2002-2004.
43. Grigoriadis S, Kennedy SH. Depression in women. C.R. Younger Foundation. 2002-2003. \$30,000.
44. Mayberg HS, Lozano A, Kennedy SH. Deep brain stimulation for refractory depression. National Alliance for Research in Schizophrenia and Affective Disorders. 2002-2005 US\$99,979.
45. Kennedy SH (PI), Grigoriadis S. Reproductive biology and depression in post menopausal women. Younger Foundation. 2001-2002. \$20,000.
46. Kennedy SH (PI), McIntyre RS, Grigoriadis S. A double blind multi-centre placebo and active controlled acute and extension study of 2 doses of MK-0869 in the treatment of patients with major depressive disorder. Merck Frosst. 2001-2003. \$121,564.
47. Segal Z, Gemar M, Kennedy SH. Predicting depressive relapse through cognitive changes following mood challenge. 2002-2005. Canadian Institutes of Health Research. \$58,703 per annum.
48. Kennedy SH (PI), McIntyre RS, Grigoriadis S. A parallel group, multicentre flexible dose study with a double-blind, randomized, placebo-controlled phase and an open-label phase to evaluate the efficacy and safety of Viagra® (Sildenafil Citrate) in males with serotonergic antidepressant associated erectile dysfunction. 2001-2002. Pfizer. \$33,600 USD.
49. Kennedy SH (PI), Levitan R, Srinivasan J. A double-blind, multicentre, randomized, placebo-controlled, parallel group study of efficacy and safety of Org 33062 ER and paroxetine in subjects who suffer from major depressive disorder. 2001-2002. Organon. \$357,000 USD
50. Kennedy SH (PI), Levitan R, Srinivasan J. A double-blind, multicentre extension trial in subjects who suffer from major depressive disorder with atypical features who participate in the placebo and paroxetine

- controlled study of Org 33062 ER. 2001-2003. Organon. \$257,040 USD.
51. Mayberg HS, Kennedy SH, Segal ZV. Limbic-cortical metabolic changes as a final common pathway of depression remission: A comparison of Venlafaxine and Cognitive Behavioural Therapy. 2001-2004. CIHR. \$129, 124
 52. Kennedy SH (PI), McIntyre RS, Cooke R, Srinivasan J. A multicentre, double-blind, randomized sertraline-controlled efficacy and safety with mirtazapine (remeron ®) in subjects with a major depressive disorder (according to DSM-IV criteria). 2001-2001. Organon. \$52,000
 53. Kennedy SH (PI), McIntyre RS, Cooke R, Srinivasan J. The efficacy, safety and tolerability of robalzotan in patients with major depressive disorder. A paroxetine and placebo controlled 8-week study. 2000-2001. AstraZeneca. \$230,000.
 54. McIntyre RS, Kennedy SH, Cooke R, Srinivasan J, Parikh S. Estimating the metabolic and reproductive endocrine effects of divalproex in females with Bipolar Disorder/add on. 2000-2001. Glaxo-Wellcome. \$10,000
 55. McIntyre RS, Kennedy SH, Cooke R, Srinivasan J, Parikh S. A placebo-controlled trial assessing the efficacy and safety of venlafaxine in bipolar depression. 2000-2001. Wyeth-Ayerst. \$150,000
 56. Meyer JH, Kennedy SH. 5-HT2A receptors in suicidality and impulsivity. 2000-2003. CIHR. \$58,000/yr.
 57. Cooke R, Kennedy SH. Utility & quality of life assessment in depression pilot phase. Innovus Inc. \$9,000
 58. Cooke R, Kennedy SH. The economic evaluation of reboxetine using conjoint analysis in patients with Major Depressive Disorder. 2000-2000. Innovus Inc. \$17,000
 59. Cooke R, Kennedy SH. A multicenter, pivotal, safety and efficacy study of the neurocybernetic prosthesis (NCR) system in patients with depression. 2000-2002. Cyberonics. \$52,000 USD
 60. Segal Z, Gemar M, Kennedy SH. Predicting depressive relapse through cognitive changes following mood challenge. 1999-2001. Medical Research Council of Canada. \$75,004
 61. Kennedy SH (PI), McIntyre RS, Cooke R. An 8-week randomized double blind placebo controlled parallel group efficacy and safety trial of flibanserin and paroxetine in titrated dosages in outpatients with major depressive disorder. (511.42) 1999-2000. Boehringer Ingelheim Canada Ltd. \$604,291
 62. Kennedy SH (PI), McIntyre RS, Cooke R, Srinivasan J. An open-label one year trial of flibanserin in depressed patients, in North America and Australia. (511.44). 1999-2001. Boehringer Ingelheim Canada Ltd. \$810,968.
 63. Kennedy SH (PI), Grigoriadis S. Reproductive biology and depression in post menopausal women – role of a selective estrogen receptor modulator. 1999-2000. Younger Foundation \$15,000
 64. Kennedy SH (PI), McIntyre RS, Cooke R, Srinivasan J. LY354740 compared with placebo and fluoxetine HCl in outpatients with Depression. 1999-2000. Eli Lilly Canada. \$424,940
 65. Kennedy SH (PI), McIntyre RS, Cooke R, Srinivasan J. An 8-week, multicentre, double-blind, double-dummy, randomized, parallel group study comparing the effects of 20mg of paroxetine to 150mg of wellbutrin® SR in patients with major depressive disorder. 1999-2000. Glaxo Wellcome Inc. \$100,000.
 66. McIntyre RS, Kennedy SH, Cooke R, Srinivasan J, Parikh S. A metabolic comparative study of Olanzapine and risperidone on body weight, leptin levels and lipid homeostasis in bipolar disorder. 1999-2000. Janssen-Ortho Inc. \$50,000

67. McIntyre RS, Kennedy SH, Cooke R, Srinivasan J, Parikh S. Estimating the metabolic and reproductive endocrine effects of divalproex in females with Bipolar Disorder. 1999-2000 Glaxo-Wellcome. \$10,000.
68. McIntyre RS, Kennedy SH, Cooke R, Srinivasan J, Parikh S. An open trial to document the safety and efficacy of risperidone (RISPERIDONE-CAN 25) as add-on therapy to mood stabiliser in the treatment of the manic phase of bipolar disorder. 1999-2000 Janssen-Ortho Inc. \$20,000.
69. McIntyre RS, Kennedy SH, Cooke R, Srinivasan J, Parikh S. Randomized, single-blind study comparison of topiramate and bupropion SR add-on therapy in bipolar depression. 1999-2000. Janssen-Ortho Inc. \$50,000
70. Kennedy SH (PI), Cooke R, Parikh S, Raskin J. A multicentre double-blind placebo controlled randomized fixed dose evaluation of the safety and efficacy of lamotrigine in the long term prevention of relapse and recurrent of depression and/or mania in bipolar I affective disorder. 1998-1999. Glaxo Wellcome Inc. \$195,000
71. Kennedy SH (PI), Raskin J, Parikh S, Cooke R. A multicentre double-blind double dummy placebo and lithium controlled randomized flexible dose evaluation of the safety and efficacy of lamotrigine in the long term prevention of relapse and recurrence of mania and/or depression in bipolar. 1998-1999. Glaxo Wellcome Inc. \$117,000
72. Kennedy SH (PI), Raskin J, Parikh S, Sealy K. Olanzapine added to mood stabilizers in the treatment of bipolar disorder. 1998-1999. Eli Lilly Canada Ltd. \$222,750
73. Kennedy SH (PI), Raskin J, Vaccarino FJ. A 4-week double blind placebo controlled dose funding study of BIMT 17 20mg qd 20mg bid, 50mg qd and 50mg bid and 100 mg qd in patents with major depressive disorder (511.18) 1997. Boehringer Ingelheim Ltd. \$745,612
74. Kennedy SH (PI), Raskin J. The evaluation of health resources utilization during antidepressant treatment in pilot project. 1997. Boehringer Ingelheim Ltd. \$4,494
75. Levitan R, Kennedy SH, Kaplan AS, Kennedy J. Polymorphism in serotonin system genes: putative role increased food intake in bulimia nervosa and seasonal affective disorder. 1997-1999. Ontario Mental Health Foundation. \$120,000. *Extended to 2001. (\$120,000)*
76. Kennedy SH (PI), Meyer JH, Kapur S, Houle S. PET study of 5HT₂ receptors in major depression before and after paroxetine treatment. 1997-1998. Canadian Psychiatric Research Foundation \$30,000
77. Kennedy SH (PI), Kapur S, Meyer JH. A comparative positron emission tomography (PET) study of 5HT₂ receptors with major depression (before and after treatment) and in healthy volunteers. 1997-2000. Medical Research Council of Canada (MRC). \$74, 440
78. Kennedy SH (PI), Cohen NL. Development of a self-report scale to predict drug compliance in depression. 1997-2000. Social Science and Humanities Research Council (SSHRC). \$3,416
79. Kennedy SH (PI), Parikh S. Guidelines in depression disorders (extension). 1997-1998. Ontario Ministry of Health Drug Programs Branch. \$25,000
80. Kapur S, Kennedy SH. 5HT₂ antagonism of nefazadone and its relevance to the therapeutics of depression and schizophrenia: a PET study. 1997-1998. Bristol-Meyers Squibb. \$125,000
81. Kennedy SH (PI), Segal ZV, Bagby RM, Levitan. Cognitive therapy versus lithium as antidepressant augmentation strategies in partially responsive patients. 1996-1997 Canadian Psychiatric Research Foundation. \$24,000

82. Kusmaker V, Kennedy SH, Parikh SV, Yatham L. Guidelines for bipolar mood disorders (awarded to Canadian Network for Mood and Anxiety Treatments (CANMAT). 1996-1997 Abbott Laboratories. \$63,000
83. Levitan R, Shaprio C, Kennedy SH. Hypnotic and augmentation effects of L-tryptophan in combination with fluoxetine. 1996-1997. ICN Canada Ltd. \$72,000
84. Kennedy SH (PI), Bradwejn J, Parikh S. Guidelines in depression and anxiety disorders. 1996-1998 Ontario Ministry of Health Drug Program Branch. \$50,000
85. Kennedy SH (PI). Venlafaxine acute and continuation effects as an antidepressant. 1995. Wyeth-Ayerst Canada Inc. \$60,000
86. Kennedy SH (PI), Levitan R. A double-blind comparative study of moclobemide and sertraline in the treatment of atypical depression in outpatients. 1995-1996. Pfizer Canada Inc. \$52,500
87. Kennedy SH (PI), Vaccarino FJ, Brown GM, Houle S, Raskin J. The effects of chronic and acute dosing of paroxetine on regional brain metabolism and quantified EEG. 1995-1996. Boehringer Ingelheim Canada Inc. \$214,285
88. Kennedy SH (PI), Vaccarino FJ, Brown GM, Houle S, Raskin J. The effects of BIMT-17 on regional brain metabolism and quantified EEG in severely depressed patients. 1995-1997. Boehringer Ingelheim Canada Inc. \$305,415
89. Vaccarino Fj, Baker GB, Bradwejn J, Gutkowska J, Kennedy SH, Martin I, Palmour R. Cholecystokinin and anxiety: Neurobiological and behavioural characterization. This is a three site group grant to study the role of CCK in anxiety at the clinical, preclinical and molecular levels. 1995-1998. Medical Research Council Group. \$1,581,171
90. Brown GM, Fu C, Kennedy SH. CNS responses to clonidine in major depression. 1995-1996. Canadian Psychiatric Research Foundation. \$37,000
91. Brown GM, Kennedy SH, Swinson RP, Meyer JH. Brain serotonin in depression and panic disorder. 1995-1998. Medical Research Council of Canada (MRC). \$186,792
92. Davis R, Kennedy SH. Community Outreach Programme for eating disorders. 1994-1996 Ontario Ministry of Health. \$224,285
93. Kennedy SH (PI). A double blind dose ranging study of CGP 25 454 A in patients with major depression. 1993-1994. Ciba- Geigy. \$50,000
94. Katzman D, Kennedy SH. Estrogen therapy for the prevention and the treatment of osteoporosis in younger women with anorexia nervosa. 1993-1996. The Physicians Services Incorporated (PSI). \$121,000
95. Davis C, Kennedy SH. The role of personality differences in the reporting of adverse reactions to moclobemide and placebo: A non-clinical study of men and women. 1993-1994 Hoffman LaRoche. \$25,000
96. Ramasubbu R, Kennedy SH. Serotonergic functioning in post stroke depression. 1993-1994. Canadian Psychiatric Fellowship Research Foundation (Personal Support)
97. Davis C, Kennedy SH. Sequencing of cognitive-behavioural treatments for bulimia nervosa. 1993-1995. Health Care Systems Research Grant, Ontario Ministry of Health \$101,610

98. Kennedy SH (PI), Kocerginski D, Gnam W. Duloxetine versus placebo and clomipramine in major depression. 1993-1995. Eli Lilly Canada. \$110,000
99. Kennedy SH (PI). Moclobemide versus fluoxetine in the treatment of major depression: A multicentre trial. 1992-1993. Hoffman LaRoche. \$80,000
100. Davis C, Kennedy SH. The relationship between exercise and eating disorder. 1991. Canadian Fitness & Lifestyles. \$7,500
101. Kennedy SH (PI), Black R, Kaplan AS. Energy expenditure in bulimia nervosa: A paradigm for nutritional and metabolic investigation of eating disorders. 1991-1992. Ontario Mental Health Foundation. \$15,000.
102. Kennedy SH (PI), Vaccarino FJ. Growth Hormone and feeding in anorexia nervosa. 1991-1992 Ontario Mental Health Foundation. \$15,000
103. Kennedy SH (PI). Melatonin response to noradrenergic challenges: A pilot study. 1990-1991 Ontario Mental Health Foundation. \$15,000
104. Kennedy SH (PI). Brofaromine: A multicentre placebo controlled trial in Major Depression. 1990-1991. Ciba-Geigy. \$50,000
105. Kennedy SH (PI). The effect of brofaromine –(A Monoamine Oxidase – A inhibitor) in the treatment of bulimia nervosa. 1989-1990. Ciba-Geigy. \$90,000.
106. Kennedy SH (PI). Toronto General Hospital Affective and Eating Disorder Programme. 1988-1989. Canadian Psychiatric Research Foundation \$32,000
107. Kennedy SH (PI). DeGroot J. Andinazolam in the treatment of Major Depressive Disorder. 1987-1989. Upjohn (Canada). \$80,000.
108. Kennedy SH (PI), Brown GM. Neurohormonal and Electrophysiological disturbances in Affective Eating Disorder patients. 1986-1988. Physicians' Services Incorporated Foundation. \$76,000
109. Kennedy SH (PI), Piran N. The Relationship between Eating Disorders and Affective Disorders. 1985-1986 Canadian Psychiatric Research Foundation(Formerly CK Clarke). \$25,000
110. Kennedy SH (PI). Establishment of a Clinical Psychopharmacology Programme. 1984 Rhone Poulenc. \$10,000
111. Kennedy SH (PI), Piran N. The Development of an Affective Disorder Programme. 1983-198 C.K. Clarke Foundation. \$20,000

XII. PUBLICATIONS

i. Articles in Refereed Journals

386. Fettes PW, Moayedi M, Dunlop K, Mansouri F, Vila-Rodriguez F, Giacobbe P, Davis KD, Lam RW, **Kennedy SH**, Daskalakis ZJ, Blumberger DM, Downar J. Abnormal functional connectivity of frontopolar cortical subregions to salience and non-reward network regions in major depressive disorder. *Cerebral Cortex*. 2017. Submitted.
385. Giacobbe P, Rakita U, Lam RW, Milev R, **Kennedy SH**, McIntyre RS. Efficacy and Tolerability of Lisdexamfetamine as an Antidepressant Augmentation Strategy: A Meta-Analysis of Randomized Controlled Trials. *The Journal of Affective Disorders*. 2017. Submitted.
384. Maciukiewicz M, Marshe VS, Hauschild AC, Foster JA, Rotzinger S, Kennedy JL, **Kennedy SH**, Müller DJ

- Geraci J. Genome-wide association studies (GWAS) - based machine learning approach to predict duloxetine response in major depressive disorder. *The Pharmacogenomics Journal*. 2017. Submitted.
383. Soczynska J, **Kennedy SH**, Alsuwaidan M, Mansur R, Li M, McAndrews MP, Brietzke E, Woldeyohannes H, Taylor V, McIntyre RS. A Pilot, Open-label, 8-Week Study Evaluating the Efficacy, Safety and Tolerability of Adjunctive Minocycline for the Treatment of Bipolar I/II Depression. *Bipolar Disorders*. 2017. Submitted.
382. Allega O, Leng X, Vaccarino A, Skelly M, Lanzini M, Hidalgo MP, Soares C, **Kennedy SH**, Frey B. Performance of the biological rhythms interview for assessment in neuropsychiatry: an item response theory and actigraphy analysis. *Chronobiology International*. 2017. Submitted.
381. McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, **Kennedy SH**, Rong C, Jerrell JM. The Efficacy of Psychostimulants in Major depressive Disorder: A Systematic Review and Meta-Analysis. *Journal of Clinical Psychopharmacology*. 2017. Submitted.
380. Zihang P, Mansur RB, Cha DS, Dale RM, Muzina DJ, Subramaniapillai M, **Kennedy SH**, McIntyre RS. Anhedonia scores positively co-vary with waist circumference in adults with Major Depressive Disorder (MDD) and Bipolar Disorder (BD): Results from the International Mood Disorders Collaborative Project (IMDCP). 2016. Submitted.
379. Sankar T, Chakravarty M, Jawa NJ, Li SX, Giacobbe P, **Kennedy SH**, Rizvi SJ, Mayberg HS, Hamani C, Lozano AM. Neuroanatomical predictors of response to deep brain stimulation for treatment resistant depression. *Biological Psychiatry*. 2016. Submitted.
378. Vaccarino AL, Chen J, Dharasee M, Feilotter H, Kupchak P, Javadi M, **Kennedy SH**, Lutz K, Meyer J, Mo A, Evans K. Candidate-based Proteomics in search for Biomarkers of Antidepressant Treatment Response. 2016. Submitted.
377. Farzan F, Atluri S, Frehlich M, Dhama P, Kleffner K, Price R, Lam R, MacQueen G, Frey B, Milev R, Ravindran R, McAndrews MP, Wong W, Blumberger D, Daskalakis ZJ, Brenner C, Liotti M, Dharsee M, Arnott S, Strother S, Evans K, Rotzinger S, **Kennedy SH**. Standardization of Electroencephalography for Multi-site, Multi-platform and Multi-investigator Studies: Insights from the Canadian Biomarker Integration Network in Depression. 2016. In Press.
376. Soczynska J, **Kennedy SH**, Alsuwaidan M, Mansur R, Li M, McAndrews MP, Brietzke E, Woldeyohannes H, Taylor V, McIntyre RS. A Pilot, Open-label, 8-Week Study Evaluating the Efficacy, Safety and Tolerability of Adjunctive Minocycline for the Treatment of Bipolar I/II Depression. *Bipolar Disorders*. 2017. In Press.
375. Al Shirawi MI, **Kennedy SH**, Ho KT, Byrne Roisin, Downar J. Oral Ketamine in Treatment Resistant Depression: A Clinical Effectiveness Case Series. *Journal of Clinical Psychopharmacology*. 2017. In Press.
374. Baskaran A, Milev R, Farzan F, Brenner CA, McAndrews MP, Alturi S, **Kennedy SH**. The Comparative Effectiveness of Electroencephalographic Biomarkers of Escitalopram Response in Depression: A Pilot Study. 2017. In Press.
373. Bhat V, **Kennedy SH**. Recognition and Management of Antidepressant Discontinuation Syndrome. *Journal of Psychiatry and Neuroscience*. 2017. In Press.
372. Lopez JP, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, Heller EA, Vialou V, Ku SM, Gerald C, Han MH, Foster J, Rotzinger S, Feilotter H, Tyryshkin K, CANBIND working group, Lewis CM, Aitchison KJ, Wittenberg GM, Mechawar N, Nestler EJ, Uher R, **Kennedy SH**, Turecki G. MicroRNAs 146a/b-5p, 425-3p and 24-3p are consistent mediators of antidepressant response and regulate MAPK/Wnt-system genes. *Nature Communications*. 2017. In Press
371. Giacobbe P, Hamani C, Lipsman N, McIntyre RS, **Kennedy SH**, Lozano A. Further evidence for deep brain stimulation potentiating the effect of medication: a case of serotonin syndrome. *Biological Psychiatry Communications*. In Press.
370. Forsenka T, McKinley GP, **Kennedy SH**. Is Tetraethyl Lead Poison affecting Contemporary Indigenous Suicides in Ontario, Canada? *Psychiatry Research*. 2017. 251: 253-254.
369. Mir-Moghtadaei A, Dunlop K, Mansouri F, Giacobbe P, **Kennedy SH**, Lam RW, Vila-Rodriguez F, Daskalakis Z, Blumberger DM, Downar J. Scalp-based heuristics for locating the nodes of the salience network for use in

- neuristimulation. *Brain Stimulation*. 2017. 10(2): 479.
368. Dunlop K, Peter SK, Giacobbe P, Daskalakis Z, **Kennedy SH**, Lam RW, Vila-Rodriguez F. Cortico-cortical and cortico-striatal resting- state functional connectivity differentially predicts response to 10 Hz rTMS and intermittent TBS to the DLPFC. *Brain Stimulation*. 2017. 10(2): 464.
367. McInerney SJ, McNeely HE, Geraci J, Giacobbe Peter, Rizvi SJ, Ceniti AK, Cyriac A, Mayberg HS, Lozano AM, **Kennedy SH**. Neurocognitive Predictors of Response in Treatment Resistant Depression to Subcallosal Cingulate Gyrus Deep Brain Stimulation. *Frontiers in Human Neuroscience*. 2017. doi:10.3389/fnhum.2017.00074.
366. Zhou AJ, Lee Y, Salvatore G, Hsu B, Fonseka TM, **Kennedy SH**, McIntyre RS. Sirukumab: A Potential Treatment for Mood Disorders?. *Advances In Therapy*. 2017. 34(1): 78-90.
365. Mak LE, Minuzzi L, MacQueen G, Hall G, **Kennedy SH**, Milev R. The Default Mode Network in Healthy Individuals: A Systematic Review and Meta-Analysis. *Brain Connectivity*. 2017. 7(1):25-33.
364. Cha DS, Best MW, Bowie CR, Gallagher LA, Woldeyohannes HO, Soczynska JK, Lewis G, MacQueen G, Shahkian BJ, **Kennedy SH**, Lui JP, Mansur RB, McIntyre RS. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. *Journal of Affective Disorders*. 2017. 210:57-65.
363. Parikh SV, Quilty L, Ravitz P, Rosenbluth M, Pavlova B, Grigoriadis S, Velyvis V, Uher R, **Kennedy SH**, Lam RW, MacQueen GM, Milev R, Ravindran AV. Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. *Canadian Journal of Psychiatry*. 2017. 62(1):77-78.
362. Habert J, Katzman MA, Oluboka OJ, McIntyre RS, McIntosh D, MacQueen GM, Khullar A, Milev RV, Kjernisted KD, Chokka PR, **Kennedy SH**. Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment. *Primary Care Companion CNS Disorder*. 2016.18(5): doi:10.4088/PCC.15r01926.
361. Lam RW, **Kennedy SH**, Parikh SV, MacQueen GM, Milev RV, Ravindran AV, CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and Methods. *Canadian Journal of Psychiatry*. 2016. 61(9):506-509.
360. Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, Sareen J, Song W-Y, **Kennedy SH**, MacQueen GM, Milev RV, Parikh SV, Ravindran AV, CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. *Canadian Journal of Psychiatry*. 2016. 61(9): 510-523.
359. Parikh SV, Quilty LC, Ravitz P, Rosenbluth M, Pavlova B, Grigoriadis S, Velyvis V, **Kennedy SH**, Lam RW, MacQueen GM, Milev RV, Ravindran AV, Uher R, CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. *Canadian Journal of Psychiatry*. 2016. 61(9): 524-539.
358. **Kennedy SH**, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R, CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. *Canadian Journal of Psychiatry*. 2016. 61 (9): 540-560.
357. Milev RV, Giacobbe P, **Kennedy SH**, Blumberger DM, Daskalakis ZJ, Downar J, Modirrousta M, Patry S, Vila-Rodriguez, Lam RW, MacQueen GM, Parikh SV, Ravindran AV, CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. *Canadian Journal of Psychiatry*. 2016. 61(9): 561-575.
356. Ravindran AV, Balneaves LG, Faulkner G, Ortiz A, McIntosh D, Morehouse RL, Ravindran L, Yatham LN, **Kennedy SH**, Lam RW, MacQueen GM, Milev RV, Parikh SV. CANMAT Depression Work Group. *Canadian*

- Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. *Canadian Journal of Psychiatry*. 2016. 61(9): 576-587.
355. MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Van Lieshout RJ, **Kennedy SH**, Lam RW, Milev R, Parikh SV, Ravindran AV, CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. *Canadian Journal of Psychiatry*. 2016. 61(9): 588-603.
354. Schulze L, Remington G, Giacobbe P, **Kennedy SH**, Blumberger DM, Daskalakis ZJ, Downar J. Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent-theta burst stimulation for refractory depression. *Journal of Psychopharmacology*. 2016. Epub ahead of print.
353. Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Geraci J, Giacobbe P, Feliotter HE, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, Liotti M, MacQueen G, MacAndrews MP, Minuzzi L, Müller DJ, Parikh SV, Placenza FM, Quilty LC, Ravindran AV, Salomons TV, Soares CN, Strother SC, Turecki G, Vaccarino AL, Vila-Rodriguez F, **Kennedy SH**. Discovering biomarkers for antidepressant response: Protocol from the Canadian Biomarker Integration Network in Depression (CAN-BIND) and clinical characteristics from the first patient cohort. *BMC Psychiatry*. 2016. 16(1): 105-118.
352. Vaccarino AL, Evans KR, Kalali AH, **Kennedy SH**, Engelhardt N, Frey BN, Greist JH, Kobak KA, Lam RW, MacQueen G, Milev R, Placenza FM, Ravindran AV, Sheehan DV, Sills T, Williams JBW. The Depression Inventory Development Workgroup: A Collaborative, Empirically-driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. *Innov Clin Neurosci*. 2016; 13(9-10):20-31.
351. McIntyre, RS, Woldeyohannes HO, Soczynska JK, Vinberg M, Cha DS, Lee Y, Gallagher LA, Roman D, Alsuwaidan MT, Mansur RB, Muzina DJ, Carvalho A, **Kennedy SH**. The prevalence and clinical characteristics associated with DSM-5-defined anxious distress specifier in Adults with Major Depressive Disorder: Results from the International Mood Disorders Collaborative Project. *Ther Adv Chronic Dis*. 2016. 7 (3): 153-159.
350. Malhi GS, Byrow Y, Cassidy F, Cipriani A, Demyttenaere K, Frye MA, Gitlin M, **Kennedy SH**, Ketter TA, Lam RW, McShane R, Mitchell AJ, Ostacher MJ, Rizvi SJ, Thase ME, Tohen M. Ketamine: Stimulating antidepressant treatment? *B J Psych Open*. 2016. 2(3): e5-e9.
349. Rizvi SJ, Pizzagalli D, Sproule BA, **Kennedy SH**. Assessing anhedonia in depression: Potentials and pitfalls. *Neuroscience & Biobehavioural Reviews*. 2016. 65: 21-35.
348. Vittengl JR, Jarrett RB, Weitz E, Hollon SD, Twisk J, Cristea I, David D, DeRubeis RJ, Dimidjian S, Dunlop BW, Faramarzi M, Hegerl U, **Kennedy SH**, Kheirkah F, Mergl R, Miranda J, Mohr DC, Rush AJ, Segal ZV, Siddique J, Simons AD, Cuijpers P. Divergent outcomes in cognitive-behavioural therapy and pharmacotherapy for adult depression. *Am J Psychiatry*. 2016. 173(5): 481-490.
347. McIntyre RS, Woldeyohannes H, Soczynska JK, Maruschak NA, Wium-Anderson IK, Vinberg , Cha D, Xiao H, Gallagher LA, Dale R, Alsuwaidan MT, Mansur RB, Muzina DJ, Carvalho A, Jerrell J, **Kennedy SH**. Anhedonia and Cognitive Function in Adults with MDD: Results from the International Mood Disorders Collaborative Project. *CNS Spectrums*. 2015. 5:362-366
346. **Kennedy SH**, Avedisova A, Belaidi C, Picarel-Blanchot F, de Boudinat C. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with Major Depressive Disorder: A placebo-controlled study over 6 months. *European Neuropsychopharmacology*. 2015. 26(2): 378-389.
345. Fonseka TM, **Kennedy SH**. Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications. *Molecular Neuropsychiatry*. 2016. 2: 1-14.
344. Fonseka TM, Wen XY, Foster JA, **Kennedy SH**. Zebrafish models of major depressive disorder. *Journal of Neuroscience Research*. 2016. 94: 3-14.
343. Woldeyohannes HO, Soczynska JK, Maruschak NA, Syeda K, Wium-Andersen IK, Lee Y, Cha DS, Xiao HX, Gallagher LA, Dale RM, Alsuwaidan MT, Mansur RB, Muzina DJ, Carvalho AF, **Kennedy SH**, McIntyre RS.

- Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project. *Obesity Research & Clinical Practice*. 2015. 5: 531-543
342. Maciukiewicz M, Marshe VS, Tiwari AK, Fonseka TM, Freeman N, Rotzinger S, Foster JA, Kennedy JL, **Kennedy SH**, Muller D. Genetic variation in IL-1 β , IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder. *Pharmacogenomics*. 2015; 16: 1919-1929.
341. Dunlop K, Gagliell P, Blumberger D, Daskalakis ZJ, **Kennedy SH**, Giacobbe P, Downar J. MRI-guided dmPFC-rTMS as a treatment for treatment-resistant Major Depressive Disorder. *Journal of Visualized Experiments*. 2015; 11: 102
340. Weitz E, Hollon SD, Twisk J, van Straten A, David D, DeRubeis RJ, Dimidjian S, Dunlop BW, Faramarzi M, Hegerl U, Jarrett RB, Kheirkhah F, **Kennedy SH**, Mergl R, Miranda J, Mohr DC, Rush AJ, Segal ZV, Siddique J, Simmons AD, Vittengl JF, Cuijpers P. Baseline Depression Severity as Moderator of Depression Outcomes between Cognitive Behavioural Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis. *JAMA Psychiatry*. 2015; 72: 1102-1109.
339. Rizvi SJ, Cyriac A, Grima E, Tan M, Lin P, Gallagher LA, McIntyre RS, **Kennedy SH**. Depression and Employment Status in Primary and Tertiary Care settings. *Canadian Journal of Psychiatry* 2015; 60 (1): 14-22.
338. Rizvi SJ, Sproule BA, Gallagher L, McIntyre RS, **Kennedy SH**. Correlates of benzodiazepine use in major depressive disorder: the effect of anhedonia. *Journal of Affective Disorders*. 2015; 187: 101-105.
337. Lam RW, **Kennedy SH**, McIntyre RS, Khullar A. Cognitive dysfunction in major depressive disorder: Effects on psychosocial functioning and implications for treatment. *Canadian Journal of Psychiatry* 2014; 59: 649-654.
336. Rizvi SJ, Quilty LC, Sproule BA, Cyriac A, Bagby MR, **Kennedy SH**. Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression. *Psychiatry Research*. 2015; 229:109-119.
335. Sun Y, Giacobbe P, Tang CW, Barr MS, Rajji T, **Kennedy SH**, Fitzgerald PB, Lozano AM, Wong W, Daskalakis ZJ. Deep Brain Stimulation Modulates Gamma Oscillations and Theta-Gamma Coupling in Treatment Resistant Depression. *Brain Stimulation*. 2015; 8(6): 1033-1042.
334. Fonseka TM, McIntyre RS, Soczynska JK, **Kennedy SH**. Evidence to support peripheral and central IL-6 signaling targets to treat depression. *Expert Opinion Investigational Drugs*. 2015; 24: 991-992.
333. Lam RW, Parikh SV, Michalak EE, Dewa CS, **Kennedy SH**. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. *Annals Clinical Psychiatry*. 2015; 60: 14-22.
332. Srejic LR, Prescott IA, Zhang P, Strauss I, Dostrovsky JO, Giacobbe P, **Kennedy SH**, Lozano AM, Hamani C, Hutchison WD. Paired pulse depression in the subcallosal cingulate region of depression patients. *Biological Psychiatry*. 2015; 78: e3-4.
331. Rizvi SJ, Cyriac A, Grima E, Tan M, Lin P, Gallagher LA, McIntyre RS, **Kennedy SH**. Depression and employment status in primary and tertiary care settings. *Canadian Journal of Psychiatry*. 2015; 60: 14-22.
330. Lam RW, **Kennedy SH**. STAR*D and measurement-based care for depression: don't toss out the baby! *Canadian Journal of Psychiatry*. 2015; 60: 6-8.
329. Fonseka TM, McIntyre RS, Soczynska JK, **Kennedy SH**. Novel investigational drugs targeting IL-6 for the treatment of depression. *Expert Opinion on Investigational Drugs*. 2015; 24: 459-475.
328. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan MT, Cha DS, Carvalho AF, Jerrel JM, Dale RM, Gallagher LA, Muzina DJ, **Kennedy SH**. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. *Comprehensive Psychiatry*. 2015; 56: 279-282.
327. Fonseka TM, Tiwari AK, Goncalves VF, Lieberman JA, Meltzer HY, Goldstein BI, Kennedy JL, **Kennedy SH**, Mueller DJ. The role of genetic variation across IL-1 β , IL-2, IL-6 and BDNF in antipsychotic-induced weight

- gain. *World Journal of Biological Psychiatry*. 2015; 16: 45-56.
326. McIntyre RS, Soczynska JK, Cha D, Woldeyohannes H, Dale R, Alsuwaidan MT, Gallagher LA, Mansur R, Muzina DJ, Carvalho A, **Kennedy SH**. The prevalence and illness characteristics of DSM-5-defined "Mixed Feature Specifier" in adults with Major Depressive Disorder: Results from the International Mood Disorders Collaborative Project. *Journal of Affective Disorders*. 2015; 172: 259-64.
325. McInerney S, **Kennedy SH**. Review of evidence for use of antidepressants in bipolar depression. *Primary Care Companion CNS Disorder*. 2014; 16.
324. Bakker N, Shahab S, Giacobbe P, Blumberger DM, Daskalis ZJ, **Kennedy SH**, Downar J. rTMS of the dorsomedial prefrontal cortex for depression: a comparison of safety, tolerability, efficacy, and outcome predictors for 10 Hz versus intermittent theta-burst stimulation in 185 consecutive clinical cases. *Brain Stimulation*. 2014; 8: 208-215.
323. Rizvi SJ, **Kennedy SH**. Psychopharmacology for the clinician: Management strategies for SSRI-induced sexual dysfunction. *Journal of Psychiatry and Neuroscience*. 2014; 38: 360.
322. Cuijpers P, Weitz E, Twisk J, Kuehner C, David D, DeRubeis RJ, Dimidjian S, Dunlop BW, Hegerl U, Jarrett RB, **Kennedy SH**, Miranda J, Mohr DC, Segal ZV, Siddique J, Vittengl J & Hollon SD. Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: An "individual patient data" meta-analysis. *Depression and Anxiety*. 2014; 31: 941-51.
321. Rizvi SJ, Geraci J, Ravindran A, **Kennedy SH**. Predictors of response to adjunctive osmotic release methylphenidate or placebo in patients with Major Depressive Disorder: Effects of apathy/anhedonia and fatigue. *J Clin Psychopharmacol*. 2014; 34: 755-59.
320. Soczynska JK, Ravindran L, Styra R, McIntyre RS, Cyriac A, Manierka MS, **Kennedy SH**. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. *Psychiatry Res*. 2014; 220: 245-50.
319. **Kennedy SH**, Giacobbe P, Placenza FM, Hudson CJ, Seeman P, Seeman MV. Depression treatment by withdrawal of short-term low-dose antipsychotic, a proof-of-concept randomized double-blind study. *J Affect Disord*. 2014; 166: 139-43.
318. Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP, Bakker N, Blumberger DM, Daskalakis ZJ, **Kennedy SH**, Flint AJ, Giacobbe P. Anhedonia and reward-circuit dysfunction distinguish nonresponders from responders to dorsomedial prefrontal rTMS in major depression. *Biol Psychiatry*. 2014; 76(3):176-85.
317. Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, McIntyre RS, **Kennedy SH**. Treatment Resistant Depression in Primary Care across Canada: Results from the InSight Study. *Can J Psychiatry*. 2014; 59 (7): 349-57.
316. **Kennedy SH**, Avedisova A, Giménez-Montesinos N, Belaidi C, de Bodinat C. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder. *Eur Neuropsychopharmacol*. 2014; 24(4):553-63.
315. Quraan MA, Protzner A, Giacobbe P, **Kennedy SH**, Lozano A, McAndrews P. EEG Power asymmetry and functional connectivity as a marker of treatment effectiveness in DBS surgery for depression. *Neuropsychopharmacology*. 2014; 39(5):1270-81.
314. Salomons TV, Dunlop K, **Kennedy SH**, Flint A, Geraci J, Giacobbe P, Downar J. Resting state cortico-thalamic-striatal connectivity predicts response to dorsomedial prefrontal rTMS in major depressive disorder. *Neuropsychopharmacology*. 2014; 39: 488-98.
313. Lipsman N, Sankar T, Downar J, **Kennedy SH**, Lozano AM, Giacobbe P. Neuromodulation for treatment-refractory major depressive disorder. *CMAJ*. 2014; 186: 33-39.
312. Lam RW, Parikh SV, Ramasubbu R, Michalak EE, Tam EM, Axler A, Yatham LN, **Kennedy SH**, Manjunath CV. Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. *Br J Psychiatry*. 2013; 203:358-65.
311. Rizvi SJ, **Kennedy SH**. Psychopharmacology for the clinician. *J Psychiat & Neurosc*. 2013; 38(5):360.

310. McIntyre RS, Alsuwaidan M, Soczynska JK, Szpindel I, Bilkey TS, Almagor D, Woldeyohannes HO, Powell AM, Cha DS, Gallagher LA, **Kennedy SH**. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. *Human Psychopharmacology*. 2013; 28(5) 421-7.
309. **Kennedy SH**. A review of antidepressant therapy in primary care: current practices and future directions. *Primary Care Companion CNS Disord*. 2013;15(2).
308. Rizvi SJ, Salomons TV, Konarski JZ, Downar J, Giacobbe P, McIntyre RS, **Kennedy SH**. Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. *J Affect Disord*. 2013;151:573-81.
307. Thase ME, Larsen KG, Reines E, **Kennedy SH**. The cardiovascular safety profile of escitalopram. *Eur Neuropsychopharmacol*. 2013; 23:1391-400.
306. Leen J, Soczynska JK, Gallagher LA, Woldeyohannes HO, Alsuwaidan MT, Cha DS, Dale RM, Muzina DJ, **Kennedy SH**, McIntyre RS. The Effect of Personality Dimensions on Functional Outcomes in Mood Disorders. *Adv Ther*. 2013; 30:671-83.
305. Stein DJ, Picarel-Blanchot F, **Kennedy SH**. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. *Human Psychopharmacology Clin Exp* 2013; 28:151-159.
304. Yatham LN, **Kennedy SH**, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI. The evolution of CANMAT Bipolar Disorder Guidelines: past, present and future. *Bipolar Disord*. 2013. 15:58-60.
303. Yatham LN, **Kennedy SH**, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. *Bipolar Disord*. 2013. 15:1-44.
302. Clayton AH, **Kennedy SH**, Edwards JB, Gallipoli S, Reed CR. The effect of Vilazodone on sexual function during the treatment of major depressive disorder. *J Sex Med*. 2013; 10:2465-76.
301. Hamani C, Giacobbe P, Diwan M, Balbino ES, Tong J, Bridgman A, Lipsman N, Lozano AM, **Kennedy SH**, Nobrega JN. Monoamine oxidase inhibitors potentiate the effects of deep brain stimulation. *American Journal of Psychiatry*. 2012; 169:1320-1.
300. McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Vaccarino A, MacQueen G, Lewis G, **Kennedy SH**. A randomized double-blind controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. *Bipolar Disorder*. 2012; 14:697-706.
299. Soczynska JK, Mansur RB, Brietzke E, Swardfaer W, **Kennedy SH**, Woldeyohannes HO, Powell AM, Manierka MS, McIntyre RS. Novel therapeutic targets in depression: Minocycline as a candidate treatment. *Behavioral Brain Res* 2012; 235:302-17.
298. **Kennedy SH**, Downar J, Evans KR, Feilotter H, Lam RW, MacQueen GM, Milev R, Parikh SV, Rotzinger S, Soares C. The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction. *Curr Pharmaceutical Design* 2012; 18(36): 5976-89.
297. **Kennedy SH**, Cyriac A. A dimensional approach to measuring antidepressant response: Implications for agomelatine. *Psychology: Special Issue: Depression*. 2012; 3:864-869.
296. Rizvi SJ, **Kennedy SH**. Emerging Drugs for Major Depressive Disorder: An Update. *Expert Opin Emerg Drugs*. 2012; 17:285-94.
295. Zhu T, De Luca V, Gallagher LA, Woldeyohannes HO, Soczynska JK, **Kennedy SH**, McIntyre RS. Admixture analysis of age at onset in major depressive disorder. *Gen Hosp Psychiat*. 2012; 34:686-91.
294. Parikh SV, Zaretsky A, Beaulieu S, Yatham LN, Young LT, Patelis-Siotis I, MacQueen GM, Levitt A, Arenovich T, Cervantes P, Velyvis V, **Kennedy SH**, Streiner DL. A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: A CANMAT study. *J Clin Psychiatry*, 2012; 73(6):803-10.

293. McIntyre RS, Soczynska JK, Liauw SS, Woldeyohannes HO, Brietzki E, Nathanson J, Alswaidan M, Muzina D, Taylor V, Cha DS, **Kennedy SH**. The association between childhood adversity and components of metabolic syndrome in adults with mood disorders: Results from the International Mood Disorders Collaborative Project *Int J Psychiat Med*. 2012; 43:165-77.
292. Harkness KL, Bagby RM & **Kennedy SH**. Childhood maltreatment and differential treatment response and recurrence in adult major depressive disorder. *J Consult & Clin Psychol*:2012; 80:342-53.
291. Lozano AM, Giacobbe P, Hamani C, Rizvi SJ, **Kennedy SH**, Kolivakis T, DebonnelG, Sadikot A, Lam RW, Howard A, Ilcewicz M, Honey C, Mayberg HS. A multicenter pilot study of subcallosal cingulate cortex deep brain stimulation for treatment resistant depression. *J Neurosurg*. 2011; 116(2):315-22.
290. Montejo AL, Majadas S, Rizvi SJ, **Kennedy SH**. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. *Hum Psychopharmacol Clin Exp*. 2011; 26:537-542.
289. Rizvi SJ, Donovan M, Giacobbe P, Placenza F, **Kennedy SH**. Neurostimulation therapies for treatment resistant depression: A focus on vagus nerve stimulation and deep brain stimulation. *International Review of Psychiatry*, 2011; 23:424-36.
288. Li M, Soczynska JK, **Kennedy SH**. Inflammatory biomarkers in depression: An opportunity for novel therapeutic interventions. *Curr Psychiatry Reports*. 2011; 13:316-320.
287. Molnar MZ, Czira ME, Rudas A, Ujszaszi A, Lindner A, Fomadi K, Kiss I, Rempert A, Novak M, **Kennedy SH**, Rosivall L, Kovesdy CP, Mucsi I. Association of the malnutrition-inflammation score with clinical outcomes in kidney transplant recipients. *Am J Kidney Dis*. 2011; 58:101-108.
286. Sockalingam SS, Hawa R, Wnuk S, Strimas R, **Kennedy SH**. Weight loss following roux-en-y gastric bypass surgery: A systematic review of psychosocial predictors, *Current Psychiatry Reviews*, 2011; 7(3) 226-233.
285. Yim CY, Soczynska JK, **Kennedy SH**, Woldeyohannes HO, Brietzke E, McIntyre RS. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. *European Psychiatry*, 2011; (3):223-8.
284. Morehouse R, MacQueen G, **Kennedy SH**. Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. *J Affect Disord*, 2011; 132 Suppl 1:S14-20.
283. **Kennedy SH**, Young AH, Blier P. Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets. *J Affect Disord* 2011; 132 Suppl 1:S21-8.
282. **Kennedy SH**. Improving the clinical effectiveness of antidepressant treatment. *J Affect Disord* 2011; 132 Suppl 1:S1-2.
281. Thase ME, Larson KG, **Kennedy SH**. Assessing the true effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. *Br J Psychiatry*, 2011; 199:501-507.
280. Rizvi SJ, **Kennedy SH**. The keys to improving depression outcomes. *European Neuropsychopharmacology*. 2011; 21:S694-S702.
279. **Kennedy SH**, Dugre H, Defoy I. A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. *Intl Clin Psychopharm*. 2011; 26:151-158.
278. **Kennedy SH**, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y, Mayberg HS, Lozano AM. Deep brain stimulation for treatment resistant depression: follow-up after 3 to 6 years. *Am J Psychiatry*, 2011; 168:502-10.
277. Rizvi SJ, Yeung NW, **Kennedy SH**. Instruments to measure sexual dysfunction in community and psychiatric populations. *J Psychosom Res*. 2011; 70:99-109.
276. Czira ME, Lindner AV, Szeifert L, Molnar MZ, Fomadi K, Kelemen A, Laszlo G, Mucsi I, Keszei AP, **Kennedy SH**, Novak M. Association between the malnutrition-inflammation score and depressive symptoms in kidney transplanted patients. *Gen Hosp Psychiatry* 2011; 33:17-65.
275. **Kennedy SH**, Rizvi SJ, Fulton K, Ellis J, Quilty LC, Ravindran L. The sex effects scale: validation in a healthy

- population. *Psychopharmacol Bull* 2010; 43:15-25.
274. Lipsman N, McIntyre RS, Giacobbe P, Torres C, **Kennedy SH**, Lozano AM. Neurosurgical treatment of bipolar depression: Defining treatment resistance and identifying surgical targets. *Bipolar Disorders*, 2010; 12:691-701.
273. Soczynska JK, **Kennedy SH**, Woldeyohannes, Liauw SS, Alsuwaidan M, Yim CY, McIntyre RS. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. *Neuromol Med*. 2010; 13:93-116.
272. **Kennedy SH**. Flibanserin: Initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. *J Sex Med*. 2010; 7:3449-3459.
271. Giacobbe P, Lipsman N, Hamani C, Lozano AM, **Kennedy SH**. Subgenual cingulated gyrus deep brain stimulation: current status and future directions. *Annals of Psychiatry*. 2010; 40:485-491.
270. Pangallo BA, Zhang Q, Desai D, Perahia DGS, Detke MJ, **Kennedy SH**. Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. *CMRO*, 2010; 26:2643-2651.
269. McIntyre RS, Woldeyohannes HO, Soczynska JK, Miranda A, Lachowski A, Liauw SS, Grossman T, Lourenco MT, Kim B, Alsuwaidan MT, **Kennedy SH**. The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. *Adv Ther*, 2010; 27:828-36.
268. Mansfield JK, **Kennedy SH**. Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin. *Evid Based Ment Health*, 2010; 13:89.
267. **Kennedy SH**, Welsh BR, Fulton K, Soczynska JK, McIntyre RS, O'Donovan C, Milev R, le Mellodo J-M, Bisserbe J-C, Zimmerman M, Martin N. Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder. *Can J Psychiatry*, 2010; 55:568-76.
266. McIntyre RS, Park KY, Law CW, Sultan F, Adams A, Lourenco MT, Lo AKS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Yoon J. **Kennedy SH**. The Association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. *CNS Drugs*. 2010; 24:741-53.
265. Grigoriadis S, Bouffard B, **Kennedy SH**, Bagby RM, Joffe RT. A comparison of desipramine response in younger and older women. *J Clin Psychopharm*. 2010; 30:80-82.
264. Rizvi SJ, **Kennedy SH**, Ravindran LN, Giacobbe P, Eisfeld BS, Mancini D, McIntyre RS. The relationship between testosterone and sexual function in depressed and healthy men. *J Sex Med*, 2010; 7:816-825.
263. McIntyre RS, **Kennedy SH**, Soczynska JK, Nguyen HTT, Bilkey T, Woldeyohannes H, Nathanson J, Joshi S, Cheng JSH, Benson K, Muzina DJ. Attention Deficit/Hyperactivity Disorder in adults with bipolar disorder or major depressive disorder: Results from the international mood disorders collaborative project. *Primary Care Comparison*. *J Clin Psychiatry* 2010; 12:e1-e7.
262. McIntyre RS, Kenna HA, Nguyen HT, Law CW, Sultan F, Woldeyohannes HO, Adams AK, Cheng JS, Lourenco M, **Kennedy SH**, Rasgon NL. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? *Adv Ther*. 2010; 27:63-80.
261. **Kennedy SH**, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness. *CNS Drugs*. 2010; 24:479-499.
260. Grigoriadis S, Barrett J, Pittini R, Herer E, Zaltz A, Bazinet RP, Bradley L, **Kennedy SH**, Steiner M, Levitt A. Omega-3 supplements in pregnancy: Are we too late to identify the possible benefits? *JOGC*. 2010; 32:209-216.
259. Quilty LC, Godfrey KM, **Kennedy SH**, Bagby RM. Harm avoidance as a mediator of treatment response to antidepressant treatment of patients with major depression. *Psychother & Psychosom*. 2010; 79:116-22.
258. **Kennedy SH**, Rizvi SJ. Comparative efficacy of newer antidepressants for major depression: A Canadian perspective. *Can J Diagnosis*. 2009; 26:81-86.
257. McIntyre RS, Muzina DJ, Adams A, Lourenco MT, Law C, Soczynska JK, Woldeyohannes H, Nathanson J, **Kennedy SH**. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to

- conventional antidepressants in the acute and maintenance treatment of major depressive disorder: A review of registration trials. *Expert Opin Pharmacother.* 2009; 10:3061-3075.
256. **Kennedy SH.** Agomelatine: Efficacy at each phase of antidepressant treatment. *CNS Drugs.* 2009; 23:41-47.
255. Hamani C, Mayberg H, Snyder B, Giacobbe P, **Kennedy SH**, Lozano AM. Deep brain stimulation of the subcallosal cingulate gyrus for depression: Anatomical location of active contacts in clinical responders and suggested guideline for targeting. *J Neurosurg.* 2009; 111:209-215.
254. **Kennedy SH**, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. *J Affect Disord.* 2009; 117:S1-S2.
253. Patten SB, **Kennedy SH**, Lam RW, O'Donovan C, Filteau MJ, Parikh SV, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management. *J Affect Disord.* 2009; 117:S5-S14.
252. Parikh SV, Segal ZV, Grigoriadis S, Ravindran AV, **Kennedy SH**, Lam RW, Patten SB. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. *J Affect Disord.* 2009; 117:S15-S25.
251. Lam RW, **Kennedy SH**, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. *J Affect Disord.* 2009; 117:S26-S43.
250. **Kennedy SH**, Milev R, Giacobbe P, Ramasubbu R, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the management of major depressive disorder in adults. IV. Neurostimulation Therapies. *J Affect Disord.* 2009; 117:S44-S53.
249. Ravindran AV, Lam RW, Filteau MJ, Lesperance F, **Kennedy SH**, Parikh SV, Patten SB. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. *J Affect Disord.* 2009; 117:S54-S64.
248. Chopra KK, Ravindran A, **Kennedy SH**, Mackenzie B, Matthews S, Anisman H, Bagby RM, Faarvolden P, Levitan RD. Sex differences in hormonal responses to a social stressor in chronic major depression. *Psychoneuroendocrinology.* 2009; 34:1235-41.
247. **Kennedy SH**, Rizvi SJ. Emerging drugs for major depressive disorder. *Expert Opin Emerging Drugs.* 2009; 15:1-15.
246. Soczynska JK, **Kennedy SH**, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: Novel hypothesis-driven treatments for bipolar depression? *Neurotoxicology.* 2009; 34:175-180.
245. Yatham LN, **Kennedy SH**, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. *Bipolar Disorders.* 2009; 11:225-255.
244. **Kennedy SH**, Rizvi SJ. Sexual dysfunction, depression and the impact of antidepressants. *J Clin Psychopharm.* 2009; 29:157-164.
243. Levitan RD, Atkinson L, Pedersen R, Buis T, **Kennedy SH**, Chopra K, Leung EM, Segal ZV. A novel examination of atypical major depressive disorder based on attachment theory. *J Clin Psychiatry.* 2009; 70:879-887.
242. Konarski JZ, **Kennedy SH**, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS. Predictors of nonresponse to cognitive behavioral therapy or venlafaxine using glucose metabolism in major depressive disorder. *J Psychiatry & Neurosci.* 2009; 34:175-180.
241. Nierenberg A, **Kennedy SH**, Lydiard RB, Rapaport M. CME Course Director: Chou JC-Y. Efficacy, safety and

- tolerability considerations in the novel treatment of major depressive disorder. *CNS Spectrums*. 2009; 14:Suppl 5:13-17.
240. Lourenco MTC, **Kennedy SH**. Desvenlafaxine in the treatment of major depressive disorder. *Neuropsych Dis & Treatment*. 2009; 5:127-136.
239. **Kennedy SH**, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. *Curr Med Research & Opinions*, 2009; 25:161-175.
238. Cascade E, Kalali AH, **Kennedy SH**. Trend Watch: Real-world data on SSRI antidepressant side effects. *Psychiatry*, 2009; 6:15-17.
237. **Kennedy SH**. Treating each and every depressed patient. *J Psychopharm*, 2009; 22:19-23.
236. Chopra KK, Segal ZV, Buis T, **Kennedy SH**, Levitan R. Investigating associations between cortisol and cognitive reactivity to sad mood provocation and the prediction of relapse in remitted major depression. *Asian J Psychiatry*. 2008; 1:33-36.
235. Giacobbe P, McIntyre RS, Goldstein BI, **Kennedy SH**, Flint AF. Rates and patterns of treatment seeking by individuals with mood and anxiety disorders. *Psychiatric Services*. 2008; 59:1099.
234. McIntyre RS, Soczynska JK, Mancini D, Lam C, Woldeyohannes HO, Moon S, Konarski JZ, **Kennedy SH**. The relationship between childhood abuse and suicidality in adult bipolar disorder. *Violence Vict*. 2008; 23:361-372.
233. Neimat JS, Jamani C, Giacobbe P, Merskey H, **Kennedy SH**, Mayberg HS, Lozano AM. Neural stimulation successfully treats depression in patients with prior ablative cingulotomy. *Am J Psychiatry*. 2008; 165:687-693.
232. Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, **Kennedy SH**. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. *Biol Psychiatry*. 2008; 64:461-467.
231. **Kennedy SH**, Rizvi SJ, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. *J Clin Psychopharm*. 2008; 28:329-333.
230. Soczynska JK, **Kennedy SH**, Chow C, Woldeyohannes H, Konarski JZ, McIntyre RS. Acetyl-L-Carnitine and α -Lipoic Acid: Possible neurotherapeutic agents for mood disorders?. *Expert Opinion*. 2008; 17:827-843.
229. Quilty LC, De Fruyt F, Rolland JP, **Kennedy SH**, Rouillon F, Bagby RM. Dimensional personality traits and treatment outcome in patients with major depressive disorder. *J Affect Disord*. 2008; 108:241-250.
228. McNeely HE, Mayberg HS, Lozano AM, **Kennedy SH**. Neuropsychological impact of Cg25 deep brain stimulation for treatment resistant depression. *J Nervous Mental Disease*. 2008; 196:405-410.
227. Bagby RM, Quilty LC, Segal ZV, McBride CC, **Kennedy SH**, Costa PT. Personality and differential treatment response in major depression: A randomized controlled trial comparing cognitive-behavioral therapy and pharmacotherapy. *Can J Psychiatry*, 2008; 53:361-370.
226. McIntyre RS, Panjwani ZD, Nguyen HT, Woldeyohannes HO, Alsuwaidan M, Soczynska JK, Lourenco MT, Konarski JZ, **Kennedy SH**. The hepatic safety profile of duloxetine: a review. *Expert Opin Drug Metab Toxicol*, 2008; 4:281-285.
225. Ravindran AV, **Kennedy SH**, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder. Results of a double-blind, randomized, placebo-controlled trial. *J Clin Psychiatry*, 2008; 69:87-94.
224. McIntyre RS, Wilkins K, Gilmour H, Soczynska JK, Konarski JZ, Miranda A, Woldeyohannes HO, Vagic D, Alsuwaidan M, **Kennedy SH**. The effect of bipolar I disorder and major depressive disorder on workforce function. *Chronic Diseases in Canada*, 2008; 28:84-91.
223. **Kennedy SH**. Treatment resistant depression: the emergence of deep brain stimulation. *Acta Esp Psiquiatr* 2008; 36(suppl 1)35-36.

222. Konarski, JZ, McIntyre RS, **Kennedy SH**, Rafi-Tari S, Soczynska JK, Ketter TA. Volumetric neuroimaging investigations in mood disorders bipolar versus major depressive disorder. *Bipolar Disorder*. 2008; 10:1-37.
221. McIntyre RS, Soczynska JK, Mancini D, Woldeyohannes H, Konarski JZ, **Kennedy SH**. Comparing features of Bipolar Disorder to Major Depressive Disorder in a Tertiary Mood Disorders Clinic. *An Clin Psychiatry*, 2007; 19: 313-317.
220. **Kennedy SH**, Giacobbe P. Treatment Resistant Depression – Advances in somatic therapies. *An Clin Psychiatry*, 2007; 19:279-287.
219. Konarski JZ, McIntyre RS, Soczynska JK, **Kennedy SH**. Neuroimaging approaches in mood disorders: Techniques and clinical implications. *An Clin Psychiatry*, 2007; 19:265-277.
218. McIntyre RS, Soczynska JK, Konarski JZ, Woldeyohannes H, Law CWY, Miranda A, Fulgosi D, **Kennedy SH**. Should depressive syndromes be reclassified as “metabolic syndrome type II?” *An Clin Psychiatry*, 2007; 19: 257-264.
217. McIntyre RS, McElroy SL, Konarski JZ, Soczynska JK, Bottas A, Castel S, Wilkins K and **Kennedy SH**. Substance use disorders and overweight/obesity in bipolar I disorder: Preliminary evidence for competing addictions, *J Clin Psychiatry*, 2007; 68: 1352-1357.
216. Castel S, Rush B, **Kennedy SH**, Fulton K, Toneatto, T. Screening for mental health problems among patients with substance use disorders: Preliminary findings on the validation of a self-assessment instrument. *Can J Psychiatry*, 2007; 52:23-27.
215. **Kennedy SH**, Eisfeld BS. Agomelatine and its therapeutic potential in the depressed patient. *Neuropsychiat Dis and Treat*, 2007; 3:423-428.
214. McIntyre RS, McElroy, SL, Konarski JZ, Soczynska JK, Wilkins K, **Kennedy SH**. Problem gambling in bipolar disorder: Results from the Canadian Community Health Survey. *J Affective Disorders*, 2007; 102:27-34.
213. Konarski JZ, **Kennedy SH**, McIntyre RS, Rafi-Tari S, Soczynska JK, Mayberg HS. Relationship between regional brain metabolism disease severity and age in depressed subjects. *Psychiatry Res Neuroimaging*, 2007; 155:203-210.
212. McIntyre RS, Soczynska JK, Woldeyohannes H, Lewis GF, Leiter LA, MacQueen GM, Miranda A, Fulgosi D, Konarski JZ, **Kennedy SH**. Thiazolidinediones: Novel treatments for cognitive deficits in mood disorders? *Expert Opin on Pharmacother*, 2007; 8:1615-1628.
211. Grigoriadis S, Konarski JZ, **Kennedy SH**, Mancini D, McIntyre RS. Sex differences in antidepressant response in a Canadian primary-care sample. *J Clin Psychopharmacol*. 2007; 27:95-8.
210. McIntyre RS, Konarski JZ, Soczynska JK, **Kennedy SH**. Residual anxiety symptoms in depressed primary care patients. *J Psychiatr Pract*, 2007; 13:125-8.
209. McIntyre RS, Konarski JZ, **Kennedy SH**, Dickens SE, Bagby RM. Measuring depressive symptoms in the naturalistic primary-care setting. *Int J Clin Pract*, 2007; 61:1278-1282.
208. McIntyre RS, Soczynska JK, Beyer JL, Woldeyohannes HO, Law CWY, Miranda A, Konarski JZ, **Kennedy SH**. Medical comorbidity in bipolar disorder: reprioritizing unmet needs. *Curr Opinion Psychiatry*, 2007; 20:406-416.
207. **Kennedy SH**, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. *Am J Psychiatry*, 2007; 164:778-788.
206. McBride C, Segal Z, **Kennedy SH**, Gemar M. Changes in autobiographical memory specificity following cognitive behavior therapy and pharmacotherapy for major depression. *Psychopathology*. 2007; 40:147-52.
205. **Kennedy SH**. Agomelatine: An antidepressant with a novel mechanism of action. *Future Neurol*. 2007; 2:145-151.
204. Ravindran L, **Kennedy SH**. Are antidepressants as effective as claimed? Yes, But.... *Can J Psychiatry*, 2007; 52:98-99.

203. McIntyre RS, Mancini D, Eisfeld BS, Soczynska JK, Grupp L, Konarski JZ, **Kennedy SH**. Calculated bioavailable testosterone levels and depression in middle-aged men. *Psychoneuroendocrinology*. 2006; 31:1029-35.
202. Yatham LN, **Kennedy SH**, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Bealieu S: Guidelines Group, Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. *Bipolar Disorder*, 2006; 8:721-39.
201. Giacobbe P, **Kennedy SH**. Deep brain stimulation for treatment resistant depression: A psychiatric perspective. *Current Psychiatry Reports*. 2006; 8:437-44.
200. **Kennedy SH**. A review of antidepressant treatments today. *Eur Neuropsychopharm*. 2006; S5: S619-S624.
199. McIntyre RS, Soczynska JK, Bottas A, Bordbar K, Konarski JZ, **Kennedy SH**. Anxiety disorders and bipolar disorder: a review. *Bipolar Disorders*. 2006; 8:665-76.
198. Segal ZV, **Kennedy SH**, Gemar M, Hood K, Pedersen R, Buis T. Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. *Arch Gen Psychiatry*, 2006. 63:749-755.
197. McIntyre RS, Konarski JZ, Soczynska JK, Wilkins K, Panjwani G, Bouffard B, Bottas A, **Kennedy SH**. Medical comorbidity in bipolar disorder: Implications for functional outcomes and health-service utilization. *Psychiatric Services*, 2006; 57: 1140-4.
196. McIntyre RS, Soczynska JK, Lewis G, MacQueen GM, Konarski JZ, **Kennedy SH**. Managing psychiatric disorders with anti-diabetic agents: Translational research and treatment opportunities. *Expert Opin Pharmacother*, 2006; 10:1305-21.
195. McIntyre RS, Soczynska JK, Konarski JZ, **Kennedy SH**. The effect of antidepressants on lipid homeostasis: a cardiac safety concern? *Expert Opin Drug Saf*, 2006; 5:523-537.
194. **Kennedy SH**, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. *J Psych Neurosci*. 2006; 31:122:131.
193. McIntyre RS, Konarski JZ, Wilkins K, Bouffard B, Soczynska JK, **Kennedy SH**. The prevalence and impact of migraine headache in bipolar disorder: Results from the Canadian Community Health Survey. *Headache*, 2006; 46:973-82.
192. McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, **Kennedy SH**. Obesity in bipolar disorder and major depressive disorder: Results from a national community health survey on mental health and well-being. *Can J Psychiatry*, 2006; 51:274-280.
191. **Kennedy SH**, Fulton K, Bagby RM, Greene AL, Cohen NL, Rafi-Tari, S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. *Can J Psychiatry*, 2006;51:234-242.
190. McIntyre RS, Konarski JZ, Mancini DA, Zurowski M, Giacobbe P, Soczynska JK, **Kennedy SH**. Improving outcomes in depression: A focus on somatic symptoms. *J Psychosom Res.*, 2006; 60:279-282.
189. Mundt JC, Katzelnick DJ, **Kennedy SH**, Eisfeld BS, Bouffard BB, Greist JH. Validation of an IVRS version of the MADRS. *J Psych Res.*, 2006; 40: 243-246.
188. Konarski JZ, McIntyre RS, Soczynska JK, Bottas A, **Kennedy SH**. Clinical Translation of neuroimaging research in mood disorders. *Psychiatry*, 2006; 3:46-57.
187. **Kennedy SH**. Treatment guidelines for mania. 2006. *J Psychiatry Neurosc.*, 2006; 31:144.
186. McIntyre RS, Soczynska JK, Konarski JZ, **Kennedy SH**. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. *Expert Opinion Drug Saf.*, 2006; 5:157-168.
185. **Kennedy SH**, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. *Eur Neuropsychopharmacol.*, 2006; 16: 93-100.
184. Yatham LN (Co-Chair), **Kennedy SH** (Co-Chair), O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, Beaulieu S, Daigneault A, Milev R, Young T, Ravindran A, Schaffer A, Connolly M, Gorman CP. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the

- management of patients with bipolar disorder: consensus and controversies. *Bipolar Disorders*, 2005; 7:5-69.
183. McIntyre RS, Konarski JZ, Mancini D, Fulton K, Parikh SV, Grigoriadis S, Grupp L, Bakish D, Filteau M-J, Gorman C, Nemeroff CB, **Kennedy SH**. Measuring the severity of depression and remission in primary care: Validation of the HAMD-7 scale. *Can Med Assoc J.*, 2005; 173:1327-1334.
182. **Kennedy SH**, Clarkson RF. Enhancing onset of antidepressant action in late-life depression: The role of rapid disintegrating formulation mirtazapine. *Geriatrics & Aging*, 2005; 8:18-23.
181. Konarski JZ, McIntyre RS, Grupp LA, **Kennedy SH**. Is the cerebellum relevant in the circuitry of neuropsychiatric disorders? *J Psychiatry Neurosci.*, 2005; 30:178-186.
180. McIntyre R, Konarski J, Misener G, **Kennedy SH**. Bipolar disorder and diabetes mellitus: epidemiology, etiology and treatment implications. *An Clin Psychiatry*, 2005; 17:83-93.
179. Chopra K, Bagby M, Dickens S, **Kennedy SH**, Ravindran A, Levitan RD. A dimensional approach to personality in atypical depression. *Psychiatry Res.*, 2005; 134:161-167.
178. Mayberg HS, Lozano AM, Voon V, McNeeley HE, Seminowicz D, Hamani C, Schwalb JM, **Kennedy SH**. Deep brain stimulation for treatment resistant depression. *Neuron*, 2005; 45:651-660.
177. Lam RW, **Kennedy SH**. Using metaanalysis to evaluate evidence: practical tips and traps. *Can J Psychiatry*. 2005; 50:191-198.
176. McIntyre RS, Konarski JZ, Grigoriadis S, Fan N, Mancini DA, Fulton KA, Stewart DE, **Kennedy SH**. Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. *Can Med Assoc J*, 2005; 172:57-59.
175. Grigoriadis S, **Kennedy SH**, Srinivasan J, McIntyre RS, Fulton K. Antidepressant augmentation with raloxifene. *J Clin Psychopharmacol*, 2005; 25:96-98.
174. Shen J, **Kennedy SH**, Levitan RD, Kayumov L, Shapiro CM. The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses. *J Psych Neurosci*. 2005; 30:11-16.
173. McDowell I, Lindsay J, Sykes E, Verreault R, Laurin D, Hendrie HC, Hall KS, Ogunniyi A, Gao S, Frassati D, Tabib A, Lachaux B, Giloux N, Dalery J, Vittori F, Charvet D, Barel C, Bui-Xuan B, Megard R, Jenoudet LP, Descotes J, Vial T, Timour Q, Cohen NL, Ross EC, Bagby RM, Farvolden P, **Kennedy SH**, Boggild AK, Heisel MJ, Links PS, Limosin F, Loze J-Y, Zylberman-Bouhassira M, Schmidt ME, Perrin E, Rouillon F, Waraich P, Goldner EM, Somers JM, Hsu L, Callum JL, Wojciechowski AE, Pelletier G, Simpson JSA, Coodin S, Staley D, Cortens B, Desrochers R, McLandress S, Swinson R, Van Ameringen MV. Prevalence and incidence studies of mood disorders: a systematic review of the literature. *C J Psychiatry* 2004; 49:124-138.
172. McIntyre RS, Mancini DA, Srinivasan J, McCann S, Konarski JZ, **Kennedy SH**. The Antidepressant effects of risperidone and olanzapine in bipolar disorder. *Can J Clin Pharmacol*. 2004; 11:218-e223.
171. Bender A, **Kennedy SH**. Mental health and mental illness in the workplace: Diagnostic and treatment issues. Canadian Institute of Health Research Publication, Longwoods Publishing Corporation. *Healthcare Papers*. 2004; 5:1-17.
170. Montgomery SA, **Kennedy SH**, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. *Int Clin Psychopharmacol*. 2004; 19:271-280.
169. Seminowicz DA, Mayberg HS, McIntosh AR, Goldapple K, **Kennedy SH**, Segal Z, Rafi-Tari S. Limbic-Frontal Circuitry in Major Depression: A Path Modeling Metanalysis. *NeuroImage*. 2004; 22:409-418.
168. Lam RW, **Kennedy SH**. Evidence-based strategies for achieving and sustaining full remission in depression: Focus on metaanalyses. *Can J Psychiatry*. 2004; 49:17S-26S.
167. Levitan RD, Masellis M, Basile VS, Lam RW, Kaplan AS, Davis C, Muglia P, Mackenzie B, Tharmalingam S, **Kennedy SH**, Macciardi F, Kennedy JL. The Dopamine-4 Gene Associated with Binge Eating and Weight Gain in Women with Seasonal Affective Disorder: An Evolutionary Perspective. *Biological Psychiatry*. 2004; 56:665-669.

166. Cohen NL, Ross EC, Bagby RM, Farvolden P, **Kennedy SH**. The 5-Factor model of personality and antidepressant medication compliance. *Can J Psychiatry*. 2004; 49:106-113.
165. Levitan RD, Masellis M, Lam RW, Muglia P, Basile VS, Jain U, Kaplan AS, Tharmalingam S, **Kennedy SH** and Kennedy JL. Childhood inattention and dysphoria and adult obesity associated with the dopamine D4 receptor gene in overeating women with seasonal affective disorder. *J Neuropsychopharmacology*; 2004; 29: 179-186.
164. Goldapple K, Segal ZV, Garson C, Lau M, Bieling P, **Kennedy SH**, Mayberg H. Modulation of cortical-limbic pathways in major depression: Treatment specific effects of cognitive behavior therapy. *Archives of General Psychiatry*; 2004; 61:34-41.
163. Krüger S, Siminowicz D, Goldapple K, **Kennedy SH**, Mayberg HS. State and Trait Influences on Mood Regulation in Bipolar Disorder: Blood Flow Differences with an Acute Mood Challenge. *Biological Psychiatry*; 2003; 54:1274-1283
162. **Kennedy SH**, Lam RW. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. *Bipolar Disorder*; 2003; 2:36-47.
161. Grigoriadis S, **Kennedy SH**, Bagby RM, A comparison of antidepressant response in older and younger women. *J Clin Psychopharmacol*; 2003; 23: 405-407.
160. McIntyre RS, Mancini DA, Basile VS, Srinivasan J, **Kennedy SH**. Antipsychotic-induced weight gain: Bipolar disorder and leptin. *J Clin Psychopharmacol*; 2003; 23: 323-327.
159. **Kennedy SH**, Segal ZV, Cohen NL, Levitan RD, Gemar M, Bagby RM. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: An exploratory trial. *J Clin Psychiatry*; 2003; 64: 439-44.
158. **Kennedy SH**, Lam RW, Morris B; CANMAT Depression Work Group. Clinical guidelines for depressive disorders (Summary of recommendations relevant to family physicians). *Can Family Physician*. 2003; 49:489-491.
157. Meyer JH, McMain S, **Kennedy SH**, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S, Links P. Dysfunctional attitudes and 5-HT₂ receptors during depression and self harm. *Am J Psychiatry*. 2003; 160:90-9.
156. McIntyre RS, Mancini DA, McCann S, Srinivasan J, **Kennedy SH**. Valproate, bipolar disorder and polycystic ovarian syndrome. *Bipolar Disorders*. 2003; 5:28-35.
155. Farvolden P, **Kennedy SH**, Lam RM. Recent developments in the psychobiology and pharmacotherapy of depression: optimizing existing treatments and novel approaches for the future. *EOIDE*. 2003 12:65-86.
154. McIntyre RS, Fulton KA, Bakish D, Jordan J. **Kennedy SH**. The HAM-D7: A Brief Depression Scale to Distinguish Antidepressant Response From Symptomatic Remission. *Primary Psychiatry*. 2003; 10:39-42.
153. Knott V, Mahoney C, **Kennedy SH**, Evans K. EEG correlates of acute and chronic paroxetine treatment in depression. *J Affect Disord*. 2002; 69:241-249.
152. Grigoriadis S, **Kennedy SH**. Role of estrogen in the treatment of depression. *Am J Therapeutics*. 2002; 9:503-509.
151. Levitan RD, Masellis M, Basile VS, Lam RW, Jain U, Kaplan AS, **Kennedy SH**, Siegel G, Walker ML, Vaccarino FJ, and Kennedy JL. Polymorphism of the serotonin-2A receptor gene (5HT_{2A}) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. *J Affect Disord*. 2002; 71: 229-233.
150. **Kennedy SH**, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, Baker GB. Combining bupropion SR with venlafaxine, paroxetine or fluoxetine: a preliminary report on pharmacokinetic, therapeutic and sexual dysfunction effects. *J Clin Psychiatry* 2002; 63:181-186.
149. **Kennedy SH**. Full Remission: A Return to Normal Functioning. *J Psychiatry Neurosci*. 2002; 27:233-4.
148. **Kennedy SH**, McIntyre RS, Fallu A, Lam RW. Pharmacotherapy to sustain the fully remitted state. *J Psychiatry Neurosci*. 2002 ; 27 : 269-80.

147. McIntyre RS, **Kennedy SH**, Bagby RM, Bakish D. Assessing full remission. *J Psychiatry Neurosci*. 2002; 27:235-9.
146. Tranter R, O'Donovan C, Chandarana P, **Kennedy SH**. Prevalence and Outcome of Partial Remission in Depression. *J Psychiatry Neurosci*. 2002; 27:241-7.
145. Vanderkooy JD, **Kennedy SH**, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: A study of bupropion, moclobemide, paroxetine, sertraline and venlafaxine. *Can J Psychiatry*. 2002;47:174-180.
144. Lam RW, Wan DDC, Cohen NL, **Kennedy SH**. Combining antidepressants for treatment resistant depression: a review. *J Clin Psychiatry* 2002;63:685-693.
143. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, **Kennedy SH**. Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. *Bipolar Disorders* 2002; 4:207-213.
142. **Kennedy SH**, Lam RW, Cohen NL, Rosenbluth M, Sokolov ST, McIntyre RS, Chue P, Craigen G. Canadian Network for Mood and Anxiety Treatments. Reboxetine: A preliminary Report on its use through the Special Access Program. *J Psych Neurosci* 2002;27:418-422.
141. Levitan RD, Vaccarino FJ, Brown GM, **Kennedy SH**. Low-dose dexamethasone challenge in women with atypical major depression: pilot study. *J Psychiatry Neurosci* ; 2002;27:47 – 51.
140. Bagby RM, Gilchrist EJ, Rector NA, Dickens SE, Joffe RT, Levitt AJ, Levitan RD, **Kennedy SH**. The stability and validity of the sociotropy and autonomy personality dimensions as measured by the revised personal style inventory. *Cogn Ther Res*. 2001;21:765-779.
139. Meyer JH, Krueger S, Wilson AA, Christensen BK, Goulding V, Schaffer A, Minifie C, Houle S, Hussey D, **Kennedy SH**. Lower Dopamine Transporter Binding Potential in Striatum During Depression. *NeuroReport* 2001; 12:4121-5.
138. Levitan RD, Kaplan AS, Masellis M, Basile VS, Walker ML, Lipson N, Siegal GI, Woodside DB, Macciardi FM, **Kennedy SH**, Kennedy JL. Polymorphism of the Serotonin 5-HT1B Receptor Gene (HTR1B) Associated with Minimum Lifetime Body Mass Index in Women with Bulimia Nervosa. *Biol Psychiatry*. 2001;50:640 – 643.
137. **Kennedy SH**, Eisfeld BS, Meyer JH, Bagby RM. Antidepressants in Clinical Practice: Limitations of Assessment Methods and Drug Response. *Human Psychopharmacology*. 2001;16:105-114.
136. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, **Kennedy SH**. The Effect of Paroxetine Upon 5HT2A Receptors in Depression An [18F] Setoperone PET Imaging Study. *Am J Psychiatry*. 2001;45:78-85.
135. Woodside DB, Garfinkel PE, Lin E, Goering P, Kaplan AS, Goldbloom D, **Kennedy SH**. Males with full and partial syndrome eating disorders in the community - a comparison to non-eating disordered males and to females with full and partial eating symptoms *Am J Psychiatry*. 2001;158:570-574.
134. McIntyre RS, McCann SM, **Kennedy SH**. Antipsychotic Metabolic Effects: weight gain, diabetes mellitus and lipid abnormalities. *Can J Psychiatry*. 2001;46:273-281.
133. Knott V, Mahoney C, **Kennedy SH**, Evans K. EEG Power, Frequency, Asymmetry, and Coherence in Depression. *Psychiatry Res*. 2001;106:123-140.
132. Fu CH, Reed LJ, Meyer JH, **Kennedy SH**, Houle S, Eisfeld ES, Brown GM. Noradrenergic dysfunction in the prefrontal cortex in depression: an [15O] H2O PET study of the neuromodulatory effects of clonidine. *Biol Psychiatry*. 2001;49:317-25.
131. **Kennedy SH**, Evans K, Kruger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman A, Houle S, Vaccarino FJ. Changes in regional glucose metabolism with positron emission tomography following paroxetine treatment of major depression. *Am J Psychiatry*. 2001;158:899-905.
130. McIntyre RS, Mancini DA, Parikh SV, **Kennedy SH**. Lithium revisited. *Can J Psychiatry*. 2001;46:322-327.
129. Gemar MC, Segal ZV, Sagrati S, **Kennedy SH**. Mood Induced changes on the implicit association task in

- recovering depressed patients. *J Abnormal Psychology*. 2001;110:282-289.
128. Parikh SV, Lam RW, CPA/CANMAT Depression Work Group. CANMAT Clinical Guidelines for the treatment of Depressive Disorders: Section I: Major Depressive Disorder: Definitions, Prevalence and Health Burden. *Can J Psychiatry*. 2001;46:13S – 20S.
127. Reesal R, Lam RW, CPA/CANMAT Depression Work Group. CANMAT Clinical Guidelines for the treatment of Depressive Disorders: Section II: Major Depressive Disorder: Principles of Management. *Can J Psychiatry*. 2001;46:21S – 28S.
126. Segal SV, Whitney D, Lam RW, CPA/CANMAT Depression Work Group. CANMAT Clinical Guidelines for the treatment of Depressive Disorders: Section III: Psychotherapy for Major Depressive Disorder. *Can J Psychiatry*. 2001;46:29S – 37S.
125. **Kennedy SH**, Lam RW, Cohen NL, Ravindran A, CPA/CANMAT Depression Work Group. CANMAT Clinical Guidelines for the treatment of Depressive Disorders: Section IV: Pharmacotherapy and Other Biological Treatments for Major Depressive Disorder. *Can J Psychiatry*. 2001;46:38S – 58S.
124. Segal SV, **Kennedy SH**, Cohen NL, CPA/CANMAT Depression Work Group. CANMAT Clinical Guidelines for the treatment of Depressive Disorders: Section V: Treatment for major depressive disorder: Combining Psychotherapy and Pharmacotherapy. *Can J Psychiatry*. 2001;46:59S – 62S.
123. Thorpe L, Kutcher SP, **Kennedy SH**, CPA/CANMAT Depression Work Group. CANMAT Clinical Guidelines for the treatment of Depressive Disorders: Section VI: Treatment for Major Depressive Disorder: Special Populations. *Can J Psychiatry* 2001;46:63S – 76S.
122. Enns M, Swenson JR, McIntyre RS, Swinson R, **Kennedy SH**, CPA/CANMAT Depression Work Group. CANMAT Clinical Guidelines for the treatment of Depressive Disorders: Section VII: Treatment for Major Depressive Disorder: Comorbidity. *Can J Psychiatry*. 2001;46:76S – 90S.
121. **Kennedy SH**, Eisfeld BS, Cooke RG. Quality of Life: An Important Dimension in assessing the treatment of Depression. *J Psych Neurosci* 2001;26(suppl):S23 – S28.
120. **Kennedy SH**, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline and venlafaxine. *J Clinical Psych*. 2000; 61: 276-281.
119. Dalton EJ, Rotondi D, Levitan RD, **Kennedy SH**, Brown GM. Use of Slow Release Melatonin in Treatment Resistant Depression. *J Psychiatry Neurosci*. 2000;25:48-52.
118. Magder D, Aleksic I, **Kennedy SH**. Tolerability and efficacy of high dose moclobemide monotherapy in combination with lithium and trazodone. *J Clin Psychopharmacol* 2000;20:394-395.
117. Kruger S, **Kennedy SH**. Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge eating disorder. *J Psychiatry Neurosci*. 2000;5:24-50.
116. Ramasubbu R, Flint A, Brown G, Awad G, **Kennedy SH**. Neurohormonal Responses to D-fenfluramine in Healthy Elderly Subjects. A Placebo-Controlled Study. *Psychoneuroendocrinology*. 2000; 25:139-150.
115. Bezchlibnyk-Butler, K, Aleksic I., **Kennedy SH**. Citalopram – A Review of Pharmacological and Clinical Effects. *J Psychiatry Neurosci*. 2000; 25:241-54.
114. Knott V, Mahoney C, **Kennedy SH**, Evans K. Pre-treatment EEG and its relationship to depression severity and paroxetine treatment outcome. *Pharmacopsychiatry*. 2000;33:1 – 5.
113. Levitan RD, Jian-Hua S, Jindal R, Driver HS, **Kennedy SH**, Shapiro CM. Tryptophan combined with fluoxetine with treatment of major depression: antidepressant and hypnotic effects. *J Psych Neurosci*. 2000;25:337-346.
112. Ohayon MM, Shapiro CM, **Kennedy SH**. Differentiating DSM-IV anxiety disorder and depressive disorder in the general population: Comorbidity and treatment consequences. *Can J Psychiatry*. 2000;45:166-172.
111. Meyer JH, Swinson R, **Kennedy SH**, Houle S, Brown GM. Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. *Psychiatry Res*. 2000;15:133-143.

110. Cohen NL, Parikh SV, **Kennedy SH**. Medication compliance in Mood Disorders: Relevance of Health Belief Model and other determinants. *Primary Care Psychiatry*. 2000;6:101-110.
109. Lai CT, Gordon ES, **Kennedy SH**, Bateson AN, Coutts RT, Baker GB. Determination of paroxetine levels in human plasma using gas chromatography with electron-capture detection. *J Chromatogr B Biomed Sci Appl*. 2000;749:275-279.
108. Schaffer A, Levitt AJ, Bagby RM, **Kennedy SH**, Levitan RD, Joffe RT. Suicidal ideation in major depression: sex differences and impact of comorbid anxiety. *Can J Psychiatry*. 2000;45:822-826.
107. Ramasubbu R, **Kennedy SH**, Flint A, Brown G, Awad G. A neuroendocrine study of serotonin function in depressed stroke patients and healthy controls. *J Affect Disord*. 1999;52:121-133.
106. Case T, Lemieux S, **Kennedy SH**, Lewis GF. Elevated plasma lipids in patients with binge eating disorders are found only in those who are anorexic. *Int J Eat Disord*. 1999; 25:187-193.
105. Baker GB, Urchuk LJ, McKenna KF, **Kennedy SH**. Metabolism of monoamine oxidase inhibitors. *Cell Mol Neurobiol*. 1999; 19: 411- 426.
104. Parikh SV, Lesage AD, **Kennedy SH**, Goering PN. Depression in Ontario: under-treatment and factors related to antidepressant use. *J Affect Disord*. 1999; 52:67-76.
103. Davis R, McVey G, Heinmaa M, Rockert W, **Kennedy SH**. Sequencing of cognitive-behavioral treatments for bulimia nervosa. *Int J Eat Disord*. 1999; 25: 361-374.
102. Meyer JH, Kapur S, Houle S, DaSilva J, Owczarek B, Brown GM, Wilson AA, **Kennedy SH**. Prefrontal Cortex 5-HT₂ Receptors in Depression [18F] Setoperone PET Imaging. *Am J Psychiatry*. 1999; 156: 1029-1034.
101. Meyer JH, Cho R, **Kennedy SH**, Kapur S. The Effects of Single Dose Nefazodone and Paroxetine Upon 5-HT_{2a} Binding Potential in Humans Using [18F]-Setoperone PET. *Psychopharmacology (Berl)*. 1999; 144: 279-281.
100. **Kennedy SH**, Eisfeld, BS. Clinical aspects of depression. *Clinical Cornerstones*. 1999; 1: 1-16.
99. McIntyre R, Parikh SV, **Kennedy SH**. Lithium Revisited: Current status, future prospects. *Prim Care Psychiatry*. 1999; 5: 41-48.
98. Bagby RM, Levitan RD, **Kennedy SH**, Levitt AJ, Joffe RT. Selective Alteration of personality in response to noradrenergic and serotonergic antidepressant medication: evidence of non-specificity. *Psychiatry Res*. 1999; 86: 211-216.
97. Bagby RM, Rector NA, Segal SV, **Kennedy SH**, Schuller DR. Rumination and distraction in major depression: Assessing response to pharmacological treatment. *J Affect Disord*. 1999;55:225-229.
96. Javanmard M, Shlik J, **Kennedy SH**, Vaccarino Fj, Houle S, Bradwejn J. Neuroanatomic Correlates of CCK-4 induced panic attacks in healthy humans: A comparison of two time points. *Biol Psychiatry*. 1999;45:872-882.
95. **Kennedy SH**, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. *J Affect Disord*. 1999;56:201-208.
94. Bagby RM, Costa PT, McCrae RR, Livesley WJ, **Kennedy SH**, Levitan RD, Levitt AJ, Joffe RT, Young LT. Replicating the Five Factor Model of Personality in a psychiatric sample. *Personality and Individual Differences*. 1999;27:1135-1139.
93. Bagby RM, Rector NA, Bindseil K, Dickens SE, Levitan RD, **Kennedy SH**. Self-report ratings and informants' ratings of personalities of depressed outpatients. *Am J Psychiatry*. 1998;155:437-438.
92. Levitan RD, Kaplan AS, Brown GM, Vaccarino FJ, **Kennedy SH**, Levitt AJ, Joffe RT. Hormonal and subjective responses to intravenous m-chlorophenylpiperazine in women with seasonal affective disorder. *Arch Gen Psychiatry*. 1998;55:244-249.
91. Ramasubbu R, **Kennedy SH**, Flint A, Brown G, Awad G, Cooper T. Diminished serotonin mediated prolactin responses in nondepressed stroke patients compared to healthy normals. *Stroke*. 1998; 29: 1293-1298.
90. Meyer J, **Kennedy SH**, Brown GM. No effect of depression on [15O]H₂O PET response to intravenous D-

- fenfluramine. *Am J Psychiatry*. 1998; 155: 1241-1246.
89. Levitan RD, Parikh SV, Lesage AD, Hegadoren KM, Adams M, **Kennedy SH**, Goering PN. Major depression in individuals with a history of childhood physical or sexual abuse: relationship to neurovegetative features, mania and gender. *Am J Psychiatry*. 1998; 155: 1746-1752.
88. Krüger S, McVey G, **Kennedy SH**. The changing profile of anorexia nervosa. *J Psychosom Res*. 1998; 48: 533-547.
87. Esplen MJ, Garfinkel PE, Olmsted M, Gallop RM, **Kennedy SH**. A randomized controlled trial of guided imagery in bulimia nervosa. *Psychol Med*. 1998; 28: 1347-1357.
86. Levitan RD, Kaplan AS, Brown GM, Joffe RT, Levitt AJ, Vaccarino FJ, **Kennedy SH**. Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression. *Biol Psychiatry*. 1997;41:366-368.
85. **Kennedy SH**. Continuation and maintenance treatments in major depression--the neglected role of monoamine oxidase inhibitors. *J Psychiatry Neurosci*. 1997;22:127-131.
84. Lapiere YD, Joffe RT, McKenna K, **Kennedy SH**, Ingram P, Reesal R, Beauclair L, Annable L. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. *J Psychiatry Neurosci*. 1997;22:118-126.
83. Potts AJ, Bennett PJ, **Kennedy SH**, Vaccarino FJ. Depressive symptoms and alterations in sucrose taste perception: cognitive bias or a true change in sensitivity? *Can J Exp Psychol*. 1997;51:57-60.
82. Robins CJ, Bagby RM, Rector NA, Lynch TR, **Kennedy SH**. Sociotropy, autonomy, and patterns of symptoms in patients with major depression: a comparison of dimensional and categorical approaches. *Cogn Ther Res*. 1997;21:285-300.
81. Levitan RD, Lesage A, Parikh SV, Goering P, **Kennedy SH**. Reversed neurovegetative symptoms of depression: a community study of Ontario. *Am J Psychiatry*. 1997;154:934-940.
80. Neitzert CS, Davis C, **Kennedy SH**. Personality factors related to the prevalence of somatic symptoms and medical complaints in a healthy student population. *Br J Med Psychol*. 1997;70:93-101.
79. Lambe EK, Katzman DK, Mikulis DJ, **Kennedy SH**, Zipursky RB. Cerebral gray-matter volume deficits after weight-recovery from anorexia nervosa. *Arch Gen Psychiatry*. 1997;54:537-542.
78. **Kennedy SH**, Javanmard M, Vaccarino FJ. A review of functional neuroimaging in mood disorders: Positron emission tomography and depression. *Can J Psychiatry*. 1997; 42: 467-474.
77. Bagby RM, **Kennedy SH**, Dickens SE, Minifie CE, Schuller DR. Personality and symptom profiles of the angry hostile depressed patient. *J Affect Disord*. 1997;45:155-160.
76. Bagby RM, **Kennedy SH**, Schuller DR, Dickens SE, Minifie CE, Levitt AJ, Joffe RT. Differential pharmacological treatment response in high angry hostile and low angry hostile depressed outpatients. *J Affect Disord*. 1997; 45:161.
75. **Kennedy SH**, Kutcher SP, Ralevski E, Brown GM. Nocturnal melatonin and 24 hour sulphatoxymelatonin in various phases of bipolar affective disorder. *Psychiatry Res*. 1996;63:219-222.
74. **Kennedy SH**, Ralevski E, Davis C, Neitzert C. The effects of moclobemide on sexual desire and functioning in healthy volunteers. *Eur Neuropsychopharmacol*. 1996;6:177-181.
73. Al-Jeshi AA, Jeffries J, **Kennedy SH**. Overview of new anti-depressants. *Saudi Med Journal* 1996;17:553-563.
72. **Kennedy SH**, Bagby RM. Efficacy and effectiveness in the antidepressant treatment of depression: beyond metaanalysis. *Can J Psychiatry*. 1996;41:609-610.
71. Berber M, **Kennedy SH**. The Canadian National Awareness Campaign on Depression. *Prim Care Psychiatry* 1996;2:165-168.
70. Garfinkel PE, Lin E, Goering P, Spegg C, Goldbloom DS, **Kennedy SH**, Kaplan AS, Woodside B. Purging and

- non-purging forms of bulimia nervosa in a community sample. *Int J Eat Disord.* 1996;20:231-238
69. De Groot J, **Kennedy SH**. Integrating clinical and research psychiatry. *J Psychiatry Neurosci.* 1995; 20: 150-154.
68. **Kennedy SH**, Katz R, Rockert W, Mendlowitz S, Ralevski E, Clewes J. Assessment of personality disorders in anorexia nervosa and bulimia nervosa: a comparison of self-report and structured interview methods. *J Nerv Mental Dis.* 1995; 183: 358-364.
67. Belitsky C., **Kennedy SH**. Transition to psychiatric residency: unique stresses, unique rewards. *Jefferson J Psychiatry.* 1995; 12: 37-46.
66. Garfinkel PE, Lin B, Goering P, Goldbloom DS, **Kennedy SH**, Kaplan AS, Woodside DB. Bulimia nervosa in a Canadian community sample: prevalence, comorbidity early experiences and psychosocial functioning. *Am J Psychiatry.* 1995; 152: 1052-1058.
65. **Kennedy SH**, Gnam W, Ralevski E, Brown GM. Melatonin responses to clonidine and yohimbine challenges. *J Psychiatry Neurosci.* 1995; 20: 297-304.
64. **Kennedy SH**, Katz R, Neitzert CS, Ralevski E, Mendlowitz S. Exposure with response prevention treatment of anorexia nervosa-bulimic subtype and bulimia nervosa. *Behav Res Ther.* 1995; 33: 685-689.
63. Davis C, Ralevski E, **Kennedy SH**, Neitzert C. The role of personality factors in the reporting of side-effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. *J Clin Psychopharmacol.* 1995;15:347-352.
62. Garfinkel PE, **Kennedy SH**, Kaplan AS. Views on classification and diagnosis of the eating disorders. *Can J Psychiatry.* 1995;40:445-456.
61. Davis C, **Kennedy SH**, Ralevski E, Dionne M, Brewer H, Neitzert C, Ratusny D. Obsessive-compulsiveness and physical activity in anorexia nervosa and high level exercising. *J Psychosom Res.* 1995; 39:967-976.
60. Garfinkel PE, Lin E, Goering P, Spegg C, Goldbloom DS, **Kennedy SH**, Kaplan AS, Woodside DB. Should amenorrhea be necessary for the diagnosis of anorexia nervosa? Evidence from a Canadian community sample. *Br J Psychiatry.* 1996;168:500-506.
59. **Kennedy SH**, Goldbloom DS. Advances in the treatment of anorexia nervosa and bulimia nervosa. *CNS Drugs.* 1994; 1: 201-212.
58. Vaccarino FJ, **Kennedy SH**, Ralevski E, Black R. The effects of growth hormone releasing factor on food consumption in anorexia nervosa and normals. *Biol Psychiatry.* 1994; 35: 446-451.
57. **Kennedy SH**, Katz R, Ford CG, Ralevski E. Changes in perceptions and emotions before and after refeeding in anorexia nervosa. *Irish J Psychol Med.* 1994; 11: 57-63.
56. Davis BA, **Kennedy SH**, D'Souza J, Durden DA, Goldbloom DS, Boulton AA. Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behaviour and mood rating scores in brofaromine treated women with bulimia nervosa. *J Psychiatry Neurosci.* 1994; 19: 282-288.
55. Lewis GF, Ralevski E, Neitzert CS, Uffelman KD, Steiner G, **Kennedy SH**. Lipids and lipoproteins in anorexia nervosa before and after partial weight restoration. *Endocrinology and Metabolism.* 1994; 1: 109-115.
54. **Kennedy SH**. Melatonin disturbances in anorexia nervosa and bulimia nervosa. *Int J Eat Disord.* 1994; 16: 257-265.
53. Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradwejn J, **Kennedy SH**, Sharma V, Remick RA, Kukha-Mohamad SA, Belanger MD, Snaith J, Beauclair L, Pohlmann H, D'Souza J. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. *J Affect Disord.* 1994; 32: 105-114.
52. Ramasubbu R, **Kennedy SH**. Factors complicating the diagnosis of depression in cerebral vascular disease. Part I: phenomenological and nosological issues. *Can J Psychiatry.* 1994; 39: 596-600.
51. Ramasubbu R, **Kennedy SH**. Factors complicating the diagnosis of depression in cerebral vascular disease.

- Part II: neurological deficits and various diagnostic methods. *Can J Psychiatry*. 1994; 39: 601-607.
50. **Kennedy SH**, Kaplan AS, Garfinkel PE, Rockert W, Toner BB, Abbey S. Depression in anorexia nervosa and bulimia nervosa: discriminating depressive symptoms and episodes. *J Psychosom Res*. 1994; 38: 773-782.
49. Davis C, **Kennedy SH**, Ralevski E, Dionne M. The role of physical activity in the development and maintenance of eating disorders. *Psychol Med*. 1994; 24: 957-967.
48. Gallop R, **Kennedy SH**, Stern D. The therapeutic alliance on an inpatient unit for eating disorders. *Int J Eat Disord*. 1994; 16: 405-410.
47. **Kennedy SH**, Brown GM, Ford C, Ralevski E. The acute effects of starvation on sulphatoxy-melatonin output subgroups of patients with anorexia nervosa. *Psychoneuroendocrinology*. 1993; 18:131-139.
46. Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradwejn J, **Kennedy SH**, Sharma V, Remick RA, Kukha-Mohammad SA, Beauclair L, Snaith J, D'Souza J. Brofaromine in depression: a Canadian multicentre placebo trial and a review of standard drug comparative studies. *Clin Neuropharmacol*. 1993; 16: S51-S54.
45. **Kennedy SH**, Goldbloom DS, Ralevski E, Davis C, Lofchy J. Is there a role for selective MAO-Inhibitor therapy in bulimia nervosa? A placebo controlled trial of brofaromine. *J Clin Psychopharmacol*. 1993; 13: 415-422.
44. **Kennedy SH**, Davis BA, Brown GM, Ford CG, D'Souza J. Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa. *Neurochem Res*. 1993; 18: 1281-1285.
43. Grof P, Joffe RT, **Kennedy SH**, Persad E, Syortiuk J, Bradford D. An open trial of oral flesinoxan, a 5HT1A full receptor agonist in the treatment of resistant depression. *Int Clin Psychopharmacol*. 1993; 8: 167-172.
42. Davis BA, **Kennedy SH**, Boulton AA, Durden DA, D'Souza J, Goldbloom DS. The effect of the MAO-A selective inhibitor brofaromine on plasma and urine concentrations of some biogenic amines and their acid metabolites in bulimia nervosa. *Prog Neuropsychopharmacol Biol Psychiatry*. 1993; 17: 747-763.
41. **Kennedy SH**, Garfinkel PE. Advances in diagnosis and treatment of anorexia nervosa and bulimia nervosa. *Can J Psychiatry*. 1992; 37: 309-315.
40. **Kennedy SH**, Brown GM. Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. *Psych Res*. 1992; 43: 177-185.
39. De Groot J, **Kennedy SH**, Rodin G., McVey G. Correlates of sexual abuse in women with anorexia nervosa and bulimia nervosa. *Can J Psychiatry*. 1992; 37: 516-518.
39. **Kennedy SH**, Goldbloom DS. Current perspectives on drug therapies for anorexia nervosa and bulimia nervosa. *Drugs*. 1991; 41: 367-377.
38. **Kennedy SH.**, Brown GM., McVey G., Garfinkel PE. Pineal and adrenal function before and after refeeding in anorexia nervosa. *Biol Psychiatry*. 1991; 30: 216-224.
37. Goldbloom DS., **Kennedy SH**. Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. *J Clin Psychiatry*. 1991; 52: 261-262.
36. Kaplan AS., Goldbloom D., Woodside DB., **Kennedy SH.**, Rakowski H. Mitral valve prolapse in eating disorders and panic disorders. *Int J Eat Disord*. 1991; 10: 531-537.
35. Levitt AJ, Joffe RT, **Kennedy SH**. Bright light augmentation in antidepressant nonresponders. *J Clin Psychiatry*. 1991; 52: 336-337.
34. **Kennedy SH**, Joffe RT, Bradwejn J, Kusalic M. Practical issues in managing bipolar depression. *Int Clin Psychopharmacol*. 1991; 6: S 53-72.
33. **Kennedy SH.**, de Groot J., Ralevski E., Read K. A comparison of adinazolam and desipramine in the treatment of major depression. *Int Clin Psychopharmacol*. 1991; 6: 65-76.
32. Abbey SE, Toner BE, Garfinkel PE, **Kennedy SH**, Kaplan AS. Self report symptoms that predict major depression in patients with prominent physical symptoms. *Int J Psychiatry Med*. 1990; 20: 247-258.

31. **Kennedy SH**, Brown GM, Garfinkel PE, McVey G, Costa D, Parienti V. Sulphatoxy melatonin: an index of depression in anorexia nervosa and bulimia nervosa. *Psychiatry Res.* 1990; 32: 221-227.
30. **Kennedy SH**, McVey G, Katz R. Personality disorders in anorexia nervosa and bulimia nervosa. *J Psychiatry Res.* 1990; 24: 259-269.
29. **Kennedy SH**, Brown GM, Garfinkel PE. Melatonin profiles in anorexia nervosa and bulimia nervosa. *Neuroendocrinol Letters.* 1990; 12: 292.
28. Woodside DB, Walfish P, Kaplan AS, **Kennedy SH**. Graves disease in a woman with thyroid hormone abuse, bulimia nervosa and a history of anorexia nervosa. *Int J Eat Disord.* 1990; 10: 111-115.
27. Ennis J, Barnes R, **Kennedy SH**, Trachtenberg D. Depression in self-harm patients. *Br J Psychiatry.* 1989; 154: 41-47.
26. **Kennedy SH**, Craven JL, Rodin GM. Major depression in renal dialysis patients: an open trial of antidepressant therapy. *J Clin Psychiatry.* 1989; 50: 60-63.
25. **Kennedy SH**, Garfinkel PE, Parienti V, Costa D, Brown GM. Changes in melatonin but not cortisol are associated with depression in eating disorder patients. *Arch Gen Psychiatry.* 1989; 46: 73-78.
24. Goldbloom DS, **Kennedy SH**, Kaplan AS, Woodside DB. Anorexia nervosa and bulimia nervosa. *CMAJ.* 1989; 140: 1149-1154.
23. **Kennedy SH**, Garfinkel PE, Stokl S, Whynot C. Measured weight loss and the dexamethasone suppression test. *Can J Psychiatry.* 1989; 34: 707-709.
22. Garfinkel PE, Goldbloom DS, Kaplan AS, **Kennedy SH**. The clinician-investigator interface in psychiatry: I Values and problems. *Can J Psychiatry.* 1989; 34: 361-363.
21. Garfinkel PE, **Kennedy SH**, Kaplan AS, Goldbloom DS. The clinician-investigator interface in psychiatry. II The role of the clinical investigation unit. *Can J Psychiatry.* 1989; 34: 364-368.
20. **Kennedy SH**, Joffe RT. Pharmacological management of refractory depression. *Can J Psychiatry.* 1989; 34: 451-456.
19. **Kennedy SH**, Tighe S, McVey G, Brown GM. Single case study: melatonin and cortisol "switches" during mania, depression, and euthymia in a drug-free bipolar patient. *J Nerv Ment Dis.* 1989; 177: 300-303.
18. Kocerginski D, **Kennedy SH**, Swinson RP. Clonazepam and lithium: a toxic combination in the treatment of mania? *Int Clin Psychopharmacol.* 1989; 4: 195-199.
17. **Kennedy SH**, Heselgrave RJ. Cardiac regulation in bulimia nervosa. *J Psychiatry Res.* 1989; 23: 267-273.
16. **Kennedy SH**, Garfinkel PE. Patients admitted to hospital with anorexia nervosa and bulimia nervosa: psychopathology, weight gain, and attitudes toward treatment. *Int J Eat Disord.* 1989; 8: 181-190.
15. Piran N, Lerner P, Garfinkel PE, **Kennedy SH**, Brouillette C. Personality disorders in anorexic patients. *Int J Eat Disord.* 1988; 7: 589-599.
14. **Kennedy SH**, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE. A trial of isocarboxazid in the treatment of bulimia nervosa. *J Clin Psychopharmacol.* 1988; 8: 391-396.
13. Robillard M, **Kennedy SH**, Allen L, Kirschenblat D, Steiner M. Variations in dexamethasone suppression test results: RIA values exceed CPBA values. *Psychiatry J Univ Ottawa.* 1988; 13: 122-123.
12. Parienti V, **Kennedy SH**, Brown GM, Costa D. Boulimie, boulimie-anorexie et secretion nocturne de melatonine et de cortisol. *L'Encephale.* 1988; 14: 421-425.
11. Craven JL, Rodin GM, Johnson L, **Kennedy SH**. The diagnosis of major depression in renal dialysis patients. *Psychosom Med.* 1987; 49: 482-492.
10. Kerr A, **Kennedy SH**, Stern D. Inpatient treatment for anorexia nervosa and bulimia. *Br Rev An Bulim.* 1987; 2: 5-16.
9. Oyebode F, **Kennedy SH**, Davison K. Psychiatric sequelae of subarachnoid haemorrhage. *Br J Hosp Med.*

- 1986; 36: 104-108.
8. **Kennedy SH**, Piran N, Garfinkel PE. Monoamine oxidase therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid. *J Clin Psychopharmacol.* 1985; 5: 279-285.
 7. Piran N, **Kennedy SH**, Garfinkel PE, Owens M. Affective disturbance in eating disorders. *J Nerv Ment Disord.* 1985; 173; 395-400.
 6. Weiner J, **Kennedy SH**. Akinesia and mutism following methylphenidate mood challenge. *J Clin Psychopharmacol.* 1985; 5: 231-233.
 5. Ennis J, Barnes R, **Kennedy SH**. Dexamethasone suppression test and self-harm patients. *Br J Psychiatry.* 1985; 147: 419-423.
 4. Roy A, **Kennedy SH**. Risk factors for depression in Canadians. *Can J Psychiatry.* 1984; 29:11-13.
 3. **Kennedy SH**, Thompson R, Stancer HC, Roy A, Persad E. Life events precipitating mania. *Br J Psychiatry.* 1983; 142: 398-403.
 2. Roy A, Thompson R, **Kennedy SH**. Depression in chronic schizophrenia. *Br J Psychiatry.* 1983; 142: 465-470.
 1. Garfinkel PE, Garner DM, Kaplan AS, Rodin G, **Kennedy SH**. Differential diagnosis of emotional disorders that cause weight loss. *Can Med Assoc J.* 1983; 129: 939-945.

ii. Letters in refereed Journals

18. Schaffer A, Parikh SV, Kennedy SH et al. Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. *Bipolar Disorders.* 2013; 15:338-339.
17. Thase ME, Kennedy SH, Larsen KG. Can a true effect be built on a wrong model? *Br J Psychiatry.* 2012; 200(6):512-3.
16. Grigoriadis S, Bouffard BA, Kennedy SH, Bagby RM, Joffe, RT. A comparison of desipramine response in younger and older women. *J Clin Psychopharm.* 2010. 30(1):80-2.
15. Ravindran LN, Eisfeld BS, Kennedy SH. Combining mirtazapine and duloxetine in treatment resistant depression improves outcomes and sexual function. *J Clin Psychopharm.* 2008; 28:107-108.
14. Grigoriadis S, Konarski JZ, Kennedy SH, Mancini DA, McIntyre RS. Sex differences in antidepressant response in a Canadian primary-care sample. *J Clin Psychopharmacol.* 2007; 27: 95-98.
13. Kennedy SH, Segal ZV, Lam RW, Whitney DK. Short-term dynamic psychotherapies in the treatment of Major Depression. Reply to Dr. Allan Abbass. *Can J Psychiatry.* 2002;47:49-50
12. Bagby RM, Rector NA, Levitan R, Kennedy SH. Personality ratings of depressed outpatients. Reply to Dr. Reich. *Am J Psychiatry.* 1999;156:1124-1125.
11. Goldbloom DS, Davis R, Kaplan AS, Kennedy SH. Advertising meal replacement products. *Can Med Assoc J.* 1991;145: 1999-200.
10. Levitt AJ, Kennedy SH, Brown GM, Stern K. Tryptophan treatment and melatonin response in a patient with seasonal affective disorder. *J Clin Psychopharmacol.* 1991; 11:74-75.
9. Goldbloom DS, Kennedy SH. Post-residency fellowship training. *Can J Psychiatry.* 1991, 36:151.
8. Joffe RT, Levitt AJ, Kennedy SH. Thyroid function and phototherapy in seasonal affective disorder. *Am J Psychiatry.* 1991;148:393.

7. Kennedy SH, Garfinkel PE, Goldbloom DS, Kaplan AS. Clinician investigator training in Canada: a response to Dr. Myre Sim. *Can J Psychiatry*. 1990; 35: 720-721.
6. Kennedy SH, Garfinkel PE, Brown GM. Melatonin and sulphatoxy melatonin in eating disorder patients. *Br J Psychiatry*. 1989; 154: 272-273.
5. Kennedy SH. Sodium bicarbonate abuse in anorexia nervosa. *J Clin Psychiatry*. 1988; 49: 168.
4. Cooper PJ, Kennedy SH. Capgras Phenomenon: an unusual variant occurring in the setting of chronic schizophrenia. *Can J Psychiatry*. 1988; 33: 45.
3. Piran N, Kennedy SH, Garfinkel PE, Whynot C. Eating disorders, affective illness and borderline personality disorder. *J Clin Psychiatry*. 1988; 49: 125.
2. Kennedy SH, Ozersky S, Robillard M. Refractory bipolar illness may not respond to verapamil. *J Clin Psychopharmacol*. 1986; 6: 316-317.
1. Kennedy SH, Piran N, Garfinkel PE. Isocarboxazid in the treatment of bulimia. *Am J Psychiatry*. 1986; 143: 1495-1496.

ii. Books

13. Kennedy SH, Gorwood P. Successful management of Major Depressive Disorder. 2nd Edition. Future Medicine. London, UK, 2014.
12. Guide – Successful Management of Major Depressive Disorder, Kennedy SH and Gorwood P. Evolving Medicine Ltd, London, UK, 2012.
11. Psychotropic Drugs Fast Facts, Kennedy SH and McIntyre RS. Norton Professional Books. 4th Edition, 2008.
10. Treating Depression Effectively: Applying Clinical Guidelines. Kennedy SH, Lam R, Thase M and Nutt D. Informa Health Care (Second Edition) 2007.
9. Depression and Personality: Conceptual and Clinical Challenges. Rosenbluth MR, Kennedy SH and Bagby M. American Psychiatric Publishing Inc. (2005) – Spanish Translation printed 2007.
8. Treating Depression Effectively: Applying Clinical Guidelines. Kennedy SH, Lam R, Thase M and Nutt D. Martin Dunitz. 2004.
7. Clinical Guidelines for the Treatment of Depressive Disorders. Kennedy SH, Lam RW, Cohen NL, Ravindran AV, CANMAT Depression Working Group (Chair: SH Kennedy). 2004.
6. Guidelines for the Diagnosis and Pharmacological Treatment of Depression. CANMAT Depression Working Group (Chair: SH Kennedy). Republished as 1st edition. Revised September 1999.
5. Guidelines for the Diagnosis and Pharmacological Treatment of Depression. CANMAT Depression Working Group (Chair: SH Kennedy). December, 1998.
4. Defeating Depression. Kennedy SH, Parikh SV, Shapiro C (eds). Toronto. Joli Joco Publications Inc. 1998. (Also available in French, Spanish and Portuguese).
3. Clinical Advances in Monamine Oxidase Inhibitor Therapies. Kennedy SH (ed). Washington, DC. American Psychiatric Press Inc. 1994.
2. Handbook of Eating Disorders. Kennedy SH (ed). Toronto. University of Toronto. 1993.
1. The Biology of Feast and Famine - Relevance to Eating Disorders. Anderson GH, Kennedy SH (eds). New York. Academic Press. 1992.

iv. Book Chapters

54. Yatham L, Kennedy SH. Mood Disorders: Pharmacological Treatment of Depression and Bipolar Disorders. In Sadock, Sadock & Ruiz Textbook of Comprehensive Psychiatry, 10th Ed. 2016.
53. McInerney SJ, Gorwood P, Kennedy SH. Cognition and Biomarkers in MDD. In Cha D, McIntyre R. Cognitive Dysfunction in Major Depressive Disorder (2016).
52. McInerney SJ, Giacobbe P, Cyriac A & Kennedy SH. Deep Brain Stimulation: Clinical Results in Depression. In Hamani C, Lozano A, Holtzheimer P, Mayberg H: Neuromodulation in Psychiatry (2016).
51. Parikh SV, Kennedy SH. Further integration of patient, provider, and systems treatment approaches in bipolar disorder: Where new evidence meets practice reality in Mood Disorders Handbook. (Second edition) 2012.
50. Kennedy, SH, Rizvi, SJ. Melatonin receptor agonists/5-HT_{2c} antagonists. In Stein DJ (editor): Novel Antidepressants for Major Depressive Disorder. Future Science E-books. 2012.
49. Kennedy SH, Rizvi SJ, Giacobbe P. The nature and treatment of therapy resistant depression. In Cryan JF & Leonard BE's Depression: From Psychopathology to Pharmacotherapy Mood Trends Pharmacopsychiatry. Basel Karger. 2010; Vol 27:243-253.
48. Kennedy SH, Holt A, Baker G. Monoamine Oxidase Inhibitors. In Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 9th edition. Sadock BJ, Sadock VA (eds). Philadelphia, PA: Lippincott Williams and Wilkins. 2009; Vol 2:3154-64.
47. Kennedy SH, Parikh SV, Grigoriadis S. Psychiatric Disorders: Depression. Therapeutic Choices. 5th Edition Update. Canadian Pharmacist Association. 2009.
46. SH. Medical Management and Indications for Surgery in Depression. In Textbook of Stereotactic & Functional Neurosurgery. 2nd edition. Lozano AM, Gildenberg PL & Tasker RR (eds). New York: Springer. 2009; 2925-2941.
45. Eisfeld BS. Psychiatric Disorders: Depression. Therapeutic Choices. 5th Edition. Canadian Pharmacist Association. 2007; Ch. 5, 60-77.
44. Kennedy SH, Farvolden P, Cohen NL, Bagby RM, Costa PT. The Impact of Personality on the Pharmacological Treatment of Depression. In Depression and Personality: Conceptual and Clinical Challenges. Rosenbluth MR, Kennedy SH and Bagby M. Washington: American Psychiatric Publishing Inc. 2005.
43. Kennedy SH, Baker G, Holt, A. Monoamine Oxidase Inhibitors. In Comprehensive Textbook of Psychiatry. 8th edition. Sadock V, Sadock BJ (eds). New York NY: Williams and Wilkins. 2004; Ch 19, 2854-2863.
42. Kennedy SH, Holt A, Baker G. MAOI. *Antidepressants: Past, Present and Future*. Handbook of Experimental Pharmacology. Feighner J, Preskorn SH, & Stanga C (eds). Heidelberg: Springer. 2004; 209-239.
41. Parikh SV, Kennedy SH. Integration of patient, provider, and systems treatment approaches in bipolar disorder. Where evidence meets practice reality. In: Mood Disorders - A Handbook of Science and Practice. Mick Power (ed). John Wiley & Sons, Ltd. 2004; Ch.13, 247-257.
40. Kennedy SH, Eisfeld BS, Parikh SV. Depression. Therapeutic Choices. 4th Edition. Canadian Pharmacist Association. 2003; Ch. 1, 1-12.
39. Kennedy SH, Parikh S. Depression. In Therapeutic Choices (3rd Edition). Gray J (ed). Ottawa: Canadian Pharmaceutical Association. 2000; Ch.5, 33-42.
38. Kennedy SH, Baker G, McKenna K. Monoamine Oxidase Inhibitors. In Comprehensive Textbook of Psychiatry. 7th edition. Sadock V, Sadock BJ (eds). New York NY: Williams and

- Wilkins. 2000; 2397-2406.
37. Brown GM, Swinson R, Kennedy SH. Melatonin in eating and panic disorders. In *Melatonin in Eating and Panic Disorders*. Shafii M (ed). Washington DC: American Psychiatric Press. 1998. 125-146.
 36. Kennedy SH, Parikh S. Depression In Therapeutic Choices (2nd Edition). Grey J (ed). Ottawa: Canadian Pharmaceutical Association. 1998; 30-37.
 35. Vaccarino FJ, Kennedy SH. Growth hormone releasing hormone: behavioral evidence for direct central actions. In *Growth Hormone Secretagogues*. Bercu BB, Walker RW (eds.), Serono Symposia, USA. New York: Springer-Verlag. 1996; 321-333.
 34. Kennedy SH, Goldbloom DS. Research in Eating Disorders. In *Images in Psychiatry -Canada*. Rae-Grant Q (ed). Washington, DC: American Psychiatric Press Inc. 1996; 229-234.
 33. Kennedy SH, Goldbloom DS. Psychopharmacological treatments of anorexia nervosa and bulimia nervosa. In *Treatments of Psychiatric Disorders: 2nd Edition*. Gabbard GO (ed). Washington DC: American Psychiatric Press. 1995; 2153-2162.
 32. Kennedy SH. Depression. In *Therapeutic Choices*. Gray J (ed). Ottawa: Canadian Pharmaceutical Association. 1995; 32-39.
 31. Woodside DB, Kennedy SH. Gender differences in eating disorders - Review and synthesis. In *Sex Differences in Psychiatric Disorders*. Seeman MV (ed). Washington DC: American Psychiatric Press. 1995; 253-268.
 30. Shaw JR, Kennedy SH, Joffe RT. Gender differences in depression. In *Sex Differences in Psychiatric Disorders*. Seeman MV (ed). Washington DC: American Psychiatric Press. 1995; 89-112.
 29. Kennedy SH, Goldbloom DS. Psychopharmacological treatments. In *Synopsis of Treatments of Psychiatric Disorders: 2nd Edition*. Gabbard GO, Atkinson SD (eds). Washington DC: American Psychiatric Press. 1995; 901-907.
 28. Goldbloom DS, Kennedy SH. The medical complications of anorexia nervosa. In *Comprehensive Textbook of Eating Disorders and Obesity*. Brownell KD, Fairburn CG (eds). London: Guildford Press 1995; 266-270.
 27. Kennedy SH, Goldbloom DS. MAO-Inhibitors in bulimia nervosa. In *Clinical Advances in Monoamine Oxidase Inhibitor Therapies*. Kennedy SH (ed). Washington DC: American Psychiatric Press. 1994; 255-264.
 26. Kennedy SH, Glue P. MAO-Inhibitors, past, present and future. In *Clinical Advances in Monoamine Oxidase Inhibitor Therapies*. Kennedy SH (ed). Washington DC: American Psychiatric Press. 1994; 279-290.
 25. Kennedy SH, Ralevski E. Personality disorders in anorexia nervosa: relation to outcome. Proceedings of World Psychiatric Association Meeting. In *Past, Present and Future of Psychotherapy Vol. 1*. Beigel A, Lopez Ibor JJ, Costa e Silva JA (eds). New Jersey: World Scientific. 1994; 696-700.
 24. Davis C, Kennedy SH. Eating disorders in athletes. In *Current Therapies in Sports Medicine*. Shephard RJ (ed). Philadelphia: Mosby. 1994; 540-542.
 23. Goldbloom DS, Kennedy SH. Neurotransmitter and neuroendocrine disturbances in anorexia nervosa and bulimia nervosa. In *Eating Disorders and Medical Illness: The Interface*. Kaplan AS and Garfinkel PE (eds). New York: Brunner/Mazel. 1993; 123-143.
 22. Kennedy SH., Shapiro CM. Medical management of the hospitalized patient. In *Eating Disorders and Medical Illness: The Interface*. Kaplan AS and Garfinkel PE (eds). New York: Brunner/Mazel. 1993; 213-238.

21. Black R., Davis C., Kennedy SH. Metabolic and energy balance disturbances. In *Eating Disorders and Medical Illness: The Interface*. Kaplan AS and Garfinkel PE (eds). New York: Brunner/Mazel. 1993; 144-164.
20. Kennedy SH., Abbass A. Inpatient treatment for anorexia nervosa and bulimia nervosa. In *University of Toronto Handbook of Eating Disorders*. Kennedy SH (ed). Toronto. 1993; 30-36.
19. Duncan J., Kennedy SH. Inpatient group treatment. In *Group Psychotherapy for Eating Disorders*. Harper-Giuffre H and MacKenzie KR (eds). Washington DC: American Psychiatric Press. 1992: 149-160.
18. Kennedy SH, Duncan J, MacKenzie KR. Medical assessment and management. In *Group Psychotherapy for Eating Disorders*. Harper-Giuffre H and MacKenzie KR (eds). Washington DC: American Psychiatric Press. 1992; 53-69.
17. Kennedy SH, Kaplan AS, Garfinkel PE. Intensive hospital treatments for anorexia nervosa and bulimia nervosa. In *Feeding Problems and Eating Disorders*. Cooper PJ and Stein A (eds). London: Harwood Academic Publishers. 1992; 161-181.
16. Kennedy S.H., Goldbloom, D.S., Vaccarino, F.J. New drugs - New directions. In *The Biology of Feast and Famine: Relevance to Eating Disorders*. Anderson GH and Kennedy SH (eds). San Diego: Academic Press. 1992; 341-356.
15. Shekter-Wolfson L., Kennedy SH. Integrating individual and family therapy in an inpatient eating disorders unit. In *Family Approaches in Treatment of Eating Disorders*. Washington DC: American Psychiatric Press. 1991; 125-139.
14. Kennedy SH, Morris M. Affective disorders: current knowledge and future directions in treatment. In *Understanding and Treating Mental Illness*. Cleghorn JN and Lee BL (eds). Toronto: Hogrefe and Huber. 1991; 55-77.
13. Kennedy SH., Katz R., Garfinkel PE. Inpatient treatment of bulimia nervosa. In *Proceedings of 5th World Congress of Biological Psychiatry*. G. Racagni, N. Brunello, T. Fukuda (eds). Elsevier Holland. 1991; 297-299.
12. Kennedy SH, McKenzie J. Anorexia nervosa and bulimia nervosa. In *Current Therapy in Gastroenterology and Liver Disease-3*. Bayless TM (ed). Philadelphia: B.C. Decker. 1990; 147-151.
11. Kennedy SH, Garfinkel PE. Anorexia nervosa. In *Modern Perspectives in The Psychiatry of The Neuroses*. Howells JG (ed). New York: Brunner/Mazel. 1989; 73-93.
10. Brown GM, Kaplan A, Kennedy SH. Anorexia nervosa, bulimia and the affective disorder: neuroendocrine response. In *New Perspectives in The Affective Disorder*. Lerer B and Gershon S (eds). New York: Springer/Verlag. 1989; 475-479.
9. Kennedy SH. Anorexia nervosa, bulimia and the affective disorders: pharmacological similarities and differences. In *New Perspectives in the Affective Disorders*. Lerer B and Gershon S (eds). New York: Springer/Verlag. 1989; 480-483.
8. Brown GM, Chik CL, Ho AK, Kennedy SH, Garfinkel PE. Effects of food restriction on pineal function. In *Advances in Pineal Research*. Reiter RJ and Pang SF (eds). New York: John Libbey and Co. 1989; 87-92.
7. Kennedy SH. Anorexia nervosa and bulimia nervosa. *Medicine North America*. August 1989.
6. Kennedy SH, Walsh BT. Drug therapies for eating disorders: monoamine oxidase inhibitors. In *The Role of Drug Treatments for Eating Disorders*. Garfinkel PE and Garner DM (eds). New York: Brunner Mazel. 1987; 3-35.
5. Craigen G, Kennedy SH, Garfinkel PE, Jeejeebhoy KN. Drug which facilitate gastric emptying. In *The Role of Drug Treatments for Eating Disorders*. Garfinkel PE and Garner DM (eds). New York: Brunner/Mazel. 1987; 161-180.

4. Kennedy SH, Costa D, Parienti V, Brown G. Melatonin regulation in bulimia. In *Psychology of Bulimia*. Hudson J and Pope HG Jr (eds). Washington DC: American Psychiatric Press. 1987; 75-97.
3. Kennedy SH, Garfinkel PE. Neuroendocrine function in anorexia nervosa and bulimia. In *Handbook of Psychoneuroendocrinology*. Nemeroff CB and Loosen PT (eds). New York: Guildford Press. 1987; 143-159.
2. Garfinkel PE, Garner D, Kennedy SH. Special problems in inpatient management. In *Handbook of Psychotherapy for Anorexia Nervosa and Bulimia*. Garner DM and Garfinkel PE (eds). New York: Guildford Press. 1985; 344-359.
1. Kennedy SH, Garfinkel PE. Anorexia nervosa. In *Psychiatry Update: The American Psychiatric Association Annual Review IV*. Frances AJ and Hales RE (eds). Washington, DC: American Psychiatric Press. 1985; 438-463.

v. Book Reviews

5. Kennedy SH. *The Age of Melancholy: Major depression and its social origins*. Blazer DG. Routledge Taylor and Francis Group, New York and Hove: 2005 251p. *Can J Psychiatry*. 2006; 51: 678-679.
4. Kennedy SH. Talking back to Prozac. Breggin P and Breggin G. *Globe and Mail Book Review*. October 22, 1994.
3. Kennedy SH. *Straight Talk About Weight Control*. Bennion LJ., Bierman EL., Ferguson JM. Consumer Report Books. *Psychosomat Med*. 1992; 54: 525-526.
2. Kennedy SH. *Medical Aspects of Anorexia Nervosa*. Bhanji S., Mattingly D. Guildford Butterworth Scientific. *Psychosomat Res*. 1990;34:125-126.
1. Kennedy SH. *Theory and treatment of anorexia nervosa and bulimia: biomedical, sociocultural and psychological perspective*. Emmett SW (ed). *Can J Psych*. 1988;33: 163-164.

vi. Other Publications

41. Kennedy SH, Cyriac A. Restoring functioning in depression: Achieving therapeutic efficacy. *Medicographia*. 2014; 36: 435-437.
40. Kennedy SH, Einstein G, Downar J. Gender.sex differences in emotions. *Medicographia*. 2013; 35: 1-10.
39. Kennedy SH. Treating Major Depressive Disorder: New Evidence for Atypical Antipsychotic Therapy. *The Canadian Journal of Diagnosis*. October 2011;3-11.
38. Kennedy SH. Depression. *Psychiatry & Science*. Essential Scientific References at CPA October 2011; 6-7
37. Kennedy SH, Placenza FM. Guidelines for relapse prevention in the treatment of major depressive disorder. *Medicographia*.2011; 33(2):1-5.
36. Kennedy SH, Giacobbe P, Rizvi SJ. How does one measure the early onset of antidepressant response? *Medicographia*. 2010; 32:183-189.
35. Kennedy SH. The role of atypical antipsychotics for major depressive disorder. *The Canadian Journal of Diagnosis*. April 2010: 3-11.

34. Kennedy SH, Rizvi SJ. Comparative efficacy of newer antidepressants for major depression: a Canadian perspective. *The Canadian Journal of Diagnosis*. September 2009; 81-86.
33. Kennedy SH and Rizvi SJ. Achieving a unique quality of remission. In: *Treating Depression through the Restoration of Circadian Rhythm*, Ed: Hans-Jurgen Moller.
32. Kennedy SH, Rizvi SJ. Sexual functioning and quality of life in patients in remission from depression. *Medicographia* 2009; 31: 146-151.
31. Kennedy SH. Achieving quality remission: where are the gaps? *WPA Bulletin on Depression*. 2008; 13:2-4.
30. Kennedy SH. State of the Art - Core symptoms of major depressive disorder: relevance to diagnosis and treatment. *Dialogues in Clinical Neuroscience, The Core of Depression*. 2008; 10:271-277.
29. Kennedy SH. Can we achieve quality remission in depression? *Neuropotential: achieving the best for people with mental illness*. *Progress Reports in Neurology and Psychiatry* (in press).
28. Kennedy SH. State of the art in depression toward hypothesis generated treatments. *The Institute Magazine, Lundbeck Institute*. 2007.
27. Kennedy SH, Eisfeld BS. Depression pathways and pharmacotherapy: treatment selection. *Irish J Psychol Med Bull*. 2005; 13: 2-5.
26. Kennedy SH. Shortcomings of current antidepressant therapies. *Medicographia*. 2005; 27:240-253.
25. Kennedy SH, McIntyre R, Chandarana PC, Beaulieu S. Nouvelles tendances dans le traitement de la dépression réfractaire in *L'actualité médicale*, October 13, 2004.
24. Kennedy SH, Beaulieu S, Lam RW. Preliminary Findings from the Canadian Depression Study. 2004. A study by the Canadian Network for Mood and Anxiety Treatments (CANMAT).
23. Kennedy SH, McIntyre R, Chandarana PC, Beaulieu S. Emerging Trends in the treatment of resistant depression. *Colloquium 2004*. Rogers Media Healthcare.
22. Kennedy SH. Patient needs on the pathway to recovery. *The Neurology of Depression Bridging Brain and Body to Achieve Remission – A Medwrite Monograph*, University of Minnesota. 2003 5-10.
21. Kennedy SH. Treat depression with anxiety in mind. *The Canadian Journal of Diagnosis*. October 2003. 2-7. Laval University.
20. Kennedy SH. Traitez la dépression en songeant à l'anxiété. *le clinician*. October 2003. 2-7 Laval Université
19. Katzman MA, Hegadoren K, Kennedy SH. *Social Phobia & Gabapentin*. 2001.
18. Kennedy SH, Cooke RG. Recent Advances in the Treatment of Depression. *CPA Bulletin* August 2000.
17. Kennedy SH, Parikh SV. Guidelines on guidelines. *CPA Bulletin* February, 1999.
16. Kennedy SH, Kusumaker V. Applying Bipolar Disorder Guidelines in Clinical Practice. *CPA*. 1999.
15. Kennedy SH. Primeurs et valeurs sûres. *L'Omnipraticien* May, 1998
14. Kennedy SH. Do SSRIs cause amenorrhea. *Patient Care* January, 1996.
13. Kennedy SH. Trazodone to enhance male sex function? *Patient Care* March, 1996.
12. Kennedy SH. How real is the risk of serotonin syndrome? *Patient Care* April, 1996.
11. Kusumakar V, Kennedy SH. Promoting therapeutic alliance and adherence to medication

- treatment in depression. The Canadian Journal of Diagnosis Supplement October, 1996.
10. Gnam W, Kennedy SH. Review of schizoaffective disorders. The Canadian Review of Affective Disorders. 1994;4:1 - 3.
 9. Chadda-Dogra T, Kennedy SH. The challenge of chronic rapid cycling disorder. The Canadian Review of Affective Disorders. 1994.
 8. Kennedy SH. RIMA - A first choice antidepressant. Primary Care of Depression. I. 1994.
 7. Kennedy SH. RIMAs - A new generation of antidepressants. Manic Depressive Association of Metropolitan Toronto Newsletter. July, 1992.
 6. Kennedy SH, Goldbloom DS. Anorexia nervosa and bulimia nervosa: drug treatment. New Ethicals. 1991;28:129-143.
 5. Kennedy SH. Psychiatry in Canada. The Bulletin, British Journal of Psychiatry, 1989.
 4. Kennedy SH. Inpatient management of anorexia nervosa and bulimia nervosa. Current Update. Upjohn. 1988.
 3. Goldbloom DS, Kennedy SH. Drug therapies for eating disorder patients. Current Update. Upjohn. 1988.
 2. Craigen G, Kennedy SH, Garfinkel PE, Jeejeebhoy K. The use of domperidone to facilitate gastric emptying in anorexia nervosa. Perspectives in Psychiatry. 1987;6:5-6.
 1. Kennedy SH. Information Letter, Health Protection Branch. Health and Welfare Canada. Report of the expert advisory committee on psychotropic drugs; Amphetamine Congeners. 1986.

XIII PEER REVIEWED ABSTRACTS FOR POSTERS & PRESENTATIONS

1. Janzen TB, Downar J, Giacobbe P, Rotzinger S, Bartel L, **Kennedy SH**. Examining the Effects of Music and Rhythmic Sensory Stimulation on Major Depressive Disorder: Preliminary Pilot Results. CAN-BIND Annual Workshop, Toronto, Canada. January 27, 2017.
2. Lalovic A, Soares C, **Kennedy SH** McInerney S, Frank E, Kupfer D, Matthews M. M-health in depression: A pilot study to assess the user-friendliness and acceptability of a mobile health application. CAN-BIND Annual Workshop, Toronto, Canada. January 27, 2017.
3. Ceniti A, Rizvi SJ, **Kennedy SH**, Schweizer T, Baker A, Hunt C, Bhalerao S. Identifying reward based markers of suicide risk for depression and suicidality following mild traumatic brain injury. CAN-BIND Annual Workshop, Toronto, Canada. January 27, 2017.
4. Edgar NE, McInerney SJ, **Kennedy SH**, Bergmans Y, Schweizer T, Pizzagalli D, Farb N, Salomons T, Turecki G, Rizvi SJ. Pain, reward, attention and neurocircuitry: Biological Markers of Suicidality. CAN-BIND Annual Workshop, Toronto, Canada. January 27, 2017.
5. **Kennedy SH**, Grouin J, Cadour S, Robert V, Picarel-Blanchot F. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. ECNP Annual Congress. Vienna, Austria. September 17 – 20, 2016.
6. McInerney SJ, MacQueen G, Lam RW, McIntyre R, Giacobbe P, Frey B, Milev R, Ravindran A, **Kennedy SH**. CANBIND: Baseline Neurocognitive Performance on CNS-vitals in a cohort of patients with Major Depressive Disorder (MDD) relative to matched controls. Canadian Psychiatric Association Annual Meeting – Vancouver, Canada. 01-03 October, 2015.

7. Milev R, Lam RW, Parikh S, **Kennedy SH**, Ravindran A, MacQueen G. CANMAT 2015 Guidelines for Management of Depressive Disorder: The Evolution Continues. Symposium. Canadian Psychiatric Association Annual Meeting – Vancouver, Canada. 01-03 October, 2015.
8. **Kennedy SH**, Ruhe HG. Biomarkers: potential to enhance outcomes in treating depression. Brainstorming Session. ECNP Congress. Amsterdam, Netherlands. Sept 1, 2015.
9. **Kennedy SH**. Validation of anhedonia as a marker using EEG analysis. World Federation of Societies of Biological Psychiatry. Athens, Greece. 13-17 June 2015.
10. **Kennedy SH**, MacQueen G, Geraci J, Downar J. An integrated approach to treatment selection in MDD. World Federation of Societies of Biological Psychiatry. Athens, Greece. 13-17 June 2015.
11. **Kennedy SH**. Molecular Targets: An integrated approach to genetic/epigenetic and proteomic analyses. Canadian College of Neuropsychopharmacology. Ottawa, Canada. 10-11 June 2015.
12. **Kennedy SH**. Dimensional perspectives on MDD: Anhedonia is a neurobiological target for new drug development. The International College of Neuropsychopharmacology (CINP). Dublin, Ireland. 3-5 June 2015.
13. Rizvi SJ, Strafella A, Rusjan P, Giacobbe P, Cyriac A, **Kennedy SH**. Suicidal ideation attempt correlates with dopamine receptor binding in treatment resistant depression. Annual Meeting of Biological Psychiatry – Toronto, Canada. 14-16 May, 2015.
14. Rizvi SJ, Cyriac A, Rusjan P, Strafella A, Giacobbe P, Lozano AM, **Kennedy SH**. Effect of baseline D2/D3 binding potential on functional outcomes with DBS. 53rd Annual Conference of the American College of Neuropsychopharmacology - Phoenix, Airzona. 7-11 December, 2014.
15. Rizvi SJ, Cyriac A, Rusjan P, Strafella A, Sproule BA, Giacobbe P, **Kennedy SH**. Predictors of DBS response: the impact of anhedonia and dopamine. European College of Neuropsychopharmacology – Berlin, Germany. October 18-21, 2014.
16. Milev R, Parikh SV, **Kennedy SH**, Feilotter H. Identifying Biomarkers of Treatment Outcome in Depression: Canadian Network for Biomarker Integration in Depression. CPA – Toronto, Canada. September 13, 2014.
17. **Kennedy SH**. Clinical and Neuroimaging Biomarkers of Response to Escitalopram. ISAD – Berlin, Germany. April 28-30, 2014.
18. **Kennedy SH**, Avedisova A. Sustained efficacy and safety of agomelatine 10, 25 and 25-50 mg versus placebo over 24 weeks in out-patients suffering from moderate to severe major depressive disorder. 22nd European Congress of Psychiatry Meeting. Munich, Germany, March 2, 2014.
19. **Kennedy SH**, Rizvi SJ, Geraci J, Ravindran A. Early changes in apathy predict response to adjunctive oral methylphenidate in depressed patients #174. American College of Neuropsychopharmacology Annual Meeting, Hollywood, Florida. December 10, 2013.
20. Rizvi SJ, **Kennedy SH**, Holtzheimer PE, Giacobbe P, Lozano AM, Lam RW, Kolivakis TT, Mayberg HS. Investigation of the targeted effects of deep brain stimulation on depressive symptom profiles: a pooled analysis. Poster Session, Society of Biological Psychiatry Annual Meeting, San Francisco, California. May 16-19, 2013.
21. **Kennedy SH**, Rizvi SJ, Giacobbe P. Neuroimaging and neurocognitive markers of response to deep brain stimulation and pharmacotherapy in mood disorders, presented at the Society of Biological Psychiatry Annual Meeting, San Francisco, California. May 16, 2013.
22. **Kennedy SH**, Avedisova A. Efficacy and safety of 3 agomelatine dose regimens (10, 25, 25-50 mg) versus placebo in out-patients suffering from moderate to severe major depressive disorder. 21st European Congress of Psychiatry Meeting, Nice, France. April 8, 2013.
23. **Kennedy SH**, Rizvi SJ, Konarski J, Downar J, McIntyre RS, Salomons T. Emotional processing changes in depressed patients following antidepressant treatment: an fMRI study #166. Poster Session II, American College of Neuropsychopharmacology Annual Meeting, Hollywood, Florida, December 4, 2012
24. **Kennedy SH**, Michalak EE, Dewa C, Lam RW. Functional outcomes in depression treatment: A Canadian

- Consensus. 62nd Annual Conference of the Canadian Psychiatric Association. Montreal, Quebec, September 28, 2012.
25. Quraan MA, Protzner A, Giacobbe P, **Kennedy SH**, Lozano A, McAndrews MP. Power asymmetry and functional connectivity of patients with major depressive disorder after DBS surgery. 18th International Conference on Biomagnetism, Paris, France, August 2012.
 26. Downar J, Giacobbe P, Salomons T, **Kennedy SH**, Flint A. Dorsomedial prefrontal rTMS in major depression: Safety, efficacy and tolerability. *Biol Psychiatry* 2012; 71:28S. #95.
 27. Giacobbe P, Downar J, McAndrews MP, Salomons T, Flint A, **Kennedy SH**. #890 Biomarker predictors of antidepressant response to dorsomedial prefrontal rTMS in major depressive disorder. *Biol Psychiatry* 2012; 71:282S. #890.
 28. Giacobbe P, Salomons T, Flint A, **Kennedy SH**, Downar J. Clinical, behavioral and neuroimaging predictors of response to rTMS treatment in major depression. *Biol Psychiatry* 2012; 282S. #891
 29. McIntyre RS, Alsuwaidan M, Szpindel I, Bilkey TS, Almagor D, Woldeyohannes HO, Powell AM, Gallagher LA, Soczynska JK, **Kennedy SH**. Metabolic profile of lisdexamfetamine dimesylate for the treatment of ADHD with Bipolar I/II disorder. 165th American Psychiatric Association Annual Meeting, Philadelphia, Pennsylvania. May 7, 2012.
 30. **Kennedy SH**, Yatham LN, Sursun S. What lies beneath? Managing anxiety and depressive symptoms in psychiatric disorders for improved functional and clinical outcomes. Canadian Psychiatric 61st Annual Conference, Vancouver, BC. October 15, 2011.
 31. **Kennedy SH**, Milev R, Downar J, Fung K, Sinha S. Moving toward personalized medicine in mood and anxiety disorders. Canadian Psychiatric 61st Annual Conference, Vancouver, BC. October 15, 2011.
 32. **Kennedy SH**. From guideline implementation to personalized medicine in major depressive disorder. CANMAT Grand Rounds, Department of Psychiatry, University of Saskatchewan. October 7, 2011.
 33. **Kennedy SH**. The future is now: individualized patient outcomes. World Psychiatric Association Annual Meeting, Buenos Aires, Argentina. September 20, 2011. World Psychiatric Association Annual Meeting, Buenos Aires, Argentina. September 21, 2011.
 34. **Kennedy SH**. Challenges of Mood Disorder from diagnosis to treatment: Deep Brain Stimulation to the subcallosal cingulate gyrus for treatment resistant depression: an update. World Psychiatric Association Annual Meeting, Buenos Aires, Argentina. September 21, 2011.
 35. Stein DJ, **Kennedy SH**. Efficacy of the novel antidepressant agomelatine for anxiety symptoms within depression. European College of Neuropsychopharmacology Annual Meeting, Paris, France. September 5, 2011.
 36. **Kennedy SH/Rouillon (Chairs)**. Kennedy SH, Demyttenaere K, Goodwin GM, Gorwood PA. Treating depression current antidepressants and beyond: Keys to improving depression outcomes. European College of Neuropsychopharmacology Annual Meeting, Paris, France. September 5, 2011.
 37. Rizvi SJ, Konarski JK, Boutros P, Giacobbe P, McIntyre RS, **Kennedy SH**. Affective processing in major depressive disorder. Canadian College of Neuropsychopharmacology, Montreal, Canada, May 21-24, 2011.
 38. Giacobbe P, Sun Y, Tang W, **Kennedy SH**, Lozano AM, Daskalakis ZJ. Stimulation dependent increase in EEG power in the frontal cortex with subgenual cingulate gyrus deep brain stimulation: A quantitative EEG study. Biological Psychiatry 66th Annual Scientific Convention and Meeting, San Francisco, California. May 14, 2011. #626.
 39. Mansfield JK, **Kennedy SH**, Tomlinson G, Grigoriadis S, Cheung AMW. Serum estradiol levels and mood and health-related quality of life in Canadian postmenopausal women: A cross-sectional study. Biological Psychiatry 66th Annual Scientific Convention and Meeting, San Francisco, California. May 14, 2011. #595.
 40. Rizvi SJ, **Kennedy SH**, Giacobbe P, Mayberg HS, Lozano AM. Subgenual cingulate gyrus deep brain stimulation for refractory major depressive disorder: Differences in FDG-PET between responders and non-responders. Biological Psychiatry 66th Annual Scientific Convention and Meeting, San Francisco, California.

- May 14, 2011. #576.
41. **Kennedy SH**, Giacobbe P, Rizvi S, Placenza FM, Nishikawa Y, Mayberg HS, Lozano AM. Deep brain stimulation for treatment-resistant depression: Follow-up after 3 to 6 years. 49th Annual Meeting of the American College of Neuropsychopharmacology, Miami Beach, Florida. December 7, 2010. #045.
 42. Soczynska JK, **Kennedy SH**, Li M, Woldeyohannes HO, McIntyre RS. Inflammatory cytokines and cognitive deficits in euthymic individuals with bipolar disorder. Canadian Psychiatric Association 60th Annual Conference, Toronto, September 23-26, 2010.
 43. Rizvi SJ, Casanova A, Tan M, Lin P, McIntyre RS, Grima E, **Kennedy SH**. The effect of depression in the workplace and contributing factors across Canada: Results from the insight study. Canadian Psychiatric Association 60th Annual Conference, Toronto, September 23-26, 2010.
 44. Rizvi SJ, Rotzinger S, Casanova A, Tan M, Lin P, McIntyre RS, Grima E, **Kennedy SH**. Treatment resistant depression in primary care and contributing factors across Canada: Results from the insight study. Annual Meeting of the Canadian Association of Neuroscience and the Canadian College of Neuropsychopharmacology, May 14-18, 2010.
 45. **Kennedy SH**. CANMAT guidelines for major depressive disorder: Update 2009. Alberta Psychiatric Association Annual Meeting, Calgary, Alberta, March 25, 2010.
 46. **Kennedy SH**. Recent developments in the treatment of unipolar depression. Annual meeting of the European College of Psychiatry, Munich, Germany, February 28, 2010.
 47. **Kennedy SH**, Larsen KG, Thase ME. Assessing the true treatment effect of active treatment versus placebo therapy in patients with major depressive disorder using latent class analysis. American College of Neuropsychopharmacology 48th Annual Meeting, Hollywood, Florida, December 9, 2009. #179.
 48. **Kennedy SH**. Agomelatine comparison to SSRI and SNRI antidepressants. 22nd Annual Meeting of the European College of Neuropsychopharmacology, Istanbul, Turkey, September 13, 2009. #P.2.c.028.
 49. **Kennedy SH**, Ravindran AV, Milev R. CANMAT Clinical Guidelines for the Management of MDD in Adults II: Neurostimulation and Alternative Therapies. Canadian Psychiatric Association 59th Annual Conference, St. John's, Newfoundland, August 27, 2009.
 50. McIntyre RS, **Kennedy SH**, Soczynska JK, Nguyen HTT, Bilkey T, Woldeyohannes HO, Nathanson J, Joshi S, Cheng JSH, Benson K, Muzina DJ. Attention Deficit/Hyperactivity Disorder in adults with bipolar disorder and major depressive disorder. Results from the International Mood Disorders Collaborative Project. International Society of Bipolar Disorder Annual Meeting, Pittsburgh, June 2009.
 51. Giacobbe P, **Kennedy SH**, Mayberg HS, Lozano AM, Lam RW, Debonnel G, Kolivakis T, Howard A, Ilcewicz M, Sodikot A, Honey C. Subgenual cingulate gyrus deep brain stimulation for refractory major depressive disorder (MDD): A multi centre update. American Psychiatric Association, Annual Meeting, San Francisco, CA. May 18, 2009. #NR3-009.
 52. **Kennedy SH**. Circadian Rhythms and Psychopathology. SCNP/CCNP Joint Meeting, Copenhagen, April 28, 2009.
 53. **Kennedy SH**, Rizvi S, McNeely H, Giacobbe P, Mayberg HS, Lozano AM. Functional outcome after 12 months of deep brain stimulation for treatment resistant major depressive disorder. World Psychiatric Association Annual Meeting, Florence, Italy. April 2, 2009.
 54. **Kennedy SH**, Welsh BR, Fulton KA, Soczynska JK, McIntyre RS, Milev R, Bisslerbe J-C, Zimmerman M, O'Donovan C, le Melleo J-M, Martin N. Frequency and correlates of gambling problems in depressed and bipolar patients. 9th Annual NCRG Conference on Gambling and Addiction, Las Vegas, Nevada, November 16, 2008.
 55. Rizvi S, **Kennedy SH**, Ellis J, Ravindran L, Fulton K, Panjwani Z, Quilty L. Sexual dysfunction in depression: validation of the Sex-Fx Scale in healthy population. Canadian Psychiatric Association 58th Annual Conference, Vancouver, BC. September 5, 2008.
 56. Soczynska JK, McIntyre RS, Li M, **Kennedy SH**. The association between cytokines and cognitive

- performance in bipolar disorder. Canadian Psychiatric Association 58th Annual Conference, Vancouver, BC. September 5, 2008.
57. Fulton KA, Welsh BR, Soczynska JK, McIntyre RS, Milev R, Bisseurbe J-C, Zimmerman M, O'Donovan C, le Melleo J-M, Martin N, **Kennedy SH**. Frequency and correlates of gambling in depressed and bipolar outpatients. Canadian Psychiatric Association 58th Annual Conference, Vancouver, BC. September 5, 2008.
 58. **Kennedy SH**. Efficacy of agomelatine from treatment initiation to treatment completion. 21st Annual Meeting of the European College of Neuropsychopharmacology, Barcelona, Spain. September 1, 2008. #P.2.a.001.
 59. Konarski JZ, Pyke R, Wunderlich G, **Kennedy SH**. "Effects of acute flibanserin on FDG-PET brain glucose metabolism in men with major depressive disorder. 21st Annual Meeting of the European College of Neuropsychopharmacology, Barcelona, Spain. August 31, 2008. #P.1.c.044.
 60. **Kennedy SH**, Lôo H, Olié J-P. The antidepressant efficacy of agomelatine is independent of gender, age, body mass index and use of concomitant anxiolytics: Combined analysis of three placebo-controlled studies. Collegium Internationale Neuro-Psychopharmacologicum XXVII Annual Meeting, Munich, Germany. July 15, 2008. P-04.72.
 61. Lemoine P, Olié J-P, Lôo H, **Kennedy SH**. Clinical antidepressant efficacy of agomelatine as evaluated by clinical global impression scales. Collegium Internationale Neuro-Psychopharmacologicum XXVII Annual Meeting, Munich, Germany. July 15, 2008. P-04.73.
 62. McIntyre RS, Panjwani ZD, Law CW, Bilkey T, Woldeyohannes HO, Soczynska JK, Lourenco MT, Adams AK & **Kennedy SH**. The Prevalence of Adult Attention-Deficit/Hyperactivity Disorder in Individuals with Major Depression and Bipolar Disorder. Canadian College of Neuropsychopharmacology Annual Meeting, Toronto. June 7, 2008. #40.
 63. McIntyre RS, Panjwani ZD, Law CW, Woldeyohannes HO, Soczynska JK, Lourenco MT, Adams AK & **Kennedy SH**. Evaluating Polypharmacy amongst Individuals with Bipolar disorder and Major depressive disorder utilizing tertiary health services. Canadian College of Neuropsychopharmacology Annual Meeting, Toronto. June 8, 2008. 59.1
 64. Lourenco MT, Woldeyohannes HO, Law CW, Soczynska JK, Panjwani ZD, Miranda A, **Kennedy SH** & McIntyre RS. Prevalence of ATP III – Defined Metabolic Syndrome in Euthymic Individuals with Bipolar I/II Disorder. Canadian College of Neuropsychopharmacology Annual Meeting, Toronto. June 8, 2008. #58.
 65. **Kennedy SH**, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder (MDD): a pooled analysis. American Psychiatric Association, Annual Meeting, Washington, DC. May 5, 2008. #NR3-114.
 66. **Kennedy SH**, Mayberg HS, Lozano AM, Giacobbe P, Lam RW, Debonnel G, Kolivakis T, Howard A, Sadikot A, Honey CR. Deep brain stimulation for major depressive disorder (resistant to 4 or more treatments): Preliminary results of a multi-centre study. American Psychiatric Association, Annual Meeting, Washington, DC. May 5, 2008. #NR3-113.
 67. **Kennedy SH**, Mayberg HS, Lozano AM, Giacobbe P, Lam RW, Debonnel G, Kolivakis T, Howard A, Sadikot A, Honey CR. Deep brain stimulation for major depressive disorder (resistant to 4 or more treatments): Preliminary results of a multi-centre study. 63rd Annual Scientific Convention & Program, Society of Biological Psychiatry, Washington, DC. May 2, 2008. #08-P-1100.
 68. Szeifert L, Czira ME, Lindner A, Pinter N, Kelemen A, Mucsi I, Novak M, Molnar MZ. Association between depression and inflammation in a large sample of kidney transplanted patients. American Psychosomatic Society, 66th Scientific Conference, Baltimore, USA, March 12-15, 2008. #1362.
 69. **Kennedy SH**, Welsh BR, Soczynska JK, McIntyre R, Milev R, Bisseurbe J-C, Zimmerman M, O'Donovan C, le Melleo J-M, Martin N. Frequency and correlates of gambling problems in depressed and bipolar outpatients. Ontario Psychiatric Association 88th Annual Meeting, Toronto, February 8, 2008.
 70. McIntyre RS, Wilkins K, Gilmour H, Soczynska JK, Konarski JZ, Miranda A, Woldeyohannes HO, Vagic D, Alsuwaidan M, **Kennedy SH**. Workplace dysfunction in mood disorders: Results from the Canadian Community Health Survey. Canadian Psychiatric Association, 57th Annual Conference, Montreal, November

- 16, 2007.#23
71. Soczynska JK, McIntyre RS, **Kennedy SH**. The Association between cytokines and cognitive performance in euthymic individuals with bipolar disorder. Canadian Psychiatric Association, 57th Annual Conference, Montreal, November 16, 2007. #28
 72. McIntyre RS, McElroy SL, Konarski JZ, Soczynska JK, Wilkins K, **Kennedy SH**. Problem gambling in bipolar disorder: Results from the Canadian Community Health Survey. Canadian Psychiatric Association, 57th Annual Conference, Montreal, November 16, 2007. #29.
 73. **Kennedy SH**. "All for one or one for all – assessing the true treatment effect of active vs placebo therapy in severe major depressive disorder" Affective disorders and antidepressants – Antidepressants (clinical). 20th European College of Neuropsychopharmacology Annual Meeting, Vienna, Austria, October 16, 2007. P.2.c.003.
 74. **Kennedy SH**, Guillemminault C. Advantage of agomelatine over venlafaxine on sexual functioning and sleep during the treatment of major depressive disorder. U.S. Psychiatric & Mental Health 20th Annual Psychiatric Congress, Orlando, Florida, October 12, 2007. #216
 75. Bouffard BA, **Kennedy SH**, Rich JB, Styra R, Ravindran L, McIntyre RS. Memory functioning and antidepressant: A randomized controlled trial comparing escitalopram and bupropion XL. Preliminary report. American Psychiatric Association Annual Meeting, San Diego, CA, May 21, 2007. #NR74
 76. Konarski JZ, **Kennedy SH**, Segal ZV, McIntyre RS, Mayberg HS. Neurobiological correlates of remission-focused treatment with venlafaxine XR. American Psychiatric Association Annual Meeting, San Diego, CA, May 21, 2007. #NR240
 77. Konarski JZ, **Kennedy SH**, McIntyre RS, Soczynska J, Mayberg HS. Relationship between regional brain metabolism disease severity and age in depressed subjects. American Psychiatric Association Annual Meeting, San Diego, CA, May 21, 2007. #NR242
 78. Konarski JZ, McIntyre RS, Mikulis D, Woldeyohannes H, Parikh SV, Mayberg HS, **Kennedy SH**. Functional observation of response mechanisms: The FORM Study – Preliminary Analyses. American Psychiatric Association Annual Meeting, San Diego, CA, May 21, 2007. #NR244
 79. Konarski JZ, McIntyre RS, Mikulis D, Mayberg HS, Woldeyohannes H, Crawley A, **Kennedy SH**. Predicting response based on gray matter content: Results from the FORM study. American Psychiatric Association Annual Meeting, San Diego, CA, May 21, 2007. #NR247
 80. McIntyre RS, McElroy SL, Konarski JZ, Soczynska JK, Wilkins K, **Kennedy SH**. Problem gambling in bipolar disorder: Results from the Canadian Community Health Survey. American Psychiatric Association Annual Meeting, San Diego, CA, May 21, 2007. #NR324.
 81. McIntyre RS, McElroy SL, Konarski JZ, Soczynska JK, Castel S, Wilkins K, **Kennedy SH**. Substance use disorders and overweight/obesity in bipolar I disorder: Preliminary evidence for competing addictions. . American Psychiatric Association Annual Meeting, San Diego, CA, May 21, 2007. #NR533
 82. Chopra KK, Ravindran A, MacKenzie B, Anisman H, **Kennedy SH**, Matthews S, Bagby M, Levitan RD. Gender influences cortisol stress responses to the trier social stress test in chronic major depression. 62nd Annual Scientific and Program, Society of Biological Psychiatry, San Diego, CA, May 17, 2007. #220.
 83. Kelley ME, Craddock RC, Holtzheimer P, **Kennedy SH**, Mayberg HS. Resting state brain connectivity as predictors of treatment response in major depression. 62nd Annual Scientific and Program, Society of Biological Psychiatry, San Diego, CA, May 18, 2007. #478.
 84. Konarski JZ, **Kennedy SH**, Segal ZV, McIntyre RS, Mayberg HS. Neurobiological correlates of remission-focused treatment with venlafaxine XR. 62nd Annual Scientific and Program, Society of Biological Psychiatry, San Diego, CA, May 18, 2007. #480.
 85. Konarski JZ, **Kennedy SH**, McIntyre RS, Soczynska JS, Mayberg HS. Relationship between regional brain metabolism disease severity and age in depressed subjects. 62nd Annual Scientific and Program, Society of Biological Psychiatry, San Diego, CA, May 18, 2007. #481.

86. Konarski JZ, McIntyre RS, Mikulis D, Woldeyohannes H, Parikh SV, Mayberg HS, **Kennedy SH**. Functional observation of response mechanisms: The FORM study – Preliminary Analyses. 62nd Annual Scientific and Program, Society of Biological Psychiatry, San Diego, CA, May 18, 2007. #482.
87. Konarski JZ, McIntyre RS, Mikulis D, Woldeyohannes H, Crawley A, Mayberg HS, **Kennedy SH**. Predicting response based on gray matter content: results from the FORM study. 62nd Annual Scientific and Program, Society of Biological Psychiatry, San Diego, CA, May 18, 2007. #483.
88. McIntyre RS, McElroy SL, Konarski JZ, Soczynska J, Bottas A, Castel S, Wilkins K, **Kennedy SH**. Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. 62nd Annual Scientific and Program, Society of Biological Psychiatry, San Diego, CA, May 19, 2007. #722.
89. McIntyre RS, McElroy SL, Konarski JZ, Soczynska JK, Wilkins K, **Kennedy SH**. Problem gambling in bipolar disorder: results from the Canadian Community Health Survey. 62nd Annual Scientific and Program, Society of Biological Psychiatry, San Diego, CA, May 19, 2007. #723.
90. Bagby RM, Quilty LC, Segal ZV, McBride CC, **Kennedy SH**, Costa PT. Personality and the prediction of response in major depressive disorder: A randomized control trial comparing cognitive therapy and pharmacotherapy. 2nd International Congress of Biological Psychiatry, WFSBP, Santiago, Chile, April 17-21, 2007.
91. McIntyre RS, **Kennedy SH**, Carlson B, Carson W, McQuade R, Rollins L, Marcus R and Sanchez R: Aripiprazole for relapse prevention in bipolar disorder: A 100-week, double-blind, placebo-controlled study. American College of Neuropsychopharmacology 45th Annual Meeting, #78, Hollywood, Florida, December 5, 2006.
92. Giacobbe, P, **Kennedy SH**, Fulton K, Lozano AM, Mayberg HS: Predictors of response to deep brain stimulation for treatment resistant depression. American College of Neuropsychopharmacology 45th Annual Meeting, #82, Hollywood, Florida, December 6, 2006.
93. Castel S, Rush B, **Kennedy SH**, Fulton K: PS9A: A pilot project of the validation of a self-assessment instrument for screening of other mental disorders among patients with substance use disorders. Canadian Psychiatric Association 57th Annual Conference, Toronto, November 11, 2006.
94. Bouffard BA, **Kennedy SH**, Rich JB, Ravindran L, Eisfeld BS, Styra R, McIntyre RS. Memory Functioning & Antidepressant Treatment A Randomized Controlled Trial comparing Escitalopram and Bupropion-XL. Preliminary Report. 57th Canadian Psychiatric Association Annual Conference, Toronto, November 10, 2006.
95. **Kennedy SH**. Sildenafil Improves Depressive Symptoms of Men with Erectile Dysfunction and Untreated Depression not Otherwise Specified. 57th Canadian Psychiatric Association Annual Conference, Toronto, November 10, 2006.
96. **Kennedy SH**, Eisfeld B. Favourable sexual profile of agomelatine in depressed patients: Affective disorders and antidepressants. 19th European College of Neuropsychopharmacology Meeting, Paris, France, September 17, 2006. #P.2.c.012.
97. **Kennedy SH**, Guilleminault C. Antidepressant efficacy of agomelatine 25-50 mg versus venlafaxine 75-150 mg: two randomized, double-blind studies. 19th European College of Neuropsychopharmacology Meeting, Paris, France, September 17, 2006. #P.2.c.012.
98. Montgomery SA, Olié JP, Ahokas A, **Kennedy SH**. Antidepressant efficacy of agomelatine in major depressive disorder: meta-analysis of three pivotal studies. 19th European College of Neuropsychopharmacology Meeting, Paris, France, September 17, 2006. #P.2.c.012.
99. McIntyre RS, Konarski JZ, Soczynska JK, Wilkins K, Panjwani G, Bouffard B, Bottas A, **Kennedy SH**. Medical comorbidity in bipolar disorder: Implications for functional outcomes and health-service utilization. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12, 2006. #P01.006.
100. McIntyre RS, Konarski JZ, Wilkins K, Panjwani G, Bouffard B, Soczynska JK, **Kennedy SH**. The prevalence and impact of migraine headache in bipolar disorder: Results from the Canadian Community Health Survey. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12,

2006. #P01.007.
101. Levitan RD, Chopra K, Pederson R, Hood K, Buis T, **Kennedy SH**, Atkinson L, Leung EM, Segal ZV. Anxious attachment predicts increased cortisol levels following a negative mood induction in remitted depressed patients. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12, 2006. #P01.010.
 102. McIntyre RS, Soczynska JK, Mancini D, Lam C, Moon S, Woldeyohannes H, Konarski JZ, **Kennedy SH**. Childhood abuse predicts suicidality in adult bipolar disorder. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12, 2006. #P01.025.
 103. McIntyre RS, McElroy S, Konarski JZ, Soczynska JK, Bottas A, Wilkins K, **Kennedy SH**. Alcohol and illicit drug dependence in bipolar disorder: An inverse association with over weight obesity. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12, 2006. #P01.030.
 104. McIntyre RS, Mancini D, Eisfeld B, Soczynska JK, Grupp L, Konarski JZ, **Kennedy SH**. Calculated bioavailable testosterone levels and depression in middle-aged men. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12, 2006. #P02.076.
 105. Chopra K, Ravindran A, Bagby M, **Kennedy SH**. Neuroticism mediates cortisol stress responses to the trier social stress test in chronic depression. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12, 2006. #P02.093.
 106. McIntyre RS, Soczynska JK, Mancini D, Konarski JZ, **Kennedy SH**. Comparing features of bipolar disorder to major depressive disorder in a tertiary mood clinic: Results from the bipolar recognition and verification enterprise (BRAVE). Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12, 2006. #P03.023.
 107. Konarski JZ, **Kennedy SH**, Segal ZV, McIntyre RS, Mayberg HS. Neurobiological Correlates of Remission Focused Treatment with Venlafaxine XR. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12, 2006. #P03.043.
 108. **Kennedy SH**, Olie JP, Loo H, Emsley R. Efficacy of agomelatine (25/50 mg in Major Depressive Disorder. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 12, 2006. #P03.013.
 109. **Kennedy SH**, Rasmussen J, Fulton K. Sex FX differentiates depressed and non-depressed populations and demonstrates a favorable sexual side effect profile for agomelatine in the treatment of depression. Collegium Internationale Neuro-Psychopharmacologicum XXV Annual Meeting Meeting, Chicago, July 11, 2006. #P02.067.
 110. **Kennedy SH**, Konarski JZ, Segal ZV, McIntyre RS, Mayberg HS. Differences in glucose metabolism between responders to cognitive-behavior therapy and venlafaxine XR in a 16-week randomized controlled trial. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR937.
 111. **Kennedy SH**, Fulton KA, Lozano AM, Mayberg HS. Predictors of response to deep brain stimulation for treatment resistant depression. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR938.
 112. Konarski JZ, McIntyre RS, Mikulis DJ, Mayberg HS, Crawley AP, **Kennedy SH**. Affective processing in a major depressive episode: fMRI investigation in bipolar disorder and MDD. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR83.
 113. McIntyre RS, Konarski JZ, Mancini DA, Zurowski M, , Giacobbe P, Soczynska JK, **Kennedy SH**. Improving outcomes in depression: A focus on somatic symptoms. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR255.
 114. McIntyre RS, Konarski JZ, Wilkins K, **Kennedy SH**. Obesity and mood disorders: Results from a national community health survey on mental health and well-being. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR952.
 115. McIntyre RS, Konarski JZ, **Kennedy SH**. Anxious residual symptoms in depressed primary care patients.

- American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR256.
116. McIntyre RS, Konarski JZ, **Kennedy SH**. Antidepressant effectiveness in primary-care settings. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR551.
 117. McIntyre RS, Mancini DA, Eisfeld BS, Soczynska JK, Grupp LA, Konarski JZ, **Kennedy SH**. Bioavailable testosterone levels and its association with depression in middle-aged men. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR550.
 118. McIntyre RS, Mancini D, Soczynska JK, Konarski JZ, Lam C, **Kennedy SH**. Diagnosing bipolar disorder amongst pseudo unipolar patients referred to an outpatient mood clinic. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR257.
 119. McIntyre R, Mancini D, Soczynska J, Konarski JZ, Lam C, **Kennedy SH**. Childhood physical and sexual abuse predicts suicidality in adult bipolar disorder. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR258.
 120. McIntyre RS, Konarski JZ, Wilkins K, Bouffard B, Soczynska JK, **Kennedy SH**. The prevalence and impact of migraine headache in bipolar disorder: Results from the Canadian Community Health Survey. American Psychiatric Association Annual Meeting, Toronto, May 2006. #NR954.
 121. Parker G, Kellin K, Brnabic A, McBride M, **Kennedy SH**, Sagman D, Raskin J. Duloxetine in the treatment of melancholic depression. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 18, 2006. #128.
 122. McIntyre RS, Konarski JZ, Wilkins K, **Kennedy SH**. Obesity and mood disorders: Results from a national community health survey on mental-health and well-being. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 18, 2006. #57.
 123. McIntyre RS, Konarski JZ, Mancini D, Zurowski M, Giacobbe P, Soczynska J, **Kennedy SH**. Improving outcomes in depression: A focus on somatic symptoms. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 18, 2006. #58.
 124. McIntyre RS, Konarski JZ, **Kennedy SH**. Anxious residual symptoms in depressed primary care patients. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 18, 2006. #356.
 125. McIntyre RS, Konarski JZ, **Kennedy SH**. Antidepressant effectiveness in primary-care settings. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 18, 2006. #357.
 126. Konarski JZ, McIntyre RS, Mikulis DJ, Mayberg HS, Crawley AP, **Kennedy SH**. Affective processing in a major depressive episode: A functional Magnetic Resonance Imaging (fMRI) investigation in bipolar disorder and major depressive disorder. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 19, 2006. #369.
 127. **Kennedy SH**, Konarski JZ, Segal ZV, Lau M, Bieling P, McIntyre RS, Mayberg HS. Differences in glucose metabolism between responders to cognitive behavior therapy and venlafaxine XR in a 16-week randomized controlled trial. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 20, 2006. #736.
 128. Konarski JZ, **Kennedy SH**, Segal ZV, Lau M, Bieling P, Mayberg HS. Predicting response to antidepressant treatment: An evaluation of pharmacotherapy and psychotherapy with glucose positron emission tomography. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 20, 2006. #737.
 129. McIntyre RS, Mancini D, Soczynska JK, Konarski JZ, Lam C, Moon S, Woldeyohannes H, **Kennedy SH**. Childhood physical and sexual abuse predicts suicidality in adult bipolar disorder. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 19, 2006. #738.
 130. McIntyre RS, Mancini D, Soczynska JK, Konarski JZ, Lam C, Moon S, Woldeyohannes H, **Kennedy SH**. Diagnosing bipolar disorder amongst pseudo unipolar patients referred to an outpatient mood clinic. Society of Biological Psychiatry 61st Annual Meeting, Toronto, May 19, 2006. #739.
 131. **Kennedy SH**, Fulton K, Lozano AM: Deep brain stimulation for treatment resistant depression. The International Society for Affective Disorders (ISAD), Lisbon, Portugal, March 4, 2006. S4.5.

132. **Kennedy SH**, Lejoyeux M, Hawley C: Sexual function in remitted depression patients following agomelatine and venlafaxine XR Treatment. Canadian Psychiatric Association Annual Meeting, Vancouver, BC, November 4, 2005.
133. **Kennedy SH**, Fulton KA, Rasmussen J: Sex Fx: Estimation of normative values and comparison with values from patients with major depressive disorder. Candian Psychiatric Association Annual Meeting, Vancouver, BC, November 4, 2005.
134. **Kennedy SH**, Fulton KA, Rasmussen J: Sex FX: estimation of normative values and comparison with values from patients with major depressive disorder. European College of Neuropsychopharmacology 18th Annual Congress, Amsterdam, October 24, 2005. P.8.063.
135. **Kennedy SH**: Sexual function in remitted depressed patients following agomelatine and venlafaxine XR treatment. European College of Neuropsychopharmacology 18th Annual Congress, Amsterdam, October 25, 2005. P.2.111.
136. **Kennedy SH**, Andersen HF, Lam RW: A pooled analysis of selective serotonin reuptake inhibitors and venlafaxine. American Psychiatric Association Annual Meeting, Atlanta, May 26, 2005. NR873.
137. **Kennedy SH**, Lejoyeux M, Hawley CJ, Hebert A, deBodinac C: A comparison of sexual function in remitted depressed patients following treatment with agomelatine or venlafaxine. American Psychiatric Association Annual Meeting, Atlanta, May 26, 2005. NR874.
138. **Kennedy SH**: A dimensional approach to personality assessment in atypical depression using the five-factor model. American Psychiatric Association Annual Meeting, Atlanta, May 26, 2005. NR370.
139. **Kennedy SH**: A multicenter validation of the abbreviated Hamilton Depression Rating Scale (HAMD-7) to evaluate remission in primary care. American Psychiatry Association Annual meeting, Atlanta, May 26, 2005. NR643.
140. **Kennedy SH**. Integrating neurobiology into clinical practice: Appraising recent evidence in the treatment of depression. Alberta Psychiatric Association, April 2, 2005, Banff, Alberta.
141. **Kennedy SH**, Fulton KA, Bagby RM, Green AL, Cohen NL, Rafi-Tari. Differences in sexual dysfunction between men and women with depression: A comparison before and after treatment with bupropion and paroxetine. Poster session presented at the annual meeting of the ACNP 43rd Annual Meeting, San Juan, Puerto Rico, December 2004.
142. **Kennedy SH**: Personality dimensions, disorders and depression: Treating the complex patient. CPA Annual Meeting, October 15, 2004, Montreal, Quebec.
143. **Kennedy SH**, Fulton KA, Bagby RM, Green AL, Cohen NL, Rafi-Tari. Differences in sexual dysfunction between men and women with depression: A comparison before and after treatment with bupropion and paroxetine. Poster session presented at the annual meeting of the XXIVth CINP Congress, Paris, France, June 2004.
144. **Kennedy SH** & Fulton, K. Difference in sexual dysfunction between men and women with depression. APA Annual Meeting, May 4, 2004, New York. NR389.
145. McIntyre RS, **Kennedy SH**, Stewart, DE, Fulton K, Mancini D, Fan N, Grigoriadis S, Konarski JZ. HRT and SSRI Prescription Patterns: An Inverse and Reciprocal Relationship. APA Annual Meeting, May 3, 2004, New York. NR263.
146. Kennedy SH, Milev RV. Adopting evidence-based practice in the treatment of mood disorders: The Canadian experience. APA Annual Meeting, New York, May 5, 2004. Symposium 76.
147. Gold WL, Fones C, **Kennedy SH**, McGeer A, Robinson S, Hawryluck L, Styra R. The Psychological Impact of SARS on the Uninfected Health Care Worker. APA Annual Meeting, New York, May 4, 2004. 32B.
148. Mayberg H, Seminowicz D, Goldapple K, **Kennedy SH**, Segal Z. Towards a neural systems model of depression: dysfunctional limbic-cortical circuits as targets of treatment. ACNP Annual Meeting, San Juan, Puerto Rico, December 2003.
149. Ybema C. & **Kennedy SH**. Lack of anti-depressant efficacy of the selective 5-HT1A receptor antagonist

- NAD-299 – Robalzotam Study, ECNP Annual Meeting, September 22, 2003, Prague, Czechoslovakia.
150. Krueger S, Seminowicz BS, Goldapple K, **Kennedy SH**, Mayberg HS. Changes in regional CBF in bipolar disorder following transient-induced sadness measured with PET, APA Annual Meeting, San Francisco, May 2003. NR98.
 151. Katz M, **Kennedy SH**. Clinical use of mirtazapine in depressed cancer patients. APA Annual Meeting, May 17-22, 2003, San Francisco, CA.
 152. Potts AJ, Craik FIM, Segal Z, **Kennedy SH**, Levitan R, McIntyre RS, Vaccarino FJ. Conscious and automatic memory deficits in seasonal and on-seasonal depression. 2003. Biological Psychiatry.
 153. **Kennedy SH**, Rapaport MH, Reimherr FW, Davis KH. Effects of Lamotrigine on quality of life in patients with bipolar disorder. Fifth International Conference on Bipolar Disorder. June 12-14, 2003. Pittsburgh.
 154. McIntyre RS, Girgla S, Binder C, Riccardelli R, **Kennedy SH**. Efficacy of topiramate as adjunctive therapy to mood stabilizers in patients with bipolar I or II disorder. Poster session presented at the ACNP 41st Annual Meeting, San Juan, Puerto Rico, December 2002. 72.
 155. Levitan RD, Masellis M, Lam R, Muglia P, Basile V, Jain U, Kaplan A, **Kennedy SH**, Kennedy JL. Dopamine D4 receptor gene polymorphism associated with symptoms of attention deficit disorder in women with seasonal affective disorder. Poster session presented at the ACNP 41st Annual Meeting, San Juan, Puerto Rico, December 2002. 62.
 156. **Kennedy SH**, Ravindran A, Vincent P, Kusumakar V, Kjernisted K. Mirtazapine vs. sertraline: results of the first prospective onset-of-action study. Poster session presented at the Annual Meeting of the CPA, Banff, Alberta, November 2002. 32.
 157. **Kennedy SH**, Cohen NL, Fulton K, Bagby M. Sex-Fx: Defining normal scores for sexual function in a community sample compared to depressed patients. Poster session presented at the Annual Meeting of the CPA, Banff, Alberta, November 2002. 45.
 158. Cohen, N. L., **Kennedy, S. H.**, Northrup, D., Greene, A., Rafi-Tari, S., Fulton, K. A., & Bagby, R. M. (2002, November). A comparison of sexual functioning in a community sample versus untreated depressed patients using the sexual functioning questionnaire. Poster session presented at the annual meeting of the Canadian Psychiatric Association, Banff, AB.
 159. **Kennedy SH**. The novel antidepressants and efficacy: a clinical perspective. Canadian College of Neuropsychopharmacology, Ottawa, June 9-12, 2002.
 160. **Kennedy SH**. Patient needs on the pathway to recovery. Collegium Internationale Neuropsychopharmacologicum, Montreal, June 25, 2002.
 161. McIntyre RS, **Kennedy SH**, Bagby RM, Bakish D. Assessing Full Remission with the Abbreviated Hamilton Depression Rating Scale – 7 Item. American College of Neuropsychopharmacology, Waikoloa Village, Hawaii. December 2001.
 162. **Kennedy SH**, Vester-Blokland ED and RAPID study group. Onset of Antidepressant Efficacy in Depressed Patients Treated with Mirtazapine (Remeron® Soltab™) versus Sertraline. American College of Neuropsychopharmacology, Waikoloa Village, Hawaii. December 2001.
 163. Mancini DA, McIntyre RS, Srinivasan J, **Kennedy SH**. The antidepressant effects of Risperidone and Olanzapine in Bipolar Disorder. American College of Neuropsychopharmacology, Waikoloa Village, Hawaii. December 2001.
 164. Lam RW, **Kennedy SH**, Thase ME. Moving Beyond SSRIs: Mechanism of Action and Clinical Profiles of Novel Antidepressants. Canadian Psychiatric Association 51st Annual Meeting. Montreal, Quebec. November 2001. CS3.
 165. **Kennedy SH**, Reesal R, Rabheru K, Gorman J. Optimizing the Clinical Use of SSRIs across the Lifespan. Symposium Chair. Canadian Psychiatric Association 51st Annual Meeting. Montreal, Quebec. November 2001. CS6.
 166. McIntyre RS, Mayberg HS, Young T, **Kennedy SH**, Thase ME. Achieving Full Remission: From

- Neuroscience to Clinical Strategies. Canadian Psychiatric Association 51st Annual Meeting. Montreal, Quebec. November 2001. CS1.
167. **Kennedy SH.** Achieving Full Remission in the Depressed Patient: Why is it important? CPA November 2001
168. **Kennedy SH,** Lam RW and colleagues. Guidelines for the treatment of Depressive Disorders Making them Work in Clinical Practice. Canadian Psychiatric Association 51st Annual Meeting. Montreal, Quebec. November 2001.
169. Lam RW, **Kennedy SH,** Levitt A, Gorman J. Serotonin in the 21st Century: More Relevant than Ever. Canadian Psychiatric Association 51st Annual Meeting. Montreal, Quebec. November 2001. S8
170. **Kennedy SH.** Major Depressive Disorder in the 21st Century: From Psychobiology to Neuroscience. Keynote Address. The 42nd Annual Meeting of Japanese Society of Psycho-Medicine Kagoshima, Japan. May 2001
171. **Kennedy SH,** Rafi-Tari S, Meyer JH, Mayberg HS, Evans K, Houle S, Vaccarino FJ. Age and Melancholia influence cerebral metabolism in Major Depression. Biology Psychiatry Society Annual Meeting. New Orleans, Louisiana. May 2001. 49(8S):91S #317.
172. Meyer JH, McMain S, **Kennedy SH,** Brown GM, Korman L, Houle S, Fu C, Links P. Dysfunctional Attitudes & 5-HT₂ receptors during depression and self harm. Biology Psychiatry Society Annual Meeting. New Orleans, Louisiana. May 2001. 49(8S):153S #524
173. Meyer JH, Krueger S, Wilson AA, Christensen BK, Goulding V, Schaeffer A, Houle S, **Kennedy SH.** Adaptive regulation of dopamine transporters during depression. Biology Psychiatry Society Annual Meeting. New Orleans, Louisiana. May 2001. 49(8S):152S #523.
174. **Kennedy SH,** Rafi-Tari S, Meyer JH, Mayberg HS, Evans K, Houle S, Vaccarino FJ. Age and Melancholia influence cerebral metabolism in Major Depression. American Psychiatric Association Annual Meeting . New Orleans, Louisiana. May 2001. NR 329.
175. Grigoriadis S, **Kennedy SH,** Srinivasan J, Fulton K. SSRI augmentation with Raloxifene for treatment resistant depression. American Psychiatric Association Annual Meeting . New Orleans, Louisiana. May 2001. NR 136.
176. McIntyre RS, Mancini DA, McCann SM, Srinivasan J, Sagman D, **Kennedy SH.** Randomized, single-blind comparison of topiramate & bupropion SR as add on therapy in bipolar depression. American Psychiatric Association Annual Meeting . New Orleans, Louisiana. May 2001. NR 104.
177. **Kennedy SH,** Evans K, Rafi-Tari S, Meyer JH, Hussey D, Arifuzzaman AI, Houle S. The Effects of Single Dose Flibanserin (Ectris™) On Regional Brain Activity In Patients With Major Depression Disorder. New Clinical Drug Evaluation Unit (NCDEU) 39th Annual Meeting. Boca Raton, Florida. June 2001.
178. **Kennedy SH,** Rafi-Tari S, Meyer JH, Mayberg HS, Evans KR, Houle S, Vaccarino FJ. Factors Influencing Regional Cerebral Metabolism in MDD: Symptom Profiles and Patient Variables. Canadian College Neuropsychopharmacology. Banff, Alberta. June 2001.
179. McIntyre RS, Mancini DA, McCann SM, Srinivasan J, **Kennedy SH.** Divalproex & females with bipolar disorder: reproductive & metabolic risk profile. Canadian College Neuropsychopharmacology. Banff, Alberta. June 2001.
180. **Kennedy SH.** Pursuing optimal physical treatments: Promising new leads. Targeting Treatments for the 21st. Century Symposium, Chair and Speaker. The 26th Congress of the World Federation for Mental Health. Vancouver, British Columbia. July 2001.
181. **Kennedy SH.** Dual Mechanisms of Action: Is the whole greater than the sum of its parts? Restoring Normal Function – Is it Achievable? Symposium Chair and Speaker. The 26th Congress of the World Federation for Mental Health. Vancouver, British Columbia. July 2001.
182. Meyer JH, Kapur S, Brown GM, Houle S, Mayberg HS, **Kennedy SH.** 5-HT_{2A} receptors pre/post paroxetine treatment. Society of Biological Psychiatry, Chicago, IL. May 2000. 47(85) s87 #286.

183. Meyer JH, Kapur S, Brown GM, Houle S, Mayberg HS, **Kennedy SH**. 5-HT_{2A} receptors in depression and their relationship to treatment response. American Psychiatric Association. Chicago, IL. May 2000. NR 113
184. **Kennedy SH**, Zaretsky A, Markowitz J. Hard to Treat Depression: Combining and Sequencing Pharmacotherapy and Psychotherapy. Symposium organizer, Chair & Speaker. Canadian Psychiatric Association 50th Annual Meeting. Victoria. October 2000. S4 page 79.
185. **Kennedy SH**, Lam RW, Goumeniouk AD. Improving our understanding of depression: The role of norepinephrine. Canadian Psychiatric Association 50th Annual Meeting. Victoria. October 2000. 3 page 125.
186. McIntyre RS, **Kennedy SH**, Bagby RM, Bakish D. Validation of an abbreviated Hamilton Depression Rating Scale: Hamilton Rating Scale for depression six item. Canadian Psychiatric Association 50th Annual Meeting. Victoria. October 2000. (poster)71 page 61.
187. Cohen NL, **Kennedy SH**, Bagby RM, Awad AG. Development of a Self-Report Scale to Predict Medication Compliance in Major Depression. Canadian Psychiatric Association 50th Annual Meeting. Victoria. October 2000. (poster) 64. page 65.
188. **Kennedy SH**, Bagby RM, Gnam W. The Burden of Depression. Symposium Chair & Plenary Speaker Canadian Psychiatric Association 50th Annual Meeting. Victoria. October 2000.
189. McIntyre RS, Mancini D, McCann S, Srinivasan J, Sagman D, **Kennedy SH**. Topiramate Versus Bupropion SR Added to Mood Stabilizer Therapy for the Major Depressive Phase of Bipolar Disorder: A Single-Blind Study. Canadian Psychiatric Association 50th Annual Meeting. Victoria. October 2000. (poster) #47 page 65.
190. Shaffer A, Levitt AJ, Bagby M, Kennedy, SH. The role of gender and comorbid anxiety in major depression. American Psychiatric Association NR 22, Washington DC, May, 1999.
191. Meyer, J, Kapur S, Brown GM, Eisfeld, B, **Kennedy SH**. 5HT₂ receptor in depression before and after paroxetine. American Psychiatric Association NR 421, Washington DC, May, 1999.
192. **Kennedy SH**, Dickens SA, Eisfeld B, Bagby RM. Sexual dysfunction before and after moclobemide, paroxetine, sertraline and venlafaxine. Society of Biological Psychiatry. Washington DC, May, 1999. NR 422.
193. Meyer JH, Kapur, Houle S, DaSilva J, Eisfeld BS, Brown GM, Wilson AA, **Kennedy SH**. Prefrontal Cortex 5-HT_{2a} receptors in depression. Society of Biological Psychiatry, Washington DC. May 1999;45:127S #410
194. **Kennedy SH** (Chair). Functional imaging in Mood Disorders. Canadian College of Neuropsychopharmacology Symposium. Halifax, June, 1999.
195. Schaffer A, Levitt A, Bagby RM, **Kennedy SH**, Levitan RD. The effect of gender and anxiety on suicidal ideation in major depression. Canadian Psychiatric Association 49th Annual Meeting. Toronto. September 1999. NRPS11
196. **Kennedy SH**, Remington G, Kusumaker V. Psychopharmacology Update. Canadian Psychiatric Association 49th Annual Meeting. Toronto. September 1999. S12
197. **Kennedy SH**, Sachs G, Modell J. Evaluating Bupropion and SSRI's in the Management of Depression: A Comparative Analysis of Efficacy, Safety and Sexual Functioning. Canadian Psychiatric Association 49th Annual Meeting. Toronto. September 1999. SS3
198. **Kennedy SH**. Bupropion and SSRI's: A Comparative Analysis of Safety. Canadian Psychiatric Association 49th Annual Meeting. Toronto. September 1999. SS3b
199. **Kennedy SH**, Thase M, Nelson JC. The Role of Norepinephrine in the Treatment of Depression. Canadian Psychiatric Association 49th Annual Meeting. Toronto. September 1999. SS6
200. **Kennedy SH**. The Evaluation of Antidepressant Response: Beyond Symptomatic Changes. Canadian Psychiatric Association 49th Annual Meeting. Toronto. September 1999. SS6c

201. Brown GM, Levitan R, Dalton J, **Kennedy SH**. Melatonin augmentation in refractory depressed patients. Integrated Care of the Psychiatric Patient: Psychotherapies and Medication Conference. Puerto Vallarta, Mexico. March, 1998.
202. Cho R, Kapur S, Jones C, **Kennedy SH**, Zipursky RB. PET comparison of 5-HT₂ receptor blockade by SSRIs: nefazodone vs. paroxetine. Society of Biological Psychiatry. Toronto. May, 1998.
203. Meyer JH, Swinson R, Houle S, **Kennedy SH**, Brown GM. Intravenous d-fenfluramine challenge with [¹⁵O] H₂O PET in panic disorder. Society of Biological Psychiatry. Toronto. May, 1998.
204. Ketter TA, **Kennedy SH**, Kimbrell TA, Wu JC, Sackeim HA, George MS. Brain imaging studies of treatments in mood disorders. Society of Biological Psychiatry. Toronto. May, 1998.
205. Levitan R, Kaplan A, Masellis M, Kennedy J, **Kennedy SH**, Woodside B, Vaccarino F, Sam F. Serotonin genetic polymorphism and increased eating behaviour in bulimia nervosa and seasonal affective disorder. Society of Biological Psychiatry. Toronto. May, 1998.
206. **Kennedy SH**, Evans KR, Vaccarino FJ, Houle S. PET analysis of antidepressant effects of paroxetine. American Psychiatric Association Annual Meeting. Toronto. June, 1998.
207. Javanmard M, Shlik J, **Kennedy SH**, Bradwejn J. Neuroanatomical correlates of Anticipatory Anxiety: A PET study of CCK – 4 Induced Anxiety. American Psychiatric Association Annual Meeting. Toronto. June, 1998. NR369.
208. Javanmard M, Shlik J, **Kennedy SH**, Bradwejn J. A time course of CCK – 4 Induced Panic Attacks in Healthy Volunteers: A PET Study. American Psychiatric Association Annual Meeting. Toronto. June, 1998. NR370
209. **Kennedy SH**, Thase M, Levitan R, Vaccarino F, Rector N, Segal Z. Novel predictors of vulnerability to major depression. American Psychiatric Association Annual Meeting. Toronto. June, 1998.
210. **Kennedy SH**, Ralevski E, Dickens S, Bagby RM. Distinct areas of sexual dysfunction in men and women with major depression. Canadian Psychiatric Association. Halifax. September, 1998. PS5b
211. **Kennedy SH**, Ralevski E, Dickens S, Bagby RM. The relationship between antidepressant response and reported sexual side effects across new antidepressant drugs. Canadian Psychiatric Association. Halifax. September, 1998. PS5a
212. **Kennedy SH**, Evans KR, Arifuzzaman AI, Vaccarino FJ, Houle S. Enhanced hypofrontality in depressed patients following chronic but not acute SSRI therapy: a PET FDG study. Neuroscience. November, 1998.
213. Evans, KR, Arifuzzaman AI, **Kennedy SH**, Vaccarino FJ, Houle S. FDG-PET reveals a consistent pattern of differences in brain metabolism between depressed patients and healthy controls. Neuroscience. November, 1998.
214. Bagby RM, Santor DA, **Kennedy SH**, Joffe RT. Evaluating stability and change in personality and depression. International Congress on the Disorders of Personality, Vancouver. June, 1997.
215. Ramasubbu R, **Kennedy SH**, Flint A, Brown G, Awad G, Cooper T. A neuroendocrine study of serotonin function in depressed stroke patients. Biological Psychiatry, San Diego. May, 1997;41:35S #120.
216. Parikh SV, Lin E, **Kennedy SH**, Goering PN. Does severity of depression influence treatment utilization or adherence to guidelines? American Psychiatric Association, San Diego. May, 1997.
217. Ramasubbu R, **Kennedy SH**, Flint A, Brown G, Awad G, Cooper T. A placebo controlled study of d-fenfluramine induced prolactin and cortisol responses in healthy elderly subjects. Biological Psychiatry, San Diego. May, 1997;41:95S#327
218. Parikh SV, Lin E, **Kennedy SH**, Goering PN. Does severity of depression influence treatment utilization or adherence to guidelines? American Psychiatric Association. San Diego. May, 1997.
219. **Kennedy SH**, Sokolov S, Ravindran AV, Lam RW. Depression: Treatment Trials & Tribulations. Canadian Psychiatric Association. Calgary. September, 1997. S5.
220. **Kennedy SH**, Segal Z, Levitan R, Bagby M. Partial response to antidepressant therapy: Patient variables

- and treatment. Canadian Psychiatric Association. Calgary. September, 1997. S5a
221. **Kennedy SH**, Barclay CL, Lodha J, O'Neill MC. Use of blister packaging to improve patient medication compliance in the treatment of depression (poster). Canadian Psychiatric Association. Calgary. September, 1997. P28.
 222. Javanmard M, Shlik J, **Kennedy SH**, Houle S, Bradwejn J. Positron emission tomography of CCK-4 induced anxiety in healthy human volunteers (poster). Neurosciences. New Orleans. October, 1997.
 223. **Kennedy SH**. Risk factors for depression. Symposium at Ontario Psychiatric Association Annual Meeting, Toronto, Ontario. January, 1996 (Chair).
 224. **Kennedy SH**, Vaccarino FJ, Houle S, Brown GM, Evans KR. Effects of acute and chronic paroxetine in regional brain metabolism. Poster presented at Sixth Rotman Research Institute Conference, Toronto, Ontario. March, 1996.
 225. Meyer J, Swinson R, **Kennedy SH**, Houle S, Brown GM. Assessment of serotonergic function using intravenous D-fenfluramine with [¹⁵O]-PET in panic disorders and healthy women. Poster presented at Sixth Rotman Research Institute Conference, Toronto, Ontario. March, 1996.
 226. **Kennedy SH**, Vaccarino FJ, Houle S, Brown GM, Evans KR. Acute and chronic paroxetine effects on fluorodeoxyglucose PET imaging in major depression. New Research, American Psychiatric Association, New York, NY. May, 1996. NR 657.
 227. Meyer J, **Kennedy SH**, Swinson R, Houle S, Brown G. Altered response to intravenous D-fenfluramine during depression using [¹⁵O]-PET. *Biological Psychiatry* 1996;39; 516 #58. New York, NY.
 228. **Kennedy SH**, Vaccarino FJ, Houle S, Brown GM, Evans KR. Effects of acute and chronic paroxetine on regional brain metabolism in depression. CCNP, Toronto, Ontario. June, 1996.
 229. Esplen MJ, Garfinkel PE, Gallop R, Olmsted M, **Kennedy SH**. A randomized trial investigating guided imagery therapy and its effects in promoting self-soothing in bulimia nervosa: final results. Harvey Stancer Research Day, University of Toronto. June, 1996.
 230. Levitan R, Kaplan A, Brown G, **Kennedy SH**, Vaccarino F, Joffe R, Levitt A. MCPP challenge in seasonal affective disorder. Harvey Stancer Research Day, University of Toronto. June, 1996.
 231. Meyer J, **Kennedy SH**, Swinson R, Houle S, Brown G. Altered response to intravenous D-fenfluramine in depression using [¹⁵O]-PET. Harvey Stancer Research Day, University of Toronto. June, 1996.
 232. Parikh SV, Lesage AD, **Kennedy SH**, Goering PN. Depression in Ontario: Patterns of treatment and antidepressant use in a community sample. Harvey Stancer Research Day, University of Toronto. June, 1996.
 233. **Kennedy SH**, Vaccarino FJ, Houle S, Brown GM, Evans KR. Effects of acute and chronic paroxetine in regional brain metabolism. Canadian Psychiatric Association, Quebec City. October, 1996. PS 1d.
 234. **Kennedy SH**, Greist J, Docherty JP. Depression: The science of long-term therapy. Canadian Psychiatric Association, Quebec City. October, 1996. SS5
 235. Woodside BD, Garfinkel P, Lin E, Kaplan A, Goldbloom D, **Kennedy SH**. Eating Disorders & Eating symptoms in a Canadian community sample. Canadian Psychiatric Association, Quebec City. October, 1996. PS4a
 236. **Kennedy SH**, Ralevski E, Davis C. Effect of moclobemide on sexual function in healthy volunteers. Harvey Stancer Research Day, University of Toronto. June, 1995.
 237. Esplen MJ, Garfinkel PE, Gallop R, Olmsted M, **Kennedy SH**. Guided imagery and its effects in promoting self-soothing in bulimia nervosa. Harvey Stancer Research Day, University of Toronto. June, 1995.
 238. Cooke RG, Bagby RM, **Kennedy SH**. Quality of life and antidepressant drug treatment. Harvey Stancer Research Day, University of Toronto. June, 1995.
 239. **Kennedy SH**, Ralevski E, Davis C, Vaccarino FJ. Moclobemide does not produce sexual dysfunction in healthy volunteers. Canadian College of Neuropsychopharmacology Annual Meeting, Vancouver. June,

- 1995.
240. **Kennedy SH**, Ralevski E, Davis C. Individual differences in psychiatric disorders: Comorbidity and personality variables. Fifth International Neuropeptide Conference, Martha's Vineyard. June, 1995.
 241. Lapierre YD, Joffe R, McKenna K, Bland R, **Kennedy SH**, Ingram P, Rickhi B, Reesal R, Chouinard G, Annable L. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. Annual Meeting of the Canadian Psychiatric Association, Victoria, British Columbia. September, 1995.
 242. **Kennedy SH**, Ralevski E, Davis C, Neitzert C. Factors influencing the reporting of sexual dysfunction in healthy volunteers on moclobemide and placebo. Canadian Psychiatric Association Annual Meeting. Victoria, British Columbia. September, 1995.
 243. **Kennedy SH**. Is there a right antidepressant in mood disorders - reaching for the future. Symposium at Canadian Psychiatric Association Annual Meeting, Victoria, British Columbia. September, 1995 (Organizer and Symposium Chair).
 244. **Kennedy SH**, Ralevski E, Olmsted M. Personality profiles in refractory and non-refractory depression. Third International Conference on Refractory Depression, Napa Valley, California. October, 1995.
 245. Davis C, **Kennedy SH**, Ralevski E, Dionne M. The role of exercise in the development and maintenance of eating disorders. Society of Behavioral Medicine, Boston. April, 1994.
 246. Davis C, **Kennedy SH**, Ralevski E, Dionne M. The role of exercise in the pathogenesis of eating disorders. International Conference on Eating Disorders, New York. April, 1994.
 247. Davis C, **Kennedy SH**, Ralevski E, Dionne M. Activity-induced anorexia among eating disordered patients: The role of obsessive-compulsiveness. American College of Sports Medicine Meeting, Indianapolis. June, 1994.
 248. **Kennedy SH**, Goldbloom DS, Vaccarino FJ. Biological correlates of binge eating: Implications for pathogenesis and treatment. XIX Collegium International Neuro-Psychopharmacologicum. Washington, DC. June, 1994.
 249. Davis C, **Kennedy SH**, Ralevski E, Dionne M. The role of obsessive-compulsiveness in the development of self-starvation and hyperactivity among eating disordered patients. European Association of Personality Psychology, Madrid, Spain. July, 1994.
 250. Davis C, **Kennedy SH**. The role of exercise in the pathogenesis of eating disorders. European Regional Symposium of the World Psychiatric Association. Cascais, Portugal. July, 1994.
 251. **Kennedy SH**. Future directions in pharmacotherapy for bulimia nervosa. European Psychosomatic Conference. Gent, Belgium. August, 1994.
 252. Vaccarino FJ, **Kennedy SH**, Black R, Ralevski E. GRF stimulates eating in anorexia nervosa patients. CCNP, Montreal. June, 1993.
 253. **Kennedy SH**, Gnam WA, Ralevski E, Brown GM. The effect of yohimbine and clonidine on evening melatonin in female volunteers. CCNP, Montreal. June, 1993.
 254. **Kennedy SH**. Personality disorder as a perpetuating mechanism in eating disorders. World Psychiatric Association, Rio de Janeiro. June, 1993.
 255. Vaccarino FJ, **Kennedy SH**, Black R, Ralevski E. GRF stimulates eating in anorexia nervosa patients. Summer Neuropeptide Conference, Martha's Vineyard. 1993
 256. **Kennedy SH**, Kaplan AS, Garfinkel PE, Rockert W, Toner BB, Abbey SE. Depression in anorexia nervosa and bulimia nervosa: Discriminating depressive symptoms and episodes. Canadian Psychiatry Association, Winnipeg. September, 1993.
 257. **Kennedy SH**, Katz R, Rockert W, Mendlowitz S, Ralevski E, Clewes J. DSM III personality disorders in eating disorders: A comparison of structured interview and self report measures. Canadian Psychiatry Association, Winnipeg. September, 1993.
 258. Black RM, **Kennedy SH**, Kaplan AS, Allard JS. Reduced cephalic phase energy expenditure in patients

- suffering from bulimia nervosa. NAASO Annual Meeting, Milwaukee. October, 1993.
259. Black RM, Katocs R, **Kennedy SH**, Kaplan AS, Allard JS, Greenwood CE. Cephalic phase energy expenditures predicts diet induced thermogenesis in healthy subjects but not bulimia. Society for Neuroscience Annual Meeting, Washington. November, 1993.
260. **Kennedy SH**, Gallop R. Factors influencing hospital treatment for anorexia nervosa and bulimia nervosa. Presented at 5th. International Conference of Eating Disorders, New York. April, 1992 and Chairperson for Symposium "Consumer satisfaction and response to treatment".
261. **Kennedy SH**, Katz R, Ford CG. Changes in perceptions and emotions before and after refeeding in anorexia nervosa. Institute of Medical Science, University of Toronto, Science Day. May, 1992.
262. **Kennedy SH**. Anorexia nervosa and bulimia nervosa: Advances in pharmacotherapies. Canadian College of Neuropsychopharmacology, invited symposium chair, Saskatoon. June, 1992.
263. Shaw JF, Bagby M, Levitt AJ, **Kennedy SH**. Gender differences in depression. Department of Psychiatry Research Day, University of Toronto. June, 1992.
264. Vaccarino FJ, **Kennedy SH**, Black R, Ralevski E. Effects of GRF on food intake in anorexia nervosa patients and normal subjects. Department of Psychiatry Research Day, University of Toronto. June, 1992.
265. Gnam W, **Kennedy SH**, Brown GM. Melatonin response to noradrenergic challenges. Department of Psychiatry Research Day, University of Toronto, June, 1992.
266. Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradwejn J, **Kennedy SH**, Sharma V, Remick RA, Kukha-Mohamad SA, Smaitto J, D'Souza J. Efficacy and safety of brofaromine in depression: A Canadian multicentre placebo controlled trial and a review of comparative controlled studies. CNIP, Nice. July, 1992.
267. **Kennedy SH**, Davis BA, Brown GM, D'Souza J. Effects of brofaromine on trace amine and melatonin output in bulimia nervosa. 4th. International Trace Amines Meeting, Galway, Ireland. August, 1992.
268. **Kennedy SH**. Managing bulimia nervosa - the role of an intensive hospital unit. Symposium on the Current Status of Treatments for Bulimia Nervosa, Canadian Psychiatric Association, Montreal. September, 1992.
269. **Kennedy SH**. Pharmacologic approaches to the treatment of refractory depression. Symposium, Canadian Psychiatric Association, Montreal. September, 1992.
270. **Kennedy SH**. Assessing and treating anorexia nervosa and bulimia nervosa: Implications for the addiction counselor. Fourth International Conference on Addiction Interventions. Toronto, April 1991.
271. **Kennedy SH**, Goldbloom DS, D'Souza J, Lofchy J. Brofaromine: A selective MAO-inhibitor in bulimia nervosa. 5th World Congress of Biological Psychiatry, Florence. June, 1991. (Abstract 691).
272. **Kennedy SH**, Katz R, Garfinkel PE. Inpatient treatment for bulimia nervosa. 5th. World Congress of Biological Psychiatry, Florence. June, 1991 (Abstract 332).
273. **Kennedy SH**. Eating disorders: Basic and clinical research. (Chairperson) 5th. World Congress of Biological Psychiatry, Florence. June, 1991.
274. Black RM, **Kennedy SH**, Kaplan AS, Levitt AJ, Allard JS, Anderson GH. Evidence of a disturbance in diet induced thermogenesis in bulimia nervosa. Annual Research Day, Department of Psychiatry, University of Toronto. June, 1991.
275. **Kennedy SH**. Selective inhibitors of monoamine oxidase. Symposium Chairperson, Canadian Psychiatric Association, Saskatoon. October, 1991.
276. **Kennedy SH**, Goldbloom DS, Ralevski E, Lofchy J. Selective MAO-inhibitor therapy for bulimia nervosa. Canadian Psychiatric Association, Saskatoon. October, 1991.
277. Black RM, **Kennedy SH**, Kaplan AS, Levitt AJ, Allard JS, Anderson GH. Evidence of a disturbance in diet induced thermogenesis in bulimia nervosa. Int J Obesity, 15 (Suppl 3), 23 (Abstract E11), 1991.

278. Black RM, **Kennedy SH**, Kaplan AS, Levitt AJ, Allard JS, Anderson GH. Evidence of a disturbance in diet induced thermogenesis in bulimia nervosa. NAASO/SSIB Joint Annual Meeting, Sacramento, California. October, 1991.
279. **Kennedy SH**, McVey G, Katz R. Personality disorder in relation to outcome in anorexia nervosa and bulimia nervosa. 4th International Conference on Eating Disorders, New York. April, 1990.
280. **Kennedy SH**, Brown GM. Melatonin as a marker of rhythm and noradrenergic dysfunction in anorexia nervosa. American Psychiatric Association Symposium. May, 1990.
281. **Kennedy SH**, McVey G, Katz R. Personality disorder measures predict outcome in anorexia nervosa and bulimia nervosa. Research Day, Department of Psychiatry, University of Toronto. June 1990.
282. **Kennedy SH**, Brown GM, Garfinkel PE. Sulphatoxy-melatonin is a marker of acute but not chronic starvation in anorexia nervosa. International Society of Psychoneuroendocrinology, Buffalo. August 1990.
283. **Kennedy SH**. Intensive treatment for AN and BN: An integrated approach. Canadian Psychiatric Association, Toronto, September 1990.
284. **Kennedy SH**, Goldbloom DS, Vaccarino F. New drugs - New directions. Presented at Biology of Feast and Famine and Relevance to Eating Disorders, Toronto, October 1990.
285. **Kennedy SH**. Differences in anorexic and bulimic patients during and after inpatient treatment. Third International Conference on Eating Disorders. New York, April, 1988.
286. **Kennedy SH**, Garfinkel PE, Parienti V, Costa D, Brown GM. Nocturnal melatonin but not cortisol levels are associated with depression in eating disorders. Third International Conference on Eating Disorders. New York, April, 1988.
287. **Kennedy SH**, Garfinkel PE, Garner DM. Outcome in different eating disorder groups. In Eating Disorders: New Data on Course and Outcome. Symposium, American Psychiatric Association. Montreal, May, 1988.
288. **Kennedy SH**. Critical issues in pharmacotherapy of eating disorders. (Workshop) American Psychiatric Association. Montreal, 1988.
289. **Kennedy SH**, Tighe S, McVey G. Changes in melatonin and cortisol in bipolar affective disorder. Annual Research Day, Department of Psychiatry, University of Toronto. June, 1988.
290. **Kennedy SH**, Garfinkel PE, McVey G. Family and personality profiles of good versus poor outcome: Inpatients with eating disorders. Annual Research Day, Department of Psychiatry, University of Toronto. June, 1988.
291. Craven JL, Rodin GM, Johnson L, **Kennedy SH**. The diagnosis of depression in renal dialysis patients. *Psychosomatic Medicine* 49: 482-492, 1987.
292. **Kennedy SH**, Piran N, Garfinkel PE. MAO-Inhibitors in the treatment of bulimia: A double-blind trial of isocarboxazid. Canadian Psychiatric Association, 1986.
293. **Kennedy SH**, Costa D, Parienti V, Brown GM. Melatonin disturbances in anorexia nervosa. In *Psychobiology of Anorexia Nervosa - Clinical Update*. APA Washington, D.C., 1986.
294. **Kennedy SH**. The relationship between eating disorders and affective disorders: Part I - Clinical and neuroendocrine disturbances, Part II - Pharmacological response to antidepressants. University of Toronto, Research Day. June, 1986.
295. Craven JL, Rodin GM, Voshart K, **Kennedy SH**. Depression in the medically ill: Concordance of self-report and clinician rated measures with a diagnosis of major depression. *Psychosomatic Medicine*, Vol. 48: 303, 1986.
296. Craven JL, Rodin GM, Voshart K, **Kennedy SH**. The diagnosis of depression in the medically ill. *Clinical and Investigative Medicine* 9 (Supplement) R, 710, 1986.
297. **Kennedy SH**, Parienti V, Costa D, Brown GM. Patterns of melatonin production in bulimia. First Canadian Pineal Conference. October, 1986.

298. **Kennedy SH**, Piran N, Warsh JJ, Garfinkel PE. Isocarboxazid treatment for bulimia: A double blind placebo controlled trial. Research Day, Department of Psychiatry, University of Toronto. June, 1985.
299. **Kennedy SH**, Piran N, Garfinkel PE. Do monoamine oxidase inhibitors treat bulimia? - A double blind trial. International Symposium on Disorders of Eating Behaviour. Pavia, Italy, 1985.
300. **Kennedy SH**. Anorexia nervosa and bulimia: General principles of inpatient management. Workshop on Current Issues in Therapy. Toronto General Hospital, Academic Conference, 1984.
301. **Kennedy SH**, Piran N. Affective disturbance in relation to eating disorders. Toronto General Hospital, Academic Conference, 1984.
302. **Kennedy SH**, Stokl S, Garfinkel PE. Effects of weight change on the dexamethasone suppression test. Canadian Psychiatric Association. Banff, 1984.
303. **Kennedy SH**. Management of treatment resistant depression. (Course) Ontario Psychiatric Association. Toronto, 1983.
304. **Kennedy SH**, Piran N, Garfinkel PE. Monoamine oxidase inhibitors as a treatment for eating disorders. Canadian Psychiatric Association. Ottawa, 1983.
305. **Kennedy SH**, Thompson R, Stancer HC, Roy A, Persad E. Life events before mania. Royal College of Psychiatrists. Liverpool, 1982.
306. **Kennedy SH**, Thompson R, Stancer HC, Roy A, Persad E. Life events precipitating mania. Canadian Psychiatric Association. Montreal, 1982.
307. **Kennedy SH**, Tohen M, Stancer HC, Persad E. Therapy resistant depression. Canadian Psychiatric Association. Winnipeg, 1981.

XIV. INVITED PRESENTATIONS AT MEETINGS AND SYMPOSIA

1. Kennedy SH. To treat or not to treat with antidepressants: Are they effective and safe? Debate on antidepressants – CAMH. Toronto. Canada. March 30th, 2017.
2. Kennedy SH. The CAN-BIND study and RDoC. RDoCS Day. Toronto. Canada. March 22nd, 2017.
3. Kennedy SH. Heterogeneity of Depression: Pursuit of Precision Medicine. McGill University Psychiatry Grand Rounds. Montreal, Canada. March 10th, 2017.
4. Kennedy SH. Enhancing Treatment Outcomes for Depression: From Guidelines to Biomarkers. Baycrest Grand Rounds. Toronto, Canada. February 24th, 2017.
5. Kennedy SH. Enhancing Treatment Outcomes for Depression: From Guidelines to Biomarkers. Georgia Psychiatric Physicians Association Winter Meeting. Atlanta, Georgia. February 4th, 2017.
6. Kennedy SH. Major Depressive Disorder is a Heterogeneous Group of Disorders. Patient Focus Advocacy Group Meeting. Toronto, Canada. February 2nd, 2017.
7. Kennedy SH. Biomarkers in Bipolar Depression: Comparisons to MDD. Ontario Bipolar Symposium. Queens University. Kingston, Canada. January 14th, 2017.
8. Kennedy SH. Biomarkers in MDD. UHN Mood Disorder Day. Toronto, Canada. January 10th, 2017.
9. Kennedy SH. Treating Depression: The Positive Perspective. Hong Kong Association Meeting. Hong Kong, China. December 9-10th, 2016.
10. Kennedy SH. Canadian Biomarker Integration Network in Depression (CANBIND): Are we making progress? University of Toronto/CANMAT Psychopharmacology Update Day. Toronto, Canada. November 25-26th, 2016.
11. Kennedy SH. Biomarkers in Bipolar Depression: Comparisons to MDD. London, Canada. November 21st, 2016.
12. Kennedy SH. CANMAT Depression Guidelines 2016: Focus on Switching to New Agents versus Adjunctive

- Therapy. Peterborough Regional Mental Health Experts. Peterborough, Canada. November 16th, 2016.
13. Kennedy SH. Choosing Antidepressant Therapies in a climate of Precision Medicine. Rogers Mental Health Summit. Toronto, Canada. November 8th, 2016.
 14. Kennedy SH. CANMAT Depression Guidelines 2016: Focus on Switching to New Agents versus Adjunctive Therapy. North York Psychiatry Group. Toronto, Canada. November 3rd, 2016.
 15. Kennedy SH. Optimizing Antidepressant Treatments: from Guidelines to Biomarkers. Sunnybrook Hospital Grand Rounds. Toronto, Canada. October 28th, 2016.
 16. Kennedy SH. CANMAT Depression Guidelines 2016: Focus on Switching to New Agents versus Adjunctive Therapy. Montfort Hospital Psychiatry Rounds. Ottawa, Canada. October 25th, 2016.
 17. Kennedy SH. The Age of Melancholy: A window into brain disorders of the mind. Georgian Triangle Life Long Learning Institute. Collingwood, Canada. October 21st, 2016.
 18. Kennedy SH. CANMAT Depression Guidelines 2016: Sequential Approaches to treatment. Niagra Health Systems Regional Psychiatry Meeting. St. Catherine's, Canada. October 17th, 2016.
 19. Kennedy SH, Schuman B. CAN-BIND: Zebrafish Reverse Translation Depression Models. Toronto Western Hospital Grand Rounds. Toronto, Canada. October 14th, 2016.
 20. Kennedy SH. Biomarkers of MDD and BD: Predictors of Diagnosis and Treatment Response. The Indo-Canadian Psychiatric Association Annual General Meeting, Toronto, September 23rd, 2016.
 21. Kennedy SH, Lam RW, McIntosh D, Quilty L, Giacobbe P. CANMAT Clinical Guidelines for the Management of MDD 2016: Highlighting Pharmacotherapy, Psychotherapy, and Neurostimulation. Canadian Psychiatric Association Annual Meeting. Toronto, Canada. September 24th, 2016.
 22. Kennedy SH, Chokka P, Bowie C. Major Depression is a Disorder of Everyday Function. CPD Institute at Canadian Psychiatric Association Annual Meeting. Toronto, Canada. September 22nd, 2016.
 23. Kennedy SH, Stahl SM, Kasper S. From Clinical to Functional Remission in Depression: How big is the gap? ECNP Annual Congress. Vienna, Austria. September 18th, 2016.
 24. Kennedy SH, Milev R, Cleare A, Malhi G. Symposium Speaker on Contrasting Guidelines for Major Depressive Disorder: Canadian, Australian and British Perspectives. Symposium. International Society for Affective Disorders/ International Society for Bipolar Disorders Annual Conference. Amsterdam, The Netherlands. July 15th, 2016.
 25. Kennedy SH. Biomarkers of Major Depressive Disorder and Bipolar Disorder. Biomarkers as Predictors of Antidepressant Response. Keynote Address. International Society for Affective Disorders/International Society for Bipolar Disorders Annual Conference. Amsterdam, The Netherlands. July 14th, 2016.
 26. Kennedy SH. Comprehensive approaches to managing MDD: Maximizing outcomes. Bristol-Meyer Squibb Rounds – Mackenzie Health. Richmond Hill, Ontario. May 30th, 2016.
 27. Kennedy SH. Multimodal markers of treatment response in MDD. American Psychiatric Association Annual Meeting. Atlanta, Georgia. May 17th, 2016.
 28. Kennedy SH. Present and future directions in treating Major Depressive Disorder. Janssen Speaking Tour. Beijing, Shanghai, Hangzhou, Nanjing, Chengdu, Guangzhou – China. April 17th – April 23rd, 2016
 29. Kennedy SH. Comprehensive approaches to managing MDD: Maximizing outcomes. Bristol-Meyer Squibb Rounds - Royal Victoria Hospital. Barrie, Ontario. March 23rd, 2016.
 30. Kennedy SH. Present and future directions in treating depression: From guideline-based care to biosignatures of response. University of Texas Health Grand Rounds. Houston, Texas. March 2nd, 2016.
 31. Kennedy SH. Valdoxan Data in depression with Anxiety: How best to use them. Valdoxan Summit Meeting. Paris, France. February 18th – 19th, 2016.
 32. Kennedy SH. Evidence for Treating Depression Today and in the Future. Lundbeck Regional Institute. Panama City, Panama. 28th November 2015.

33. Kennedy SH. Comprehensive Approaches to Managing MDD: Maximizing Outcomes. Lakeridge Health. Grand Rounds. Oshawa, Ontario, Canada. 25 November 2015.
34. Kennedy SH. Optimizing today's treatment to relieve depression. Odense University Hospital Meeting of Medical Specialists. Copenhagen, Denmark. 22 October 2015.
35. Kennedy SH. Advances in biomarker research to identify moderators of treatment outcome. Odense University Hospital Meeting of Medical Specialists. Copenhagen, Denmark. 22 October 2015
36. Kennedy SH. Domains of dysfunction across psychiatric disorders: focus on depression. CNS Symposium. Copenhagen, Denmark. 23 October 2015.
37. Kennedy SH. In search of biomarkers to identify mediators of treatment outcome in MDD. CNS Symposium. Copenhagen, Denmark. 23 October 2015.
38. Kennedy SH. Systematic Reviews and meta-analyses: state of the art. Symposium. ECNP Congress. Amsterdam, Netherlands. August 30, 2015.
39. Kennedy SH, Ruhe HG. Biomarkers: potential to enhance outcomes in treating depression. Brainstorming Session. ECNP Congress. Amsterdam, Netherlands. Sept 1, 2015.
40. Kennedy SH. Critical Evaluation of Biomarkers to Identify subtypes within MDD and select specific treatment. Symposium Chair. International Summit. Paris, France. June 25-26, 2015.
41. Kennedy SH. Validation of anhedonia as a marker using EEG analysis. World Federation of Societies of Biological Psychiatry. Athens, Greece. 13-17 June, 2015.
42. Kennedy SH, MacQueen G, Geraci J, Downar J. An integrated approach to treatment selection in MDD. World Federation of Societies of Biological Psychiatry. Athens, Greece. 13-17 June, 2015.
43. Kennedy SH. Molecular Targets: An integrated approach to genetic/epigenetic and proteomic analyses. Canadian College of Neuropsychopharmacology. Ottawa, Canada. 10-11 June, 2015.
44. Kennedy SH. Dimensional perspectives on MDD: Anhedonia is a neurobiological target for new drug development. The International College of Neuropsychopharmacology (CINP). Dublin, Ireland. 3-5 June, 2015.
45. Kennedy SH. Targeting Neurocognition in Depression. American Psychiatric Association. Toronto, Canada. 17 May, 2015.
46. Kennedy SH. Comparisons between SSRIs and SNRI Antidepressants. Lexapro Speaker Training. Tokyo, Japan. 09-10 May, 2015.
47. Kennedy SH. Major Depressive Disorder: Applying Evidence-Based Medicine and Treatment Algorithms. American University of Beirut. Beirut, Lebanon. 29 April, 2015.
48. Kennedy SH. Treatment Resistant Depression: Aiming for Better Outcomes, INeuroscience Experts Meeting, Ixtapa Zihuatanejo, Mexico. April 25, 2015.
49. Kennedy SH. From Biomarkers to Clinical Tests in Psychiatry: The Promise and the Challenge, ECNP Biomarker Conference. Nice, France. March 16, 2015.
50. Kennedy SH. Treatment Strategies in Major Depressive Disorder, Cipralox Meeting. Sao Paulo, Brazil. March 12, 2015.
51. Kennedy SH. Is Escitalopram (Lexapro) Different from Other Antidepressants?, Cipralox Meeting. Sao Paulo, Brazil. March 10, 2015.
52. Kennedy SH. CANMAT Depression Guidelines 2016 Section III: Psychopharmacology, Psychopharmacology Update Day. Toronto, Canada. March 7, 2015.
53. Kennedy SH. Breakthroughs in the Treatment of Depression, CDRIN Conference. Ottawa, Canada. February 24, 2015.
54. Kennedy SH. Cognition in Major Depression, Lundbeck Institute. Copenhagen, Denmark. February 19, 2015.
55. Kennedy SH. Exploring Cognitive Deficits in MDD: Focus on Deep Brain Stimulation, Thinc Expert Community

- Meeting. Vienna, Austria. February 11, 2015.
56. Kennedy SH. Dose Response Findings with Agomelatine, Valdoxan Summit Meeting. Paris, France. February 5, 2015.
 57. Kennedy SH. Biomarkers in Depression and Suicide, Trillium Health Partners Grand Rounds. Mississauga, Canada. February 4, 2015.
 58. Kennedy SH. External Review of OBI, CANBIND Workshop. Toronto, Canada. January 29, 2015.
 59. Kennedy SH. New way to assess patient's improvement: New anhedonia scale, Valdoxan Advisory Board. Paris, France. January 22, 2015.
 60. Kennedy SH. Major Depressive Disorder: From Clinical Delivery to Bench, AHNI Conference. Beirut, Lebanon. January 10, 2015.
 61. Kennedy SH. Major Depressive Disorder: Aiming for Better Treatment Outcomes, Lundbeck Lexapro Expert Meeting. Costa Rica. November 8, 2014.
 62. Kennedy SH. The Next Frontier in Treating Major Depressive Disorder: Neurocognition and Function, Lundbeck Lexapro Expert Meeting. Costa Rica. November 8, 2014.
 63. Kennedy SH. Expert Advisor Meeting, Lundbeck Depression Forum (Vortioxetine). Amsterdam, Netherlands. October 31, 2014.
 64. Kennedy SH. Efficacy of 3 Agomelatine Dose Regimens Versus Placebo on the Core Symptoms of Depression, ECNP Conference. Berlin, Germany. October 18, 2014.
 65. Kennedy SH. Recovery - The New Treatment Goal in Depression? Lundbeck China Tour. Beijing, China. September 20, 2014.
 66. Kennedy SH. Challenges to Achieving the Best Symptomatic and Functional Outcomes in the Treatment of MDD, Lundbeck China Tour. Beijing, China. September 19, 2014.
 67. Kennedy SH. Progress in Treating Major Depressive Disorders. Lundbeck Institute Mood Seminar. Copenhagen, Denmark. June 20, 2014.
 68. Kennedy SH. Old drugs versus new drugs: are we right to throw the baby out? Southlake Psychiatry Rounds. Newmarket, Ontario. June 20, 2014.
 69. Kennedy SH. Biomarkers in Depression: A focus on neurocognition. Lundbeck Institute Regional Seminar. Singapore, Singapore. June 8, 2014.
 70. Kennedy SH & Gorwood P. Is cognitive impairment an epiphenomenon or an endophenotype? Lundbeck International Neuroscience Foundation Meeting. Tallinn, Estonia. May 25, 2014.
 71. Kennedy SH. Managing antidepressant non-response: Now and in the Future. Douglas Institute Grand Rounds. Montreal, Quebec. May 8, 2014.
 72. Kennedy SH. Comorbidity and Diabetes: The Challenge and the Response. Chair: APA Annual Meeting – New York City. May 5, 2014.
 73. Kennedy SH. Update on New Antidepressant Approaches: a focus on restoring positive mood. CANMAT/MENAMAT Annual Conference – Dubai. April 26-27, 2014.
 74. Kennedy SH. Responders versus non-responders: progress in selecting the right antidepressant treatment. CANMAT/MENAMAT Annual Conference – Dubai. April 26-27, 2014.
 75. Kennedy SH. Advances in Depression Therapies: Role of Biomarkers. Bahrain, Kuwait and Dubai – April 22-25, 2014.
 76. Kennedy SH. The Role of Biomarkers in identifying new targets and treatments for Depression. AstraZeneca Neuroscience iMED Meeting – Toronto, Ontario. April 15, 2014.
 77. Kennedy SH. Refining treatment targets for depression: Deep brain stimulation and beyond. Women's College Hospital Grand Rounds – Toronto, Ontario. April 11, 2014.
 78. Kennedy SH. Deciding how to initiate antidepressant treatment: What should be taken into account? World Congress on Brain, Behaviour and Emotions: Psychopharmacology Forum 2014 – Montreal, Quebec. April 9,

2014.

79. Kennedy SH. Integrating Clinical and Neurosciences in Assessment and Management of Mood Disorders 1-10. CPA Professional Education - Tahiti. March 26-April 5, 2014.
80. Kennedy SH. Implementing Biomarkers in Depression. Partnerships in Neuroscience, University of Toronto. Toronto, Ontario. March 21, 2014.
81. Kennedy SH. New and Emerging Antidepressant Strategies. Psychopharmacology Update Day – Toronto, Ontario. March 8, 2014.
82. Kennedy SH. Selecting treatments for Major Depressive Disorder: Progress in Biomarkers? McGill Grand Rounds, Allan Memorial Institute - Montreal, Quebec. February 21, 2014.
83. Kennedy SH. CAN-BIND and the Search for Biomarkers. CANMAT Neuroscience Conference – Toronto, Ontario. January 24, 2014.
84. Kennedy SH. Progress in treating Major Depression: from evidence-based practice to biomarkers. Universite de Montreal Academic Day, Louis H. Lafontaine Hospital, Keynote Speaker – Montreal, Quebec. December 13, 2013.
85. Kennedy SH. International Society of Affective Disorders Regional Meeting Presenter – Hong Kong, China. November 7-9, 2013.
86. Kennedy SH. New horizons in depression: the role of biomarkers in treatment selection . Annual Academic Day, Southlake Regional Hospital – Stouffville, Ontario. November 1, 2013.
87. Kennedy SH. Neuroinflammation and Depression. Neuroscience School of Advanced Studies Course Developer and Presenter – Cortona, Italy. October 12-20, 2013.
88. Kennedy SH. Discovering biomarkers for Major Depression: the Canadian Biomarker Integration Network for Depression. Canadian Psychiatric Association Annual Conference Symposium – Ottawa, Ontario. September 27, 2013.
89. Kennedy SH. Biomarkers for major depressive disorders: Implications for diagnostic specificity and treatment selection. State University of New York Annual Psychiatry Day Keynote Speaker - Niagara Falls, New York. September 19, 2013.
90. Kennedy SH. Antidepressant approach to treating depression with somatic symptoms. Chinese Society of Psychiatry Annual Meeting Presenter – Chengdu, China. September 13, 2013.
91. Kennedy SH. Advances in treating MDD: Can biomarkers inform treatment selection? Collegium Internationale Neuro Psychopharmacologicum India Education Talking Tour – Pune, Ahmedabad, Chennai, Kolkata, Lucknow and Delhi. July 4-15, 2013.
92. Kennedy SH. Enhancing Treatment Outcomes for Depression in Major Depressive Disorder and Bipolar Disorder: Progress with Biomarkers. Co-Chair and Presenter, the World Federation of Societies of Biological Psychiatry Congress, Kyoto, Japan. June 24, 2013.
93. Kennedy SH. DSM V: Changes in Mood Disorder criteria. Lundbeck Institute Neuroscience Foundation Faculty Meeting - Sintra, Portugal. June 7, 2013.
94. Kennedy SH. New Developments in Major Depression. CANMAT International Symposium on Mood Disorders Keynote Address - Dubai. April 28, 2013.
95. Kennedy SH. New advances in the treatment of unipolar and bipolar depression. Collegium Internationale Neuro-Psychopharmacologicum Master Class - Dublin, Ireland. April 20, 2013.
96. Kennedy SH. The Brain and Us. Senior Scholars Symposium, Gairdner Foundation - Toronto, Ontario. April 10, 2013.
97. Kennedy SH. Update on depression: Can biomarkers help? 12th Latest Advances in Psychopharmacology Symposium – Royal College of Psychiatrists, Regent’s Park, London, UK. March 13, 2013.
98. Kennedy SH. The Global Mental Health Challenge: A Canadian Perspective. Horizon 2020, CIHR-INMHA,

Toronto, January 17, 2013.

99. Kennedy SH. Neuroimaging biomarkers in depression: A tool for diagnostic subtyping and treatment selection. Joint Neuroscience Conference University of Sao Paulo and University of Toronto, Sao Paulo, Brasil, December 7, 2012.
100. Kennedy SH. A new chapter in the history of depression. Symposium Chair and Speaker Exploring dimensions of symptoms in depression: a basis for targeted antidepressant treatment. 25th European College of Neuropsychopharmacology Congress, Vienna, Austria, October 15, 2012.
101. Kennedy SH. From evidence based medicine to experience based medicine – Keynote speaker at Brazilian Psychiatric Conference, Natal, Brazil, October 12, 2012.
102. Kennedy SH. Challenges and barriers to improving depression outcomes. Toronto East General Hospital Academic Grand Rounds, October 5, 2012.
103. Kennedy SH: Exploring the relationship between vulnerability and consent: The case of investigational trials in Psychiatry. Hosted by the Neuroethics Institut de recherches. Montreal, Quebec, September 27, 2012
104. Kennedy SH, Blier P. Anhedonia: from neurobiology to clinical outcomes. 62nd Annual Conference of the Canadian Psychiatric Association, Montreal, Quebec, September 18, 2012.
105. Kennedy SH. Deep Brain Stimulation for Treatment Resistant Depression: Follow-up after 3 to 6 years. 38th Annual Harvey Stancer Research Day, Toronto, Thursday, June 14, 2012.
106. Kennedy SH, Chair Concurrent Oral Presentations: Clinical Research, including Clinical Trials – Bega S, Foussias G, Goldstein B, Hahn M, King R, Kurdyak P, Le Foll B. 38th Annual Harvey Stancer Research Day, Toronto, Thursday, June 14, 2012.
107. Krystal, J, Daskalakis J, Kennedy SH, Kennedy P. Reserch Forum 2012 Novel treatments in psychiatric disorders – Deep Brain Stimulation for Treatment Resistant Depression. Centre for Addiction and Mental Health, Toronto, Wednesday, June 13, 2012.
108. Kennedy SH, Chair: Neurostimulation therapies: Current advances and controversies – Nahas Z: Epidural cortical stimulation for treatment resistant depression – Schlaepfer T: taking deep brain stimulation for major depression one step deeper – current data and outlook – Kennedy SH: Deep brain stimulation to subcallosal cingulate gyrus for treatment resistant depression: An update. 28th Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress, Stockholm, Sweden, June 7, 2012.
109. Kennedy SH, Chair: Childhood and Adolescent Disorders: Neurodevelopmental bases for progress in pharmacotherapy in autism spectrum disorders. 28th Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress, Stockholm, Sweden, June 5, 2012.
110. Kennedy SH. Successful management of depressive symptoms: a patient centred approach. 28th Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress, Stockholm, Sweden, June 6, 2012.
111. Kennedy SH. Depression Biomarker Network Initiative – Where we are, where we aim to be. McMaster University, Department of Psychiatry & Behavioral Neurosciences, 24th Annual Research Day, Hamilton Convention Centre, Wednesday, May 23, 2012.
112. Kennedy SH. Session on Depression. University of Western Ontario London Psychiatry Review Course. London, Ontario, January 28, 2012.
113. Kennedy SH. Dep Brain Stimulation for depression: science, fact or fiction. 12th Joint European Molecular Biology Organization Conference on Science and Society, Embl Heidelberg, Germany November 5, 2011.
114. Kennedy SH. Late-Life Depression and Dementia. VII European Congress of the International Association of Gerontology and Geriatrics, Bologna, Italy, April 15, 2011.
115. Kennedy SH. Treatment Resistant Depression: Rationale for neurostimulation. Medico Legal Society Annual Dinner Meeting, Marriott Hotel, Toronto, Ontario, March 2, 2011.
116. Kennedy SH. Personalized medicine initiatives in Psychiatry, British North American Committee Meeting, Massey College, Toronto, Ontario, February 15, 2011.

117. Kennedy SH, CANMAT Consensus Conference on Functional Outcomes in Depression Clinical Trials, Ottawa, Ontario, February 10, 2011.
118. Kennedy SH. Session on Depression. University of Western Ontario London Psychiatry Review Course. London, Ontario, January 30, 2011.
119. Kennedy SH. Trouble dépressif majeur : des recommandations à la personnalisation du traitement. Grand Rounds, CHUM (Notre Dame Hospital), Montreal, Quebec, January 11, 2011.
120. Kennedy SH. Session on Depression. University of Western Ontario London Psychiatry Review Course. London, Ontario, January 30, 2010.
121. Kennedy SH. Trouble dépressif majeur : des recommandations à la personnalisation du traitement. Grand Rounds, CHUM (Notre Dame Hospital), Montreal, Quebec, January 11, 2011.
122. Kennedy SH. Improving outcomes in the treatment of depression from guidelines to personalized medicine Grand Rounds, University of Ottawa Institute of Mental Health Research (IMHR), Ottawa, December 3, 2010.
123. Kennedy SH. "Strategies to enhance treatment outcomes:from guideline based care to novel therapeutic targets". Lundbeck Institute, Skodsborg Meet the Expert Seminar. Skodsborg, Copenhagen, November 23, 2010.
124. Kennedy SH. Neurosciences and Clinical Advances in Psychiatry, CPA-CPD Event, Toronto Convention Centre, Toronto, November 19, 2010.
125. Kennedy SH. Neurosciences and Clinical Advances in Psychiatry, CPA-CPD Event, Montreal, November 5, 2010.
126. Kennedy SH. Agomelatine: Effects on circadian rhythm and antidepressant outcomes. Barcelona Spanish Congress of Psychiatry, Barcelona, Spain, October 21, 2010.
127. Kennedy SH. Keynote Lecture "Mediators and moderators of response to different antidepressant therapies", Royal College of Psychiatrists of Thailand Annual Meeting, Bangkok, Thailand, October 13, 2010.
128. Kennedy SH, Preskorn S. Understanding drug-interactions and avoiding problems: Clinical challenges and practical solutions. Canadian Psychiatric Association 60th Annual Conference, Toronto, September 25, 2010.
129. Kennedy SH, McIntyre RS, Alsuwaidan M, Li M, Abbey S. Neuroinflammatory mediators of comorbid depression and medical illness. Canadian Psychiatric Association 60th Annual Conference, Toronto, September 25, 2010.
130. Grigoriadis S, Kennedy SH, Robinson G, McIntyre RS, Hegadoren K, Spencer E, Stewart D, Bradley L, Mamissashvili L, Eisfeld B, Levitt A. The effect of life stage on antidepressant response in women. Canadian Psychiatric Association 60th Annual Conference, Toronto, September 24, 2010.
131. Kennedy SH. Depression is a major public health issue: a compelling case for action. Newfoundland Provincial Government, Department of Health Meeting, St. John's, Newfoundland, June 24, 2010.
132. Kennedy SH. Predictors, mediators and moderators of symptom improvement in Major Depression. Collegium Internationale Neuro-Psychopharmacologicum XXIX Annual Meeting, HongKong, June 7, 2010.
133. Kennedy SH. CANMAT/isbd for BD & CANMAT for MDD: consensus, controversies and impact on modern psychiatric practice. Bogota Colombia Biannual International Congress. Bogota, Colombia, April 10, 2010.
134. Kennedy SH. Signs and symptoms in MDD and related disorders: relevance to diagnosis and guidelines for the upcoming DSM-V. Bogota Colombia Biannual International Congress. Bogota, Colombia, April 9, 2010.
135. Kennedy SH. Anxiety and Bipolar Disorder: Comorbidity or change in concepts and diagnosis in affective disorders. Bogota Colombia Biannual International Congress. Bogota, Colombia, April 9, 2010.
136. Kennedy SH. Emerging novel treatments for major depressive disorder. Bogota Colombia Biannual International Congress. Bogota, Colombia, April 8, 2010.
137. Kennedy SH. CANMAT Guidelines for Major Depressive Disorder. Update 2009. Alberta Psychiatric Association Meeting, Banff, Alberta, March 26, 2010.

138. Kennedy SH. CANMAT Depression Guidelines 2010: What's changed in a decade? Grand Rounds, Department of Psychiatry, Brampton Civic Hospital, March 4, 2010.
139. Kennedy SH. More complete and sustained remission: The key to success in depression. 18th European Congress of Psychiatry (EPA), Munich, Germany, March 1, 2010.
140. Kennedy SH. Recent developments in the treatment of unipolar depression: Applying neuroimaging and neurostimulation. 18th European Congress of Psychiatry (EPA), Munich, Germany, February 28, 2010.
141. Kennedy SH. Session on Depression. University of Western Ontario London Psychiatry Review Course. London, Ontario, January 30, 2010.
142. Kennedy SH. What should dermatologists know about depression? Society of Medicine, London, UK, January 28, 2010.
143. Kennedy SH. Moderator for Resilience and Vulnerability: Depression and Somatization, Cultural and International Mental Health Conference, (Speakers: Drs. Meher Husain, Dawn Edge, Nasim Chaudhry and Salman Karim) Toronto, October 15, 2009.
144. Kennedy SH. Circadian Rhythms and Psychopathology. SCNP/CCNP Joint Meeting, Copenhagen, April 28, 2009.
145. Kennedy SH. Review of invasive treatments in depression. Mind and Body Global Education and Awareness Tour – Major Depressive Disorder and Anxiety: Bridging Research to Clinical Practice. International Conference in Psychiatry, Berlin, Germany, February 20, 2009.
146. Kennedy SH. Session on Depression. University of Western Ontario London Psychiatry Review Course. London, Ontario, January 29, 2009.
147. Kennedy SH. Deep Brain Stimulation: Does it work and why? Grand Rounds, Department of Psychiatry, University of Michigan, Ann Arbor, Michigan. January 28, 2009.
148. Kennedy SH. DBS for Depression: Does it work and who does it help. Grand Rounds, Department of Psychiatry and Psychology, Cleveland Clinic, Ohio. January 22, 2009.
149. Kennedy SH. Boundaries of depression with neurosurgery: Subcallosal cingulate gyrus deep brain stimulation for treatment resistant depression. World Psychiatric Association Annual Meeting, September 23, 2008. Prague, Czechoslovakia.
150. Kennedy SH. Innovation in the treatment of depression: a great leap forward. 21st Congress of the European College of Neuropsychopharmacology (ECNP) Annual Meeting, Barcelona, Spain. August 30, 2008.
151. Kennedy SH. State of art: Treatment of anxiety disorders – Anxiety comorbidity in mood disorders. Collegium Internationale Neuro-Psychopharmacologicum XXVII Annual Meeting, Munich, Germany. July 14, 2008.
152. Kennedy SH. History of Psychiatry Seminar: Journeys in Therapeutics. University of Toronto, The Munk Centre, Toronto. May 14, 2008.
153. Kennedy SH. Neuromodulation therapies in depression. Grand Rounds, University of Calgary, Alberta. April 11, 2008.
154. Kennedy SH. Neuroimaging in the service of treatment selection for depression. Semmelweis University, Budapest. April 3, 2008.
155. Kennedy SH. Advances in managing treatment resistant depression: From augmentation to deep brain stimulation. Toronto Psychopharmacology Update Day. March 22, 2008.
156. Kennedy SH. New perspectives in quality of life for patients with depression and anxiety. Keynote speaker – Middle East Psychiatry Symposium, Istanbul, Turkey. March 8, 2008.
157. Kennedy SH. Advances in depression management: From neurobiology to practice. International Symposium with Dr. Ron Duman. Thessalonica. , Feb 16, 2008; Athens, Feb 17, 2008.
158. Bouffard BA, Kennedy SH, Rich JB, Styra R, Ravindran L, McIntyre RS Memory and antidepressant treatment, Where are we now: Preliminary findings from a randomized controlled trial comparing escitalopram and

- bupropion-XL. Canadian Psychiatric Association, 57th Annual Conference, Montreal, November 18, 2007. Paper session #8.
159. Kennedy SK, Daskalakis J, Nahas Z, Giacobbe P. Neuromodulation therapies for depression. Canadian Psychiatric Association, 57th Annual Conference, Montreal, November 18, 2007. #S29.
160. Kennedy SH, Malizia A. "Brainstorming neuromodulation therapies in depression: way of the future or shades of the past?" 20th European College of Neuropsychopharmacology Annual Meeting, Vienna, Austria, October 14, 2007.
161. Kennedy SH: "The future of neuromodulation in the treatment of depression". Southlake Regional Health Centre, Newmarket, Ontario.
162. Kennedy SH: "Treatment resistant depression: The emergence of deep brain stimulation" Grand Rounds, Lakeridge Health, Oshawa, Ontario, Jun 27, 2007.
163. Kennedy SH: "Towards hypothesis generated treatment". CINP Certificate in Psychopharmacology, The Royal College of Physicians of Ireland, Dublin Ireland, June 9, 2007.
164. Kennedy SH: "Treatment resistant depression: The emergence of deep brain stimulation" W.G. Dewhurst Memorial Lecture, Department of Psychiatry Grand Rounds, Walter C Mackenzie Health Sciences Centre, University of Alberta, Edmonton, May 28, 2007.
165. Kennedy SH: "CANMAT Bipolar Guidelines – 2007 Update: A Focus on Depression". Grand Rounds, Scarborough General Hospital, April 27, 2007.
166. Kennedy SH: Treatment resistant depression: The Emergence of Deep Brain Stimulation. 11th Symposium Lilly Foundation, Madrid, Spain, April 10, 2007.
167. Kennedy SH: Deep Brain Stimulation for Treatment Resistant Depression – Toronto Experience. Ontario District Branch, American Psychiatric Association Inaugural Salon, Toronto, February 6, 2007.
168. Kennedy SH: Breaking new ground in depression: Diagnostic challenges and treatment alternatives. 49th Annual Psychopharmacological Conference of the Czech Neuropsychopharmacological Society, Jesenik, Czech Republic, January 11, 2007.
169. Kennedy SH: S29: The CINP Task Force Report on the use and usefulness of antidepressants: The CANMAT response. Canadian Psychiatric Association 56th Annual Conference, Toronto, November 10, 2006.
170. Kennedy SH, Grigoriadis S, Flint A, Parikh S: S36: Updating antidepressant therapies: Special populations and special treatments. Canadian Psychiatric Association 56th Annual Conference, Toronto, November 12, 2006.
171. Yatham L, Beaulieu S, Gruncze H, Kennedy SH: Satellite Symposium SS04: Bipolar disorder: Biological mechanisms, neurocognition and effects of treatment on suicide. Canadian Psychiatric Association 56th Annual Conference, Toronto, November 11, 2006.
172. Kennedy SH: S16: Expert Psychiatrist Series: Exemplary integration of clinical research and practice. Canadian Psychiatric Association 56th Annual Conference, Toronto, November 10, 2006.
173. Kennedy SH, Boksa P. (Chairs). CCNP Symposium: Convergence of psychosis pathways. 19th European College of Neuropsychopharmacology Meeting, Paris, France, September 19, 2006.
174. Kennedy SH. The melatonergic approach in depression: from pharmacology to clinical evidence – Treating depression today: clinical reality in using antidepressants. 19th European College of Neuropsychopharmacology Meeting, Paris, France, September 19, 2006.
175. Kennedy SH, Bender A, Eisfeld BS. Depression in the workplace. Association Des Médecins Psychiatres Du Québec Annual Meeting, Quebec City, June 15, 2006.
176. Kennedy SH. CANMAT Guidelines for management of bipolar disorder: An effort towards international consensus. American Psychiatric Association Annual Meeting, Toronto, May 2006. #SO28.
177. Kennedy SH, MacQueen GM, Bagby RM, Rosenbluth MB. Complex Depression: The interface between personality disorders and major depression. American Psychiatric Association Annual Meeting, Toronto, May

- 23, 2006. #S065.
178. Kennedy SH. Treatment resistant depression rationale for deep brain stimulation. St. Michael's Hospital Psychiatry Grand Rounds, May 12, 2006.
179. Kennedy SH. Guidelines for bipolar disorder: Treating acute episodes of mania and depression. Drugs and Therapeutics Update, Department of Family Practice, Toronto East General Hospital – Vaughan Estate, April 26, 2006.
180. Kennedy SH. Deep brain stimulation for depression. Toronto Psychopharmacology Update Day. Centre for Addiction and Mental Health, Toronto, March 18, 2006.
181. Kennedy SH. New developments in antidepressants. Annual Meeting of Turkish Psychiatric Association, Erzurum, Turkey, November 11, 2005.
182. Kennedy SH. CANMAT Guidelines for management of bipolar disorder: An effort toward International Consensus. Canadian Psychiatric Association Annual Meeting, Vancouver, BC, November 5, 2005.
183. Kennedy SH. Complex Depression: The interface between personality disorders and major depression – Symposium S20. Canadian Psychiatric Association Annual Meeting, Vancouver, BC, November 5, 2005.
184. Kennedy SH. Challenges and controversies in the treatment of mood disorders, Woodbridge Psychiatric Hospital, Singapore, Grand Rounds, August 26, 2005.
185. Kennedy SH. Understanding and treating mood disorders in 2005. Public Lecture. Canadian College of Neuropsychopharmacology Annual Meeting, St. John, Newfoundland, July 3, 2005.
186. Kennedy SH, Coccaro E, MacQueen G, Rosenbluth M. Understanding complex mood disorders: The role of personality variables. (Conference Chair) APA Annual Meeting, May 21-26, 2005, Atlanta, Georgia.
187. Kennedy SH. The influence of personality variables on pharmacotherapy outcomes in major depression. APA Annual Meeting, May 21-26, 2005, Atlanta, GA.
188. Kennedy SH. Treatment Resistant Depression: From pharmacotherapy to physical intervention. University of Calgary 3rd Annual Mood Disorders Day, University of Calgary, AB. Plenary Talk. April 22, 2005.
189. Kennedy SH. Remission and recovery: Why both goals matter. (Workshop) University of Calgary Mood Disorders Day, University of Calgary, AB. April 22, 2005.
190. Kennedy SH. Integrating Neurobiology into clinical practice: Recent evidence from depression. (Keynote speaker) Alberta Psychiatric Association Annual Meeting, Banff, Alberta. April 2, 2005.
191. Kennedy SH. The environment, the brain and depression: Integrating findings to enhance treatment outcomes. CPA International CPD Conference, Mexico. March 7, 2005.
192. Kennedy SH. Emerging strategies to manage bipolar disorder. CPA International CPD Conference, Mexico. March 8, 2005.
193. Kennedy SH. Treatment resistant depression. CPA International CPD Conference, Mexico. March 8, 2005.
194. Kennedy SH. How do personality variables influence depression treatment outcome? CPA International CPD Conference, Mexico. March 8, 2005.
195. Kennedy SH. Jane Chamberlain Memorial Lecture – The Impact of Depression on our Lives: Opportunity to move forward. Ontario Psychiatric Association Annual Meeting. Toronto, January 27, 2005.
196. Kennedy SH. Managing Psychiatric Dilemmas. Saturday at the University. University of Toronto, Toronto, November 6, 2004.
197. Kennedy SH. New Perspectives in the Management of Depression – The Canadian Depression Study-Computerized Neurocognitive Testing. CPA Annual Meeting, Montreal, October 14, 2004.
198. Kennedy SH. Achieving optimal remission: Physical, emotional and functional wellness, Satellite Symposium. CPA Annual Meeting, Montreal, October 15, 2004.
199. Kennedy SH. Personality dimensions, disorders and depression: Treating the complex patient. Symposium

- Chair and presenter. CPA Annual Meeting, Montreal, October 15, 2004.
200. Kennedy SH. Imaging in Psychiatry. Asia-Pacific CNS Scientific Expert Meeting III, Shanghai, China, June 2004.
201. Kennedy SH. Why dual action antidepressants provide a faster onset of action? Asia-Pacific Scientific Expert Meeting III, Shanghai, China, June 4-6, 2004.
202. Kennedy SH. Is it depression or bipolar disorder? Keynote Address - CCNP Annual Meeting, Kingston, Ontario, May 29, 2004.
203. Kennedy SH. Treatment approaches to depression. Workshop - CCNP Annual Meeting, Kingston, Ontario, May 29, 2004.
204. Kennedy SH, Coccaro E, MacQueen G, Rosenbluth M. Understanding complex mood disorders: The role of personality variables. APA Annual Meeting, May 21-26, 2004, Atlanta, GA.
205. Kennedy SH, Milev RV. Adopting evidence-based practice in the treatment of mood disorders: The Canadian experience. APA Annual Meeting, New York, May 5, 2004.
206. Gold WL, Fones C, Kennedy SH, McGeer A, Robinson S, Hawryluck L, Styra R. The Psychological Impact of SARS on the Uninfected Health Care Worker. APA Annual Meeting, New York, May 4, 2004.
207. Kennedy SH. Improving the outcome in the treatment of depression. International Congress of Biological Psychiatry. February 2004.
208. Kennedy SH. The impact of tolerability, ease of administration and long-term safety concerns on patient compliance. International Congress of Biological Psychiatry. February 2004.
209. Kennedy SH. Bipolar Disorder: An Update on Pharmacotherapies, AMPQ, Quebec City, Nov. 2003.
210. Kennedy SH. Review of Recent Developments and update of Depression Treatment, Mood & Anxiety Disorders Annual Conference, Kingston, Ontario, Nov. 2003.
211. Kennedy SH. Treating Depression Workshop, Kingston, Ontario, Nov. 2003.
212. Kennedy SH. Managing Treatment Resistant Depression, Montreal, Nov. 2003.
213. Kennedy SH. Depression and Getting Back to Work, CPA, Halifax Nova Scotia, Oct. 2003.
214. Kennedy SH. Dual Action Antidepressants across populations with Mood Disorder – CPA Symposium, Halifax, Nova Scotia, Oct. 2003
215. Kennedy SH. Adopting Evidence Based Practice: Barriers and Changing Climates – CPA Symposium, Halifax, Nova Scotia Oct. 2003.
216. Kennedy SH. Effects of Lamotrigine in Quality of Life in Patients with Bipolar Disorder, ECNP, Prague, Czech, Sept. 2003
217. Kennedy SH. Differences in sexual dysfunction between men and women with depression: A comparison of bupropion and paroxetine treatments, CCNP, Montreal, Quebec, June 2003.
218. Kennedy SH. Effects of Lamotrigine in Quality of Life in Patients with Bipolar Disorder, Bipolar Disorder Conference, Pittsburgh, June 2003.
219. Krueger S, Seminowicz BS, Goldapple K, Kennedy SH, Mayberg HS. Changes in Regional CBF in bipolar disorder following transient-induced sadness measured with PET, APA, San Francisco, CA, May 19, 2003.
220. Lam R, Ravindran A, Kennedy SH, Milev R. Successful strategies to optimize outcomes with antidepressants. CPA Annual Meeting, Banff, Alberta, November 2002. S8
221. McIntyre R, Kennedy SH, Stewart D, Schatzberg A, Kelsey J. Gender, Age and remission in depression. CPA Annual Meeting, Banff, Alberta, November 2002. CS1
222. McIntyre R, Shapiro C, Kennedy SH, Schatzberg A. The interface of depression, sleep and anxiety disorders: strategies to manage the sleepless anxious depressed patient. CPA Annual Meeting, Banff, Alberta, November 2002. CS2

223. Lam R, Kennedy SH, Blier P, Reesal RT. Rediscovering the neurochemistry, efficacy and tolerability of the serotonin system: the progression of SSRI therapy. CPA Annual Meeting, Banff Alberta, November 2002. CS3
224. Stewart D, Kennedy SH, Wise T, Dunner DL. Managing the motional and physical symptoms of depression. CPA Annual Meeting, Banff, Alberta, November 2002. CS7
225. Grigoriadis S, Kennedy SH, Bagby M. A comparison of antidepressant response in younger and older women. CPA Annual Meeting, Banff, Alberta, November 2, 2002.
226. Kennedy SH. Understanding depression and its treatment. Canada Pension Plan Appeals Board Seminar, Hilton Lac Leamy, Hull, Quebec, July 16, 2002.
227. Kennedy SH. Management strategies for the treatment of Generalized Anxiety Disorders. Global Neuroscience Summit, Scottsdale, Arizona, March 14-17, 2002.
228. Kennedy SH. Comorbidity of mood and anxiety disorders (workshop). Global Neuroscience Summit, Scottsdale, Arizona, March 14-17, 2002.
229. Kennedy SH. Depression – “Are Combination Treatment Safe and Effective?” Update 2002 for Family Physicians, Department of Family and Community Medicine, “Safety in Medical Practice”, May 2002. Toronto.
230. Kennedy SH. Advances in Antidepressant Treatment - A Critical Review of the Full Remission Story. November 2001. Edmonton.
231. Kennedy SH. Anxiety & Depression...A Family Story. Calgary Alberta. November 2001.
232. Kennedy SH. Foreshadowing the Future Beyond SSRIs: The Remeron™ Efficacy Story. Regina, Saskatoon, Edmonton, Kingston, Monton, Halifax. October & November. 2001.
233. Kennedy SH. Depression: Refractory Strategies, Novel Agents, Transcranial Magnetic Stimulation. TAPP Talk. Toronto, Ontario. October 2001.
234. Kennedy SH. Clinical Practice Guidelines for the treatment of Depressive Disorders: A Focus on Mirtazapine and Other Dual Action Antidepressants. Grand Rounds Whitby Hospital. Whitby, Ontario. September 2001.
235. Kennedy SH. Successful Strategies to Improve Treatment Response with First –Line Therapy. GP Fall Forum. Deerhurst, Ontario. September 2001.
236. Kennedy SH. Clinical Practice Guidelines for the treatment of Depressive Disorders: From Theory to Practice. UWO CME. London, Ontario. September 2001.
237. Kennedy SH. Biological Basis of Mood Disorders: From Psychobiology to Neuroscience. PGY-2 Lecture. Toronto, Ontario. September 2001.
238. Kennedy SH. Clinical Practice Guidelines for the treatment of Depressive Disorders: A Focus on Mirtazapine and Other Dual Action Antidepressants. Mississauga, Ontario. September 2001.
239. Kennedy SH. Clinical Practice Guidelines for the treatment of Depressive Disorders: A Focus on Mirtazapine and Other Dual Action Antidepressants. Grand Rounds North York General. Toronto, Ontario. September 2001.
240. Kennedy SH. Measuring Sexual Function in Clinical Practice (the Sex Fx.). Mood Disorders in Primary Care. FP-MAN. Toronto, Ontario September 2001.
241. Kennedy SH. Managing Depression: In it for the Long Haul. Auberge de Pomcier. Toronto, Ontario. June 2001.
242. Kennedy SH. Clinical Guideline for the Treatment of Depressive Disorders. Ground Rounds, St. Paul’s, Vancouver, British Columbia. June 2001.
243. Kennedy SH. Major Depressive Disorder: From Psychobiology to Neuroscience. Grand Rounds, St. Mike’s Hospital. Toronto, Ontario. June 2001.
244. Kennedy SH. The Efficacy of Acute Therapy for Major Depressive Disorder: Distilling the Evidence. Keynote Speaker. Charleston, South Carolina. June 2001.

245. Kennedy SH. Who's Who and What's What in Mood Disorders. Resident Report Program. American Psychiatric Association Annual Meeting . New Orleans, Louisiana. May 2001.
246. Kennedy SH. Long-Term Treatment Issues in Depression. American Psychiatric Association Annual Meeting . New Orleans, Louisiana. May 2001
247. Kennedy SH. Major Depressive Disorder in the 21st Century: From Psychobiology to Neuroscience. Keynote Address. The 42nd Annual Meeting of Japanese Society of Psycho-Medicine. Kagoshima, Japan. May 2001.
248. Kennedy SH. Antidepressant in Clinical Practice: Limitations of Assessment Methods and Drug Response. Keynote Speaker Prince Hotel. April 2001
249. Kennedy SH. What is an Acceptable Outcome when Managing your Depressed Patients? Keynote Speaker. Grandview, Ontario. April 2001.
250. Kennedy SH. Depressive Disorders in 2001: An Overview of Clinical Management. Keynote Speaker. UWO PGY-5 Training Program. Mont Tremblant. February 2001.
251. Kennedy SH. Pharmacotherapy to Sustain the Fully Remitted State. Chair and speaker. Full Remission Pre-Supplement Meeting. Laguna, California. February 2001.
252. Kennedy SH. The Pharmacotherapy of Major Depression: Reassessing Standards of Efficacy. Opinion Leader Meeting. Huntsville, Muskoka. February 2001.
253. Kennedy SH. Review of Mirtazapine Pharmacology, Safety & Tolerability Data. Opinion Leader Meeting. Huntsville, Muskoka. February, 2001
254. Kennedy SH. Report Card on Depression: How are we doing? Grand Rounds. Whitby Psychiatry Centre. Whitby, Ontario. January 2001.
255. Kennedy SH. IPT Rounds: Combination Treatments for Major Depression. CAMH. Toronto, Ont. December 2000.
256. Kennedy SH. Managing Depression and Providing Optimal Treatment: What does it mean in primary care? December 2000. (Teleconference Presentation: Medicine Hat, Alberta.)
257. Kennedy SH. Managing Depression and Providing Optimal Treatment: The Full Remission Story. Grand Rounds. Oshawa, Ontario. November 2000.
258. Kennedy SH. Brown Bag Ethic Discussion: Why we need placebo controlled RCTs in major depression research. November 2000.
259. Kennedy SH. Understanding & Treating Depression: Breaking down the Barriers. Public Forum. Oakville, Ont. October 2000.
260. Kennedy SH. TAPP. Using the Specialist Guidelines for Depression and Interactive Test Session. Toronto. October 2000.
261. Kennedy SH. Breaking Down the Barriers. Grand Rounds, Queens University Belfast. Northern Ireland, UK. September 2000.
262. Kennedy SH. Report Card on Depression: How are we doing? Keynote speaker. Saskatoon College of Family Physicians. Workshop Leader. Saskatoon, Sask. September 2000
263. Kennedy SH. Breaking Down the Barriers. Key Note Speaker. Saskatoon College of Family Physicians. Saskatoon, Sask. September 2000.
264. Kennedy SH. New Antidepressants – Mechanisms, Indications & Therapeutic Profile. PGY-2. Toronto. September 2000.
265. Kennedy SH. Breaking Down the Barriers to Successful Antidepressant Treatment. Victoria Keynote Speaker. Victoria Mental Health Association Mood Disorders Day. Victoria, BC. June 2000.
266. Kennedy SH. Report Card on Depression: How are we doing? Grand Roundy, St. Pauls Hospital. Vancouver, BC. June 2000.

267. Kennedy SH. Antidepressant Treatments: Advancements & Limitations. Grand Rounds, Surrey, BC. June 2000.
268. Kennedy SH. Contemporary Issues in the Treatment of Clinical Psychiatry. Tampa, Florida. June 2000.
269. Kennedy SH. Barriers to Achieving Full Remission . Vancouver, BC. May 2000.
270. Kennedy SH. Evaluating Bupropion & SSRIs in the Management of Depression. Quebec Psychiatry Association Meeting (AMPQ). Quebec City. May 2000.
271. Kennedy SH. The Canadian Experience with Reboxetine under the Special Access Program. APA. Chicago. May 2000
272. Kennedy SH. Challenges in Depression. Keynote Speaker. University of Calgary. Program for Family Physicians. Banff, Alberta. April 2000.
273. Kennedy SH. Progress in Mood Disorders. Grand Rounds London, Ontario. April 2000.
274. Kennedy SH. Report Card on Depression. Chair & Keynote Speaker. Clinical Neuroscience Conference. Niagara Inn on the Lake. April 2000.
275. Kennedy SH. Mind, Mode, Mood. Invited Speaker. University of Toronto part – time Psychiatrists Dinner Meeting. Toronto. April 2000.
276. Kennedy SH. Remission versus Response. Grand Rounds Sudbury Hospital. Sudbury, Ontario. April 2000.
277. Kennedy SH. Remission versus Response. Grand Rounds North Bay Hospital. North Bay, Ontario. April 2000.
278. Kennedy SH. A Comparative Analysis of Efficacy, Safety, and tolerability of antidepressants with a focus on Sexual Functioning. Toronto. March 2000.
279. Kennedy SH, Segal Z, Kitchen K. Pathways to Recovery: A forum on Clinical Depression. Toronto. March 2000.
280. Kennedy SH. First Line Treatment: Lessons from Research to Practice. Gravenhurst, Ontario. February 2000.
281. Kennedy SH. First Line Treatment: Lessons from Research to Practice. Arizona. February 2000.
282. Kennedy SH. Treatment Resistance in Depression. Mount Sinai Hospital. Toronto January 2000.
283. Kennedy SH, Eisfield B, Meyer J, Bagby M. Limitations of antidepressants in clinical practice: measurement and outcome. University of Galway International Symposium on Mood Disorders. September 1999.
284. Kennedy SH. Beyond Symptom Change in Depression. CPA Toronto. September, 1999.
285. Kennedy SH. CPA Institute in the Psychopharmacology of Depression. CPA Toronto. September, 1999.
286. Kennedy SH, Bagby RM, McCann SM, Dickens S, Raskin J. Placebo controlled trials in depression: bridging ethics and science. 12th Congress of the European College of Neuropsychopharmacology . London UK. September 1999.
287. Kennedy SH. Bupropion and SSRIs: a comparative analysis. Canadian Psychiatry Assoc. 49th Annual Meeting. Toronto. September 1999.
288. Schaffer A, Levitt, Bagby RM, Kennedy SH, Levitan RD, The effect of gender and anxiety on suicidal ideation in major depression. Canadian Psychiatric Association 49th Annual Meeting. Toronto. September 1999.
289. Kennedy SH, Parikh S, Goering P. Resolving best practices and evidence based guidelines in Canada. International Advisory Meeting. Barcelona, Spain. April, 1999.
290. Kennedy SH. Future opportunities for assessment of change during antidepressant therapy. University of Alberta. Edmonton. April, 1999.
291. Kennedy SH. The place of citalopram among first line antidepressants. Homewood Health Sciences Centre. Guelph. March, 1999.
292. Kennedy SH. Antidepressant therapies: Response is not enough. Grand Rounds. St. Mary's Hospital.

- Montreal. February, 1999; Montreal General Hospital . Montreal. February, 1999; Douglas Hospital. Montreal. February, 1999.
293. Kennedy SH. Response and Remission in Depression. Grand Rounds. Douglas Hospital. Montreal. February, 1999.
294. Kennedy SH. Goal of antidepressant therapy: Response or remission. Grand Rounds. Winnipeg Health Sciences and St. Boniface Hospital. February, 1999.
295. Kennedy SH. Functional Imaging in Major Depression. Grand Rounds. Winnipeg Health Sciences Centre. February, 1999.
296. Kennedy SH. Clinical and PET predictors of antidepressant response. Grand Rounds. University of British Columbia. Vancouver. January, 1999.
297. Kennedy SH. Raising the bar for assessment of antidepressant drug response. University of British Columbia. Vancouver. January , 1999.
298. Kennedy SH. Redefining antidepressant response. Canadian Psychiatric Association. Halifax. September, 1998.
299. Kennedy SH. Clinical applications for new antidepressant therapies. Canadian Psychiatric Association. Halifax. September, 1998.
300. Kennedy SH. Bupropion in major depression: a review of efficacy and safety. Canadian Psychiatric Association. Halifax. September , 1998.
301. Kennedy SH. PET studies in depression - are we any wiser? Bristol-Myers Squibb Pharmaceutical Group Psychiatry Retreat. Barrie, Ontario. June, 1998.
302. Kennedy SH. (Symposium Chairman) The evolving role of antidepressant therapy. Canadian Faculty Meeting in Psychiatry. Bristol-Myers Squibb. Toronto. May, 1998.
303. Kennedy SH. Out of the darkness: treating mood disorders in the year 2000. McGill University and Douglas Hospital Academic Day. Montreal. April, 1998.
304. Kennedy SH, Ralevski E, Cohen N, Segal Z, Bagby M. Compliance in clinical trials. British Association for Psychopharmacology and the Canadian College for Neuropsychopharmacology. Cambridge, UK. July, 1997.
305. Kennedy SH. Moderator. Seasonal affective and other mood disorders. Pfizer Dialogue. Canadian Psychiatric Association. Calgary. September, 1997.
306. Kennedy SH. (Symposium Panelist) Drug-drug interactions in psychiatry. 5th Annual Psychopharmacology Program Day, University of Toronto. October, 1997.
307. Kennedy SH. Practical issues in depression guidelines. General Practice Psychotherapy Association of Ontario Tenth Annual Conference. Erindale Campus, University of Toronto. June, 1997.
308. PET and antidepressant drug response. Boehringer Ingelheim Scientific Development Program. Nice, France. June, 1997.
309. Kennedy SH. Dichotomies and Developments. Academic lecture. Department of Psychiatry, University of British Columbia. May, 1997.
310. Kennedy SH. Therapeutic applications of Melatonin. More than an annual update of pediatrics. Hospital for Sick Children, Toronto, Ontario. April, 1997.
311. Kennedy SH. (Chair) Developing a case based educational program in depression for family physicians. Montreal, Quebec. February, 1997.
312. Kennedy SH. A 5-year review of RIMA therapy in Canada. Michigan Psychiatric Association, Michigan, Detroit. January, 1997.
313. Kennedy SH. Psychobiology of depression: lessons from PET. Grand Rounds, North York General Hospital, North York, Ontario. January, 1997.

314. Kennedy SH. (Symposium Chair) Combining psychotherapy and pharmacotherapy in depression. Ontario Psychiatric Association, Toronto, Ontario. January, 1997.
315. Kennedy SH (Chair). Placebo controlled trials in mood and anxiety disorders: ethical and regulatory aspects. CANMAT Academic Day, Hotel des Gouverneurs, Ste. Foy, Quebec. September, 1996.
316. Kennedy SH (Chair), Greist JH, Docherty JP. Depression: the science of longterm therapy. Pfizer Dialogue, Canadian Psychiatric Association, Quebec City, Quebec. October, 1996.
317. Kennedy SH. Recent insights into site of action of antidepressants - PET findings. Keynote speaker. Dalhousie Mood Disorders Academic Day, Halifax, Nova Scotia. October, 1996.
318. Kennedy SH. New developments in psychopharmacology of depression: the search for rapid onset of action. Keynote speaker. British Columbia Psychiatric Association Annual Meeting, Vancouver, BC. November, 1996.
319. Kennedy SH. RIMA therapy in family practice. Psychiatric Update Conference, Toronto. November 1995, February 1996, June 1996.
320. Kennedy SH. Ten frequently asked questions in psychopharmacology of mood and anxiety disorders. General Practice Psychotherapists of Ontario Annual Conference, Erindale Campus, University of Toronto. June, 1996.
321. Kennedy SH. Patient and treatment variables in managing depression: An interactive presentation. CCNP Family Practice Education Day, Toronto, Ontario. June, 1996.
322. Kennedy SH. From DST to PET - Advances in understanding the psychobiology of depression. Grand Rounds, Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia. April, 1996.
323. Kennedy SH. From DST to PET - Advances in understanding the psychobiology of depression. Grand Rounds, Nova Scotia Hospital, Dartmouth, Nova Scotia. April, 1996.
324. Kennedy SH. Managing depression in the nineties: Factors influencing the choice of and response to antidepressants. Grand Rounds, Royal Victoria Hospital, London, Ontario. April, 1996.
325. Kennedy SH. The psychobiology and treatment of depression. Grand Rounds, Markham-Stouffville Hospital. May, 1996.
326. Kennedy SH. A day in depression - Using antidepressants in family practice. University of Toronto Faculty of Medicine Continuing Education, Toronto. February, 1996.
327. Kennedy SH. Treatment failures in depression: Not an end point. Keynote speaker. Greater Vancouver Mental Health Semi-Annual Conference, Vancouver. February, 1996.
328. Kennedy SH. Middle and late life depression: Issues of maintenance and relapse. Grand Rounds, St. Vincent's Hospital, Vancouver. February, 1996.
329. Kennedy SH. Comorbidity in depression: An interactive case based presentation. North Vancouver Psychiatric Association, Vancouver. February, 1996.
330. Kennedy SH. Mechanisms of action and practical use of antidepressants. Grand Rounds, North York Branson Hospital. February, 1996.
331. Kennedy SH. Psychotherapy and pharmacotherapy in depression - The state of the union. Grand Rounds, Humber Memorial Hospital. January, 1996.
332. Kennedy SH. Middle life depression. Keynote Address. Soldier's Memorial Hospital. Orillia, Ontario. October, 1995.
333. Kennedy SH. Motivation in clinical research. Clinical Trials Research Group, Dallas, Texas. December, 1995.
334. Kennedy SH. Continuation and maintenance treatments with MAOI and RIMA therapies. 4th International Symposium on Prophylactic Treatments of Mood Disorders. Royal Ottawa Hospital. September, 1995.
335. Kennedy SH. Managing depression in the 90s. Canadian Association of Physicians of Indian Origin. Toronto. June, 1995.

336. Kennedy SH. RIMA agents in depression and related disorders. Annual Family Practice Conference, Niagara-on-the-Lake. June, 1995.
337. Kennedy SH. Managing depression in the community. Leamington, Ontario. May, 1995.
338. Kennedy SH. Practical approaches to pharmacotherapy in depression. General Practice Psychotherapists Conference. University of Toronto, Erindale Campus. May, 1995.
339. Kennedy SH. Clinical cases in depression - An interactive workshop. Niagara-on-the-Lake. May, 1995.
340. Kennedy SH. RIMA - A review of 3 years in Canada. McMaster University Mood Disorders Group, Hamilton. May, 1995.
341. Kennedy SH. SNRI - From old to new antidepressant mechanisms. Doctor's Hospital Community Psychiatrists. April, 1995.
342. Kennedy SH. Diagnosis and management of depression in primary care settings. Keynote address. Issues in Primary Care Symposium. Deerhurst Inn. March, 1995.
343. Kennedy SH. Partnerships in psychiatry. Professorial Lecture. Department of Psychiatry, University of Toronto. January, 1995
344. Kennedy SH. Depression and comorbidity. Second Primary Care Rounds on Depression Symposium, Toronto. January, 1995.
345. Kennedy SH. Doing psychotherapy and pharmacotherapy for depression. Grand Rounds, York County Hospital, Newmarket. November, 1994.
346. Kennedy SH. New antidepressants. Dalhousie University Mood Disorders Group, Dalhousie, Nova Scotia. November, 1994.
347. Kennedy SH. An update on antidepressants. Grand Rounds, Koffler Student Services Centre, University of Toronto, Toronto. November, 1994.
348. Kennedy SH. Comorbidity in eating disorders: Implications for management. Waterside Hospital Academic Day, Memorial University, St. Johns, Newfoundland. November, 1994.
349. Kennedy SH. Pharmacotherapy and psychotherapy. Are two better than one in the treatment of depression? Grand Rounds, St. Joseph's Hospital, Toronto. October, 1994.
350. Kennedy SH. Beyond SSRI's: New and old antidepressant therapies. Sarnia Medical Association, Sarnia. May, 1994.
351. Kennedy SH. Recent developments in understanding and treating Eating Disorders, Grand Rounds, Winnipeg Health Sciences Centre, Winnipeg. May, 1994.
352. Kennedy SH. Advances in antidepressant therapies. From SSRIs to RIMA. University of Manitoba, Winnipeg. May, 1994.
353. Kennedy SH. RIMA agents - current developments and future directions. Edmonton, Alberta. April, 1994.
354. Kennedy SH. From MAOI's to RIMA - a historical perspective. Grand Rounds, Calgary General Hospital, Calgary. April, 1994.
355. Kennedy SH. Choosing an antidepressant in primary care. Lincoln County Medical Society, St. Catharines. April, 1994.
356. Kennedy SH. Pharmacotherapy for depression - beyond the SSRI agents. Whitby Psychiatric Hospital, Whitby. March, 1994.
357. Kennedy SH. Assessing and treating eating disorders in a community practice. Lambton County Medical Society, Windsor. February, 1994.
358. Kennedy SH. Implications of risk factors for anorexia nervosa and bulimia nervosa in treatment planning. McMaster-Chedoke Hospital, Hamilton. January, 1994.
359. Kennedy SH. Advances in pharmacological and psychological treatments of depression. Richmond Hill

- Medical Society. December, 1993.
360. Kennedy SH. Advances in antidepressant therapy - The relative merits of RIMA and SSRI therapies. Toronto Hospital Mood Disorders Evening Presentation, Toronto. November, 1993.
361. Kennedy SH. Treatment advances in bulimia nervosa. Grand Rounds, North York General Hospital, Department of Psychiatry, North York. October, 1993.
362. Kennedy SH. The eating disorders: Early recognition, pathogenesis and treatment. North American Association for the Study of Obesity / American Society for Clinical Nutrition (Sponsored Program), Medical College of Wisconsin, Milwaukee. October, 1993.
363. Kennedy SH. Drug therapies in eating disorders: Limitations and future directions. Grand Rounds, University of Ottawa. October, 1993.
364. Kennedy SH. Recent advances in MAO Inhibitors. Grand Rounds, Hotel Dieu. Queens University, Kingston. October, 1993.
365. Kennedy SH. Diagnosis and etiology of eating disorders. The Toronto Hospital, Practical Approaches to Eating Disorders Course. September 1993.
366. Kennedy SH. Monoamine oxidase inhibitors in general psychiatry: New developments. Windsor Medical Society, Windsor. September, 1993.
367. Kennedy SH, Weiss M. Cultural factors in diagnosing and treating major depression. Toronto Chinese Medical Association. July, 1993.
368. Kennedy SH. Current issues in eating disorders. Keynote Speaker, Atlantic Provinces Psychiatric Conference, Baddeck, Nova Scotia. June, 1993.
369. Kennedy SH. Medication and its future. National Institute of Mental Health, Scientific Symposium on Eating Disorders, Chicago. May, 1993.
370. Kennedy SH. Eating Disorders: Recent advances and their implication for treatment. Keynote Address, St. Pauls Hospital 4th. Annual Eating Disorder Symposium, Vancouver. May, 1993.
371. Kennedy SH. Monoamine oxidase inhibitors in psychiatry: Recent developments. Windsor General Hospital, Windsor. May, 1993.
372. Kennedy SH. Selective MAO inhibitor therapies: New developments in the treatment of depression. Penetanguishene Psychiatric Hospital, Penetanguishene. May, 1993.
373. Kennedy SH. Melatonin as an index of noradrenergic function in psychiatric illness? Graduate Programme in Exercise and Health Science, York University, Toronto. April, 1993.
374. Kennedy SH. The Toronto Hospital Programme for Eating Disorders - A range of treatment approaches to bulimia nervosa. Grand Rounds, Department of Psychiatry, Johns Hopkins Medical School, Baltimore. February, 1993.
375. Kennedy SH. Understanding and treating anorexia nervosa and bulimia nervosa. North Bay Medical Society, North Bay. November, 1992.
376. Kennedy SH. Advances in antidepressant therapy - the reversible inhibitors of MAO-A. Sudbury Medical Society, Sudbury. November, 1992.
377. Kennedy SH. Pharmacology and clinical use of reversible MAO inhibitors. North Bay Psychiatric Hospital Grand Rounds, North Bay. November, 1992.
378. Kennedy SH. Advances in treating depression - Reversible and selective MAO inhibitors. Kitchener & Wellington County Medical Association. November, 1992.
379. Kennedy SH. Anorexia nervosa: The neglected eating disorder: Advances in etiology and treatment. Grand Rounds, St. Michael's Hospital, Toronto. October, 1992.
380. Kennedy SH. From MAO-inhibitors to RIMAs. Grand Rounds, Douglas Hospital, Montreal. October, 1992.

381. Kennedy SH. Augmentation and alternative approaches to refractory depression. Grand Rounds, Oshawa General Hospital, Oshawa. October, 1992.
382. Kennedy SH. Anorexia nervosa and bulimia nervosa: An integrated and community orientated perspective on treatment. Chair and Symposium Organizer, Institute of Hospital and Community Psychiatry, Toronto. October, 1992.
383. Kennedy SH. From MAOIs to RIMAs. McMaster University Mood Disorder Clinic, Ancaster. October, 1992.
384. Kennedy SH. The efficacy and tolerability of moclobemide versus SRIs. Workshop on moclobemide: Its place in antidepressant therapy. Montreal, September, 1992.
385. Kennedy SH. Advances in understanding and managing eating disorders. Keynote address. Kananaskis Conference on Eating Disorders, Alberta. May, 1992.
386. Kennedy SH. Overview of depression - origins and treatment. Hoffman La Roche Symposium, Niagara-on-the-Lake. April, 1992.
387. Kennedy SH. The therapeutic role of MAO-inhibitors in depression: Present treatments and recent developments. Marriott Hotel, Toronto. February, 1992.
388. Kennedy SH. Pharmacological and psychological treatments of anorexia nervosa and bulimia nervosa. Grand Rounds, Mount Sinai Hospital. January, 1992.
389. Kennedy SH. Refractory bipolar and unipolar depression. Grand Rounds, Whitby Psychiatric Hospital. January, 1992.
390. Kennedy SH. Phenomenology and polarity as factors which influence choice of mood disorder therapies. Grand Rounds, Department of Psychiatry, University of British Columbia. January, 1992.
391. Kennedy SH. Psychological and pharmacological treatments for mood disorders. Grand Rounds, Riverview Hospital, Vancouver. January, 1992.
392. Kennedy SH. What next? A sequential approach to managing mood disorders. Medical Grand Rounds, Greater Victoria Hospital, Victoria, B.C. January, 1992.
393. Kennedy SH. The relevance of the pineal gland and melatonin to anorexia nervosa and bulimia nervosa. North American Symposium on Eating Disorders in Adolescence, Seattle, Washington. December, 1991.
394. Kennedy SH. Advances in understanding and treating anorexia nervosa and bulimia nervosa. Thunder Bay Medical Society, Academic Day. November, 1991.
395. Kennedy SH. Factors influencing the choice of treatment for depression. Thunder Bay Medical Society, Academic Day. November, 1991.
396. Kennedy SH. Bipolar depression: The neglected pole. Douglas Hospital, Montreal. November, 1991.
397. Kennedy SH. Factors influencing the course and treatment of bipolar mood disorder. Grand Rounds, Montreal General Hospital. November, 1991.
398. Kennedy SH. Advances in understanding and treating bulimia nervosa. Grand Rounds, Calgary General Hospital. June, 1991.
399. Kennedy SH. New directions in treating eating disorder patients. Symposium, Edmonton. June, 1991.
400. Kennedy SH. Recognition and differential diagnosis of depression. Oakville Trafalgar Hospital. May 1991.
401. Kennedy SH. Bipolar depression: The neglected pole. Intercity Grand Rounds, Department of Psychiatry, Memorial University, St. John's, Newfoundland. April 1991.
402. Kennedy SH. How has our understanding of eating disorders influenced treatment? Academic Lecture, Health Sciences Centre, Memorial University, St. John's, Newfoundland. April 1991.
403. Kennedy SH. Pharmacological issues in eating disorders. Grand Rounds, Scarborough Grace Hospital. March, 1991.
404. Kennedy SH. Managing depression: Intensification and augmentation strategies. Kingston General Hospital,

- Intercity Grand Rounds. March, 1991.
405. Kennedy SH. New drugs - New directions in treating depression. Grand Rounds, St. Joseph's Hospital, Toronto. December, 1990.
406. Kennedy SH, Bradwejn J, Joffe RT, Kusalic M. Managing bipolar depression. Conference on Resistant Depression. London (UK). November, 1990.
407. Kennedy SH. Bipolar mood disorders: Principles of treatment. Hamilton Psychiatric Hospital, Grand Rounds. November, 1990.
408. Kennedy SH. Diagnosis and management of the eating disorders: A medical perspective. Medical Grand Rounds, Queensway General Hospital. November, 1990.
409. Kennedy SH. Eating disorders: Identification and early intervention. An overview of risk factors. Symposium for Family Physicians, Toronto, October 1990.
410. Kennedy SH. New treatments for depression - the honeymoon and the morning after. Grand Rounds, Women's College Hospital, September 1990.
411. Kennedy SH. Managing depression in the community. Sault Ste. Marie, June, 1990.
412. Kennedy SH. Practical aspects of the course of mood disorders: Implications for treatment. North York General Hospital, Academic Day. May, 1990.
413. Kennedy SH. Mood disorders: Old and new therapies. Scarborough Centenary Hospital, Grand Rounds. May, 1990.
414. Kennedy SH. Eating disorders: Implications for the nineties. Carrier Foundation, Academic Day, New Jersey. April, 1990.
415. Kennedy SH. Is there a rational approach to the treatment of mood disorders? British Columbia Medical Association, Section of Psychiatry, Vancouver. March, 1990.
416. Kennedy SH, McVey G, Katz R. Personality disorders in anorexia nervosa and bulimia nervosa: A changing profile. University of British Columbia, Grand Rounds, Vancouver. March, 1990.
417. Kennedy SH, de Groot J. The clinician-investigator: implications for residency training. UBC Resident Seminar, Vancouver. March, 1990.
418. Kennedy SH. Programme development and evaluation for eating disorders. St. Paul's Hospital, Vancouver. March, 1990.
419. Kennedy SH. New directions in antidepressant therapies. Windsor Academy of Psychiatry. February, 1990.
420. Kennedy SH. Clinical research as a career in psychiatry. Psychiatric Residents Association, Toronto. February, 1990.
421. Kennedy SH. Choosing an antidepressant. Depression Update Conference, Toronto General Hospital, Family Practice Symposium. December, 1989.
422. Kennedy SH. Changing rhythms - Changing moods. North York General Hospital, Grand Rounds. November, 1989.
423. Kennedy SH. Alcoholism and depression. (Workshop) Dual Diagnosis Conference. November, 1989.
424. Kennedy SH. Etiological aspects of eating disorders: Implications for treatment and outcome. Victoria General Hospital, Academic Lecture, Halifax. November, 1989.
425. Kennedy SH. Anorexia nervosa: The complexities of medical and psychological management. St. Michael's Hospital, Grand Rounds. October, 1989.
426. Kennedy SH. New directions in antidepressant therapies. Oakville-Trafalgar Hospital, Grand Rounds. October, 1989.
427. Kennedy SH. Neuroendocrine-neurotransmitter-neuroreceptor changes in depression. Mount Sinai Hospital, Medicine Grand Rounds. October, 1989.

428. Kennedy SH. Beyond tricyclics: The management of depression. London Psychiatric Hospital, Academic Lecture. October, 1989.
429. Kennedy SH. Anorexia nervosa. (Workshop) College of Family Physicians of Canada -Ontario Chapter. December, 1988.
430. Kennedy SH. Recent advances in pharmacotherapy for the eating disorders. Toronto General Hospital, Eating Disorder Conference. November, 1988.
431. Kennedy SH. Practical issues in the management of inpatients with anorexia nervosa. (Workshop) Toronto General Hospital, Eating Disorder Conference. November, 1988.
432. Kennedy SH. Depression in association with anorexia nervosa and bulimia nervosa. Clarke Institute of Psychiatry, Conference in Affective Disorders. November, 1988.
433. Kennedy SH. An overview of the evaluation and management of anorexia nervosa and bulimia nervosa. Victoria General Hospital. Halifax, Nova Scotia. October, 1988.
434. Kennedy SH. Rhythm dysregulation and the affective disorders. Victoria General Hospital, Grand Rounds. Halifax, Nova Scotia. October, 1988.
435. Kennedy SH. Alternatives to lithium in the management of bipolar affective disorder. The Nova Scotia Psychiatric Hospital, Nova Scotia. October, 1988.
436. Kennedy SH. Non-pharmacological aspects of treatment for depression: Changes in nutrition, light and sleep. St. Thomas Psychiatric Hospital. September, 1988.
437. Kennedy SH. Advances in mood disorder pharmacotherapies. Peterborough Civic Hospital, Grand Rounds. September, 1988.
438. Kennedy SH. Alternative strategies in the management of bipolar affective disorder. Sudbury Algoma Psychiatric Hospital and Sudbury General Hospital, Grand Rounds. June, 1988.
439. Kennedy SH. Treatment advances in unipolar and bipolar affective disorders. Telemedicine Canada, April, 1988.
440. Kennedy SH. Practical issues in treating anorexia nervosa and bulimia nervosa. Kitchener Waterloo Hospital. March, 1988.
441. Kennedy SH. Refractory bipolar patients: Pharmacological and non-pharmacological treatments. North Bay Psychiatric Hospital. January, 1988.
442. Kennedy SH. Alternatives in lithium in bipolar affective disorders. Whitby Psychiatric Hospital, Grand Rounds. December, 1987.
443. Kennedy SH. Antidepressant treatments in bulimia nervosa. City-wide Psychopharmacology Rounds. Department of Psychiatry, University of Toronto. November, 1987.
444. Kennedy SH. Treating eating disorders patients in a nonspecialized general hospital. North York, Grand Rounds. November, 1987.
445. Kennedy SH. Anorexia nervosa and bulimia: Predictors of outcome for inpatient treatment. Institute of Psychiatry, London, England. July, 1987.
446. Kennedy SH, Garfinkel PE. The inpatient treatment of eating disorders: Unit variables and patient variables. Conference Sponsored by Anorexia Nervosa Aid Society of Springfield, Massachusetts. May, 1987.
447. Kennedy SH. Clinical and management issues in anorexia nervosa and bulimia. Central Nursing Registry of Toronto. May, 1987.
448. Kennedy SH, Parienti V, Costa D, Brown GM. Melatonin as a marker of noradrenergic dysfunction in bulimia. Psychoendocrinology Rounds, Clinical Investigation Unit, Toronto General Hospital. May, 1987.
449. Kennedy SH. Anorexia nervosa, bulimia and their relationship to affective disorders. International Conference on New Directions in Affective Disorders. Symposium Chairman. Jerusalem, April, 1987.

450. Kennedy SH. Anorexia nervosa and bulimia: Update on origins, symptoms and treatment. (Workshop) Homewood Sanitarium. Guelph, February, 1987.
451. Kennedy, SH. Anorexia nervosa and bulimia: Management in an inpatient setting. Grand Rounds, Ottawa Civic Hospital. Ottawa, November, 1986.
452. Kennedy SH. Advances in antidepressant treatment of depression. Grand Rounds, University of Toronto, Health Service. November, 1986.
453. Kennedy SH. Eating disorders: Issues of diagnosis and management in a family practice setting. Mount Sinai Hospital. Toronto, October, 1986.
454. Kennedy SH. Anorexia nervosa, bulimia and obesity. Rationale for pharmacological treatments. Canadian Society of Hospital Pharmacists. October, 1986.
455. Kennedy SH. Living with manic depressive illness. Manic Depressive Association of Ontario. September, 1986.
456. Kennedy SH. Inpatient psychiatric treatment of eating disorders. Clarke Institute of Psychiatry, 20 Year Anniversary Symposium, 1986.
457. Kennedy SH. Eating disorders among young people: Treatment methods and family support. Alliance for Children Ontario. June, 1986.
458. Kennedy SH. Medical issues in the management of eating disorders. Ontario Psychological Association, 1986.
459. Kennedy SH. Physical, psychological and cultural aspects of anorexia nervosa and bulimia. University of Toronto, Department of Anatomy, 1986.
460. Kennedy SH. Predictors of antidepressant drug response. Grand Rounds, Women's College Hospital. Toronto, 1985.
461. Kennedy SH. Therapy resistance in bipolar affective disorder. (Discussant) City-Wide Psychopharmacology Rounds. University of Toronto, 1985.
462. Kennedy SH, Garfinkel PE. Anorexia nervosa. American Psychiatric Association, Psychiatry Update on Eating Disorders. Dallas, 1985.
463. Kennedy SH, Garfinkel PE. Consultation with American Psychiatric Association, Psychiatry Update on Eating Disorders. Dallas, 1985.
464. Kennedy SH, Kerr A. Theory and treatment of anorexia nervosa. (Workshop) Ontario Association of Professional Social Workers. Guelph, 1985.
465. Kennedy SH. Current trends in psychiatry. Queen's University, Belfast, 1985.
466. Kennedy SH. Psychopharmacological treatment of bulimia. International Psychiatric Research Society. Toronto, 1985.
467. Kennedy SH. Anorexia nervosa and bulimia. York-Finch General Hospital, Clinical Day, 1984.
468. Kennedy SH. Bulimia and depression. York Central Hospital, Grand Rounds, 1984.
469. Kennedy SH. Anorexia nervosa: An overview. Central Nursing Registry. Toronto, 1984.
470. Kennedy SH. Current concepts of depression. Huronia Association of Social Workers, 1984.
471. Kennedy SH. Good grief - bad grief. Professional Symposium on Bereavement. Humber College, 1983.
472. Kennedy SH, Kerr A. Inpatient programs for eating disorder patients. Community Occupational Therapy Associates, 1983.
473. Kennedy SH. Anorexia nervosa and bulimia. (Public Forum) Etobicoke Social Development Council, 1983.

XV. MEDIA PROJECTS

1. A discussion about suicide and depression. In support of Bell Let's Talk. Live Twitter Event. January 25th, 2017.
2. Understanding why some people take their lives – and some don't. The Toronto Star. April 10th, 2016.
3. Suicide indicators. CBC Metro Morning. March 17th, 2016.
4. Biomarkers for adolescent depression. CTV News Channel, Toronto, February 18, 2014.
5. Evening with Paul Kennedy, Centre for Addiction and Mental Health Foundation, Toronto – June 13, 2013.
6. The Irish Times – Tuesday, October 12, 2010 – Depression's invisibility fuels stigma.
7. The Interview: Dr. Norman Doidge and "Brain Man" Daniel Tammet. The Agenda with Steve Paikin - TVO Panel Guest - January 16, 2009.
8. How to mend a broken mind? The Globe and Mail, Mental Health Supplement on Deep Brain Stimulation – June 28, 2008.
9. Are we over-prescribing antidepressants? CTV News – April 2007.
10. Promising results of Deep Brain Stimulation for Treatment Resistant Depression, CTV News – 2006.
11. Promising results of Deep Brain Stimulation for Treatment Resistant Depression, CBC Newsworld – 2006.
12. Promising results of Deep Brain Stimulation for Treatment Resistant Depression, Readers Digest – 2006.
13. Impact of the Canadian Depression Survey. Various TV and radio interviews – June-July 2004.
14. Mind Mood on Mental Health – Host for weekly radio shows - 2003-2004.
15. Kennedy SH and the Honorable Michael Wilson. "Health on the Line" Discovery Channel, January 2002.
16. Kennedy SH, Kutcher SP, McQueen G. CTV (Avis Favro) and Globe and Mail series on Depression, December 2001.
17. Kennedy SH, McIntyre RS. HAMD-7 – a brief rating scale for psychiatrists and family practitioners (VIDEO). Cameron McCleery Productions. 2001.
18. Consultant to TV Ontario. David Way in production of "The Placebo Effect". 2001
19. Consultant to DreamWorks Productions and Sue Rideout in New Directions in treating Depression. 2001
20. Health Matters segment on Global News. Global Television Network. June 2001
21. Kennedy SH, Kutcher SA, Lam RW, Bakish D: Using the Hamilton Depression Rating Scale: Clinical and Research Aspects (videotape) Toronto, Cameron McCleery Productions. 1999.
22. Doctor on Call. Women's Television Network. January, 1998.
23. Male Depression. Arlene Bynon, Prime Network/Global Television Network. September, 1998.
24. Doctor on Call. Women's Television Network. June, 1997
25. Advances in understanding and treating bipolar disorders: Keynote address. Mood Disorders Association of Ontario. May, 1997.
26. Doctor on Call. Women's Television Network, May, 1997.
27. Parikh S, Kennedy SH. Recognizing and treating Depression. Telemedicine, April, 1997.
28. Physician and Public Awareness Day on Depression and Anxiety. Park Plaza Hotel. September, 1996.
29. The circle of depression. Canadian Psychiatric Research Foundation, C-PAC Annual Dinner. February, 1996.
30. Depression is a treatable disorder. Crossroads Christian Communications, November, 1995.
31. Recognizing depression and getting the help you need. CHCH Television, Jane Hawtin Live, November, 1995.
32. Research advances in Depression at the Clarke Institute. Public Forum with Mike Wallace and Helen

- Hutchinson, February 1995.
33. Vaccarino FJ, Kennedy SH. New approaches to treating anorexia nervosa. CIUT FM, June 1993.
 34. Kennedy SH, Vaccarino FJ. The role of growth hormone releasing factor as a stimulus to eat. CFTO News, March 1993.
 35. Reversible and selective inhibitors of monoamine oxidase: New directions in psychopharmacology. Medifacts Specialist Audiotapes, June 1992.
 36. Update on diagnosis and treatment for bulimia nervosa. Telemedicine, Canada, February 1992.
 37. Vincent G, Kennedy SH. Discussion of the impact of eating disorders on our society. Joe Coté, CBC Radio, 1992.
 38. Eating disorders: Feast or famine. City TV, Breakfast Show, October 1990.
 39. Manic depression: Recognition and treatment. Doris Epstein Show, Scarborough Cable Television, March 1990.
 40. Eating disorders: Individual and family perspective. Public Forum, B.C. District of Canadian Mental Health Association, March 1990.
 41. Recognizing and dealing with anorexia nervosa and bulimia nervosa. Phil Good Radio Interview, Vancouver, March 1990.
 42. Seasonal mood disorders. Global Television News, February 1990.
 43. Etiological issues in the development of anorexia nervosa. Public Forum, Eating Disorders Awareness Week, October 1989.
 44. The weight craze: Anorexia nervosa and bulimia nervosa. TV Ontario, April 1989.
 45. Eating disorders among teenagers. The Dini Petty Show, City TV, January 1989.
 46. Coping with manic depression. CBC Radio, Peter Gzowski, February 1988.
 47. Stress and nutrition: Impact on lifestyle. Young Presidents Organization, Family University, April 1988.
 48. Anorexia nervosa and bulimia: Recognition and treatment. Cable Television Broadcast, March 1987.
 49. Depression: Clinical Symptoms and Signs. Instructional Media Services (Video Tape), December 1986.
 50. Depression: Biological treatments. Instructional Media Services (Video Tape), December 1986.
 51. The management of depression. Telemedicine for Ontario, 1983
 52. The nature and treatment of depression. That's Life, Global Television, 1983.